Mesothelioma
To our knowledge, there is no peer reviewed data to associate mesothelioma and cancer, however if you know of something, please let us know and we will correct our postion.
However, there are several clinical trials being conduct (see below) and there is an informative treatment page at Lanier Law Firm. There is also another information page regarding Mesothelioma & Seniors on the Gori Law Firm website.
Clinical Trials in Mesothelioma but not obesity related
| NCT Number | Study Title | Study URL | Acronym | Study Status | Interventions | Sponsor | Collaborators | Enrollment | Study Type | Locations |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT04857372 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | https://clinicaltrials.gov/study/NCT04857372 | RECRUITING | DRUG: IAG933 | Novartis Pharmaceuticals | 156 | INTERVENTIONAL | University of Chicago Medical Center, Chicago, Illinois, 60637-1470, United States|Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Novartis Investigative Site, Melbourne, Victoria, 3000, Australia|Novartis Investigative Site, Montreal, Quebec, H2W 1T8, Canada|Novartis Investigative Site, Villejuif, 94800, France|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan|Novartis Investigative Site, Rotterdam, Zuid Holland, 3015 GD, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Zuerich, 8091, Switzerland|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom | ||
| NCT05041062 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT05041062 | COMPLETED | DRUG: Nivolumab|DRUG: Ipilimumab | University of Chicago | 2 | INTERVENTIONAL | The University of Chicago, Chicago, Illinois, 60637, United States | ||
| NCT00003046 | Interleukin-12 in Treating Patients With Cancer in the Abdomen | https://clinicaltrials.gov/study/NCT00003046 | COMPLETED | BIOLOGICAL: Recombinant Interleukin-12 | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | 29 | INTERVENTIONAL | University of Texas – MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States | |
| NCT01024946 | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | https://clinicaltrials.gov/study/NCT01024946 | COMPLETED | DRUG: everolimus | Memorial Sloan Kettering Cancer Center | Novartis Pharmaceuticals|Dana-Farber Cancer Institute|University of Pennsylvania | 11 | INTERVENTIONAL | Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104-4283, United States | |
| NCT03241173 | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | https://clinicaltrials.gov/study/NCT03241173 | COMPLETED | DRUG: INCAGN01949|DRUG: Nivolumab|DRUG: Ipilimumab | Incyte Biosciences International Sàrl | 52 | INTERVENTIONAL | The University of Alabama Birmingham (UAB), Birmingham, Alabama, 90025, United States|Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, 85258, United States|The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|Mount Sinai Medical Center of Florida, Inc., Miami, Florida, 33140, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|John Theurer Cancer Center At Hackensack UMC, Hackensack, New Jersey, 07601, United States|Rutgers, The State University, New Brunswick, New Jersey, 08901, United States|New York University Clinical Cancer Center, New York, New York, 10016, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Carolina BioOncology Institute, Huntersville, North Carolina, 28078, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Sarah Cannon Research Institute, LLC (SCRI), Nashville, Tennessee, 37203, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States | ||
| NCT01134146 | Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) | https://clinicaltrials.gov/study/NCT01134146 | COMPLETED | RADIATION: IMRT | M.D. Anderson Cancer Center | 11 | INTERVENTIONAL | University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States | ||
| NCT01126346 | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | https://clinicaltrials.gov/study/NCT01126346 | HOPE | COMPLETED | BEHAVIORAL: HIPEC Orientation|BEHAVIORAL: Consultation with Survivorship Navigator|OTHER: Questionnaires | Wake Forest University Health Sciences | 10 | INTERVENTIONAL | Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States | |
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | https://clinicaltrials.gov/study/NCT03502746 | ACTIVE_NOT_RECRUITING | DRUG: Nivolumab|DRUG: Ramucirumab | Arkadiusz Z. Dudek, MD | HealthPartners Institute Regions Cancer Care Center|Eli Lilly and Company|Bristol-Myers Squibb | 35 | INTERVENTIONAL | Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Karmanos Cancer Center (Wayne State University), Detroit, Michigan, 48201, United States|HealthPartners Institute Regions Cancer Care Center, Minneapolis, Minnesota, 55440, United States | |
| NCT05960773 | Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma | https://clinicaltrials.gov/study/NCT05960773 | NOT_YET_RECRUITING | DRUG: Decitabine/cedazuridine | National Cancer Institute (NCI) | 15 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT04106973 | Mesothelioma Early Detection by VOCs | https://clinicaltrials.gov/study/NCT04106973 | MED-VOC | TERMINATED | Ascension South East Michigan | International Association of Heat and Frost Insulators and Allied Workers|Owlstone Ltd|Fujirebio Diagnostics, Inc. | 12 | OBSERVATIONAL | Consultants in Sleep and Pulmonary Medicine, Farmington Hills, Michigan, 48336, United States | |
| NCT03126110 | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | https://clinicaltrials.gov/study/NCT03126110 | COMPLETED | DRUG: INCAGN01876|DRUG: Nivolumab|DRUG: Ipilimumab | Incyte Biosciences International Sàrl | 145 | INTERVENTIONAL | The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|University of Florida, Gainesville, Florida, 32610, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Washington University – Siteman Cancer Center, Saint Louis, Missouri, 37201, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Memorial Sloan Kettering Cancer, New York, New York, 10065, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|University of Oklahoma, Sarah Cannon Research Institute, Oklahoma City, Oklahoma, 73104, United States|Providance Portland Medical Center, Portland, Oregon, 97213, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|University of Pittsburgh, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, 15232, United States|Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, 37201, United States|BUMC Mary Crowley Cancer Research Centers, Dallas, Texas, 75230, United States|MD Anderson, Houston, Texas, 77030, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, 2148, Australia|Scientia Clinical Research, Randwick, New South Wales, 2148, Australia|Greenslopes Private Hospital, Brisbane, Queensland, 4120, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Linear Clinical Research, Perth, Western Australia, 6009, Australia|CHA Centre Hospitalier de l’Ardenne, Libramont, Chevigny, 6800, Belgium|Saint Augustinus Hospital, Antwerpen, 2610, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|CHU Brugmann, Bruxelles, 1020, Belgium|Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Charleroi, 6000, Belgium|Ghent University Hospital, Ghent, 37201, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|Hospital Clinic I Provincial, Barcelona, 08036, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, 08036, Spain|Institut Catala D’Oncologia-Badalona, Barcelona, 08916, Spain|Hospital Vall de Hebron, Barcelona, Spain|Hospital Reina Sophia, Córdoba, 14004, Spain|University Hospital Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Doce de Octubre, Madrid, 28041, Spain|Hospital HM Sanchinarro, Madrid, 28050, Spain|Clinica Universidad De Navarra (CUN), Pamplona, 31008, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41015, Spain | ||
| NCT01119664 | Combination Gene Transfer and Chemotherapy | https://clinicaltrials.gov/study/NCT01119664 | COMPLETED | DRUG: SCH 721015 | Abramson Cancer Center at Penn Medicine | 40 | INTERVENTIONAL | University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | https://clinicaltrials.gov/study/NCT03175172 | TERMINATED | BIOLOGICAL: CRS-207|BIOLOGICAL: Pembrolizumab | Aduro Biotech, Inc. | Merck Sharp & Dohme LLC | 10 | INTERVENTIONAL | UCSF Comprehensive Cancer Center, San Francisco, California, 94115, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|NIH National Cancer Institute, Bethesda, Maryland, 20892, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | |
| NCT00309946 | Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery | https://clinicaltrials.gov/study/NCT00309946 | COMPLETED | DRUG: cediranib maleate | National Cancer Institute (NCI) | 51 | INTERVENTIONAL | University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637-1470, United States | ||
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT04173338 | TERMINATED | DRUG: Cabozantinib|DRUG: Pemetrexed | Augusta University | 9 | INTERVENTIONAL | Augusta University Georgia Cancer Center, Augusta, Georgia, 30912, United States | ||
| NCT00398138 | Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | https://clinicaltrials.gov/study/NCT00398138 | COMPLETED | BIOLOGICAL: WT-1 analog peptide vaccine|BIOLOGICAL: incomplete Freund’s adjuvant|BIOLOGICAL: sargramostim|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: immunoenzyme technique | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI)|Innovive Pharmaceuticals | 22 | INTERVENTIONAL | Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | |
| NCT04481672 | Intravenous Magnesium in Patients Receiving Cisplatin | https://clinicaltrials.gov/study/NCT04481672 | COMPLETED | DRUG: Magnesium Sulfate | Dana-Farber Cancer Institute | 5 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02215, United States | ||
| NCT00299962 | Gene Therapy for Pleural Malignancies | https://clinicaltrials.gov/study/NCT00299962 | COMPLETED | BIOLOGICAL: Adenoviral-mediated Interferon-beta|BIOLOGICAL: SCH 721015 | University of Pennsylvania | National Cancer Institute (NCI)|Biogen | 17 | INTERVENTIONAL | Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | |
| NCT01590472 | Do Your Genes Put You at a Higher Risk of Developing Mesothelioma | https://clinicaltrials.gov/study/NCT01590472 | COMPLETED | Wake Forest University | University of Pennsylvania|Mayo Clinic|NYU Langone Health|Johns Hopkins University|Memorial Sloan Kettering Cancer Center|Mesothelioma Applied Research Foundation, Inc. | 69 | OBSERVATIONAL | Johns Hopkins University, Baltimore, Maryland, 21287, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|New York University School of Medicine, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT00459862 | Pazopanib in Treating Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00459862 | COMPLETED | OTHER: laboratory biomarker analysis|DRUG: pazopanib hydrochloride | National Cancer Institute (NCI) | 34 | INTERVENTIONAL | North Central Cancer Treatment Group, Rochester, Minnesota, 55905, United States | ||
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | https://clinicaltrials.gov/study/NCT04034238 | COMPLETED | DRUG: LMB-100|DRUG: Tofacitinib|DEVICE: Mesothelin Expression | National Cancer Institute (NCI) | 19 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | https://clinicaltrials.gov/study/NCT02071862 | COMPLETED | DRUG: CB-839|DRUG: Pac-CB|DRUG: CBE|DRUG: CB-Erl|DRUG: CBD|DRUG: CB-Cabo | Calithera Biosciences, Inc | 210 | INTERVENTIONAL | UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94143, United States|Stanford University Medical Center, Stanford, California, 94305, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Winship Cancer Institute of Emory School of Medicine, Atlanta, Georgia, 30322, United States|NIH – NCI – Center for Cancer Research, Bethesda, Maryland, 20892, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Columbia University Medical Center, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States | ||
| NCT00535951 | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00535951 | COMPLETED | DRUG: LBH589 | Novartis Pharmaceuticals | 18 | INTERVENTIONAL | Highlands Oncology Group, Fayetteville, Arkansas, 72703, United States|Medical College of Georgia, Augusta, Georgia, 30912, United States|RUSH Medical Center, Chicago, Illinois, 60612, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Novartis Investigative Site, Ontario, Canada | ||
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT03517488 | DUET-2 | COMPLETED | BIOLOGICAL: XmAb20717 | Xencor, Inc. | ICON plc | 150 | INTERVENTIONAL | Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, 90048, United States|UCLA Hematology-Oncology Clinic (Westwood), Los Angeles, California, 90095, United States|University of California San Diego Moores Cancer Center, San Diego, California, 92093-0698, United States|University of California San Francisco Medical Center, San Francisco, California, 94115, United States|Emory University, Atlanta, Georgia, 30322, United States|University of Chicago Medicine, Chicago, Illinois, 60637, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, 66205, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|Columbia University Medical Center – Herbert Irving Pavilion, New York, New York, 10032, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, 22903, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT00703638 | COMPLETED | DRUG: cisplatin|DRUG: pemetrexed disodium|DRUG: sorafenib | Masonic Cancer Center, University of Minnesota | 16 | INTERVENTIONAL | Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, 55455, United States | ||
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | https://clinicaltrials.gov/study/NCT05461430 | TraveraRTGx | RECRUITING | Travera Inc | xCures | 200 | OBSERVATIONAL | xCures, Oakland, California, 94612, United States | |
| NCT01085630 | Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy | https://clinicaltrials.gov/study/NCT01085630 | COMPLETED | DRUG: pemetrexed disodium|OTHER: clinical observation | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 72 | INTERVENTIONAL | Mayo Clinic Scottsdale, Scottsdale, Arizona, 85259-5499, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94115, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, 06105, United States|George Bray Cancer Center at the Hospital of Central Connecticut – New Britain Campus, New Britain, Connecticut, 06050, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, 19958, United States|CCOP – Christiana Care Health Services, Newark, Delaware, 19713, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, 83706, United States|Illinois CancerCare – Bloomington, Bloomington, Illinois, 61701, United States|St. Joseph Medical Center, Bloomington, Illinois, 61701, United States|Illinois CancerCare – Canton, Canton, Illinois, 61520, United States|Illinois CancerCare – Carthage, Carthage, Illinois, 62321, United States|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States|Eureka Community Hospital, Eureka, Illinois, 61530, United States|Illinois CancerCare – Eureka, Eureka, Illinois, 61530, United States|Galesburg Clinic, PC, Galesburg, Illinois, 61401, United States|Illinois CancerCare – Havana, Havana, Illinois, 62644, United States|Illinois CancerCare – Kewanee Clinic, Kewanee, Illinois, 61443, United States|La Grange Memorial Hospital, La Grange, Illinois, 60525, United States|Illinois CancerCare – Macomb, Macomb, Illinois, 61455, United States|Illinois CancerCare – Monmouth, Monmouth, Illinois, 61462, United States|OSF Holy Family Medical Center, Monmouth, Illinois, 61462, United States|BroMenn Regional Medical Center, Normal, Illinois, 61761, United States|Community Cancer Center, Normal, Illinois, 61761, United States|Illinois CancerCare – Community Cancer Center, Normal, Illinois, 61761, United States|Community Hospital of Ottawa, Ottawa, Illinois, 61350, United States|Oncology Hematology Associates of Central Illinois, PC – Ottawa, Ottawa, Illinois, 61350, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, 61554, United States|Illinois CancerCare – Pekin, Pekin, Illinois, 61603, United States|Proctor Hospital, Peoria, Illinois, 61614, United States|CCOP – Illinois Oncology Research Association, Peoria, Illinois, 61615, United States|Oncology Hematology Associates of Central Illinois, PC – Peoria, Peoria, Illinois, 61615, United States|Methodist Medical Center of Illinois, Peoria, Illinois, 61636, United States|OSF St. Francis Medical Center, Peoria, Illinois, 61637, United States|Illinois CancerCare – Peru, Peru, Illinois, 61354, United States|Illinois Valley Community Hospital, Peru, Illinois, 61354, United States|Illinois CancerCare – Princeton, Princeton, Illinois, 61356, United States|Illinois CancerCare – Spring Valley, Spring Valley, Illinois, 61362, United States|Elkhart Clinic, LLC, Elkhart, Indiana, 46514-2098, United States|Michiana Hematology-Oncology, PC – Elkhart, Elkhart, Indiana, 46514, United States|Elkhart General Hospital, Elkhart, Indiana, 46515, United States|Howard Community Hospital, Kokomo, Indiana, 46904, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, 46350, United States|Michiana Hematology-Oncology, PC – South Bend, Mishawaka, Indiana, 46545-1470, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, 46545-1470, United States|Michiana Hematology Oncology PC – Plymouth, Plymouth, Indiana, 46563, United States|CCOP – Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States|Memorial Hospital of South Bend, South Bend, Indiana, 46601, United States|Michiana Hematology Oncology PC – La Porte, Westville, Indiana, 46391, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, 51101, United States|Mercy Medical Center – Sioux City, Sioux City, Iowa, 51102, United States|St. Luke’s Regional Medical Center, Sioux City, Iowa, 51104, United States|Cancer Center of Kansas, PA – Chanute, Chanute, Kansas, 66720, United States|Cancer Center of Kansas, PA – Dodge City, Dodge City, Kansas, 67801, United States|Cancer Center of Kansas, PA – El Dorado, El Dorado, Kansas, 67042, United States|Cancer Center of Kansas – Fort Scott, Fort Scott, Kansas, 66701, United States|Cancer Center of Kansas-Independence, Independence, Kansas, 67301, United States|Cancer Center of Kansas, PA – Kingman, Kingman, Kansas, 67068, United States|Lawrence Memorial Hospital, Lawrence, Kansas, 66044, United States|Cancer Center of Kansas, PA – Liberal, Liberal, Kansas, 67901, United States|Cancer Center of Kansas, PA – McPherson, McPherson, Kansas, 67460, United States|Cancer Center of Kansas, PA – Newton, Newton, Kansas, 67114, United States|Cancer Center of Kansas, PA – Parsons, Parsons, Kansas, 67357, United States|Cancer Center of Kansas, PA – Pratt, Pratt, Kansas, 67124, United States|Cancer Center of Kansas, PA – Salina, Salina, Kansas, 67401, United States|Cancer Center of Kansas, PA – Wellington, Wellington, Kansas, 67152, United States|Associates in Womens Health, PA – North Review, Wichita, Kansas, 67208, United States|Cancer Center of Kansas, PA – Medical Arts Tower, Wichita, Kansas, 67208, United States|Cancer Center of Kansas, PA – Wichita, Wichita, Kansas, 67214, United States|CCOP – Wichita, Wichita, Kansas, 67214, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, 67214, United States|Cancer Center of Kansas, PA – Winfield, Winfield, Kansas, 67156, United States|Ochsner Health Center – Bluebonnet, Baton Rouge, Louisiana, 70809, United States|Ochsner Health Center – Covington, Covington, Louisiana, 70433, United States|New Orleans Cancer Institute at Memorial Medical Center, New Orleans, Louisiana, 70115, United States|CCOP – Ochsner, New Orleans, Louisiana, 70121, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201, United States|Veterans Affairs Medical Center – Baltimore, Baltimore, Maryland, 21201, United States|Union Hospital of Cecil County, Elkton, Maryland, 21921, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, 48106-0995, United States|CCOP – Michigan Cancer Research Consortium, Ann Arbor, Michigan, 48106, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, 48123-2500, United States|Genesys Hurley Cancer Institute, Flint, Michigan, 48503, United States|Hurley Medical Center, Flint, Michigan, 48503, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, 48439, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, 48236, United States|Foote Memorial Hospital, Jackson, Michigan, 49201, United States|Sparrow Regional Cancer Center, Lansing, Michigan, 48912-1811, United States|St. Mary Mercy Hospital, Livonia, Michigan, 48154, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, 48341-2985, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, 48060, United States|Seton Cancer Institute at Saint Mary’s – Saginaw, Saginaw, Michigan, 48601, United States|Lakeland Regional Cancer Care Center – St. Joseph, Saint Joseph, Michigan, 49085, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, 49085, United States|St. John Macomb Hospital, Warren, Michigan, 48093, United States|St. Joseph’s Medical Center, Brainerd, Minnesota, 56401, United States|Essentia Health – Duluth Clinic, Duluth, Minnesota, 55805-1983, United States|CCOP – Duluth, Duluth, Minnesota, 55805, United States|Miller – Dwan Medical Center, Duluth, Minnesota, 55805, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, 89102, United States|CCOP – Nevada Cancer Research Foundation, Las Vegas, Nevada, 89106, United States|Cancer Institute of New Jersey at Cooper – Voorhees, Voorhees, New Jersey, 08043, United States|CCOP – Hematology-Oncology Associates of Central New York, East Syracuse, New York, 13057, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, 27534, United States|Kinston Medical Specialists, Kinston, North Carolina, 28501, United States|Iredell Memorial Hospital, Statesville, North Carolina, 28677, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, 58501, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, 58501, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, 58502, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, 44309-2090, United States|Barberton Citizens Hospital, Barberton, Ohio, 44203, United States|Cleveland Clinic Beachwood Family Health and Surgery Center, Beachwood, Ohio, 44122, United States|Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, 44111, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210-1240, United States|Cleveland Clinic Cancer Center, Independence, Ohio, 44131, United States|Hillcrest Cancer Center at Hillcrest Hospital, Mayfield Heights, Ohio, 44124, United States|Parma Community General Hospital, Parma, Ohio, 44129, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, 44870, United States|Cleveland Clinic Foundation – Strongsville, Strongsville, Ohio, 44136, United States|Cleveland Clinic – Wooster, Wooster, Ohio, 44691, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, 97015, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, 97222, United States|Providence Newberg Medical Center, Newberg, Oregon, 97132, United States|Willamette Falls Hospital, Oregon City, Oregon, 97045, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, 97213-2967, United States|CCOP – Columbia River Oncology Program, Portland, Oregon, 97225, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|Rosenfeld Cancer Center at Abington Memorial Hospital, Abington, Pennsylvania, 19001, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, 17822-0001, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, 18201, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104-4283, United States|Fox Chase Cancer Center – Philadelphia, Philadelphia, Pennsylvania, 19111-2497, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, 15232, United States|Geisinger Medical Group – Scenery Park, State College, Pennsylvania, 16801, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, 18711, United States|Roper St. Francis Cancer Center at Roper Hospital, Charleston, South Carolina, 29401, United States|Danville Regional Medical Center, Danville, Virginia, 24541, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, 98664, United States|Northwest Cancer Specialists at Vancouver Cancer Center, Vancouver, Washington, 98684, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, 54601, United States | |
| NCT00066651 | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT00066651 | COMPLETED | BIOLOGICAL: SS1(dsFv)-PE38 immunotoxin | National Cancer Institute (NCI) | INTERVENTIONAL | Warren Grant Magnuson Clinical Center – NCI Clinical Studies Support, Bethesda, Maryland, 20892-1182, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, 27157-1096, United States | |||
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | https://clinicaltrials.gov/study/NCT02599194 | COMPLETED | DRUG: 18F-FSPG|DRUG: 18F-FDG | Andrei Iagaru | National Cancer Institute (NCI) | 7 | INTERVENTIONAL | Stanford University Medical Center, Stanford, California, 94304, United States | |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | https://clinicaltrials.gov/study/NCT05627960 | RECRUITING | DRUG: AG-01 Compound | A&G Pharmaceutical Inc. | University of Maryland Greenebaum Cancer Center | 77 | INTERVENTIONAL | University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States | |
| NCT00528619 | A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT00528619 | COMPLETED | DRUG: Sunitinib, Pemetrexed, Cisplatin, Carboplatin | Pfizer | 96 | INTERVENTIONAL | Pfizer Investigational Site, Aurora, Colorado, 80045, United States|Pfizer Investigational Site, Ottawa, Ontario, K1H 8L6, Canada|Pfizer Investigational Site, Montreal, Quebec, H2L 4M1, Canada | ||
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | https://clinicaltrials.gov/study/NCT01583686 | TERMINATED | DRUG: Fludarabine|BIOLOGICAL: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|DRUG: Cyclophosphamide|DRUG: Aldesleukin | National Cancer Institute (NCI) | 15 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT02875548 | A Study to Assess the Long-term Safety of Tazemetostat | https://clinicaltrials.gov/study/NCT02875548 | TRuST | ACTIVE_NOT_RECRUITING | DRUG: Tazemetostat | Epizyme, Inc. | 100 | INTERVENTIONAL | University of Arizona Cancer Center, Tucson, Arizona, 85724, United States|Moffitt, Tampa, Florida, 33612, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Columbia University Medical Center, New York, New York, 10019, United States|Monash Medical Centre- Monash Campus, Clayton, 3168, Australia|Geelong Hospital, Geelong, Australia|Peter MacCallum Cancer Institute, Melbourne, 3002, Australia|University Hospital (UZ) Leuven, Leuven, 3000, Belgium|Institut Bergonie, Bordeaux Cedex, 33076, France|CHU de Caen – Hôpital Côte de Nacre, Caen, 14033, France|CHRU de Lile- Hopital Claude Huriez, Lille Cedex, 59037, France|Hôpital Saint Louis – AP-HP, Paris, 75010, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, 69310, France|CHU Rennes- Hopital Pontchaillou, Rennes Cedex, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|Gustave Roussay, Villejuif, 94805, France|Pratia MCM Krakow, Kraków, 30-510, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Klinika Endokrynologii Onkologicznej i Medycyny Nuklearnej, Warszawa, Poland|S.P. Grigoreva Institute of Medical Radiology and Oncology of NAMS of Ukraine”, Kharkiv, 61024, Ukraine|Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom|Oncology and Haematology Clinical Trials Unit, Leicester, LEI 5WW, United Kingdom|Clatterbridge Cancer Centre, Liverpool, L7 8XP, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom | |
| NCT02709512 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin | https://clinicaltrials.gov/study/NCT02709512 | ATOMIC | COMPLETED | DRUG: ADI-PEG 20 plus Pem Platinum|OTHER: Placebo plus Pem Platinum | Polaris Group | 249 | INTERVENTIONAL | Mayo Clinic, Phoenix, Arizona, 85054, United States|UCLA Hematology & Oncology – Santa Monica, Los Angeles, California, 90095, United States|University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California, 94115, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Maryland, Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Chris O’Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Tweed Hospital (NNSW LHD), Tweed Heads, New South Wales, 2486, Australia|Princess Alexandria Hospital and Health Services, Woolloongabba, Queensland, 4102, Australia|Southern Adelaide Local Health Network, Inc., Bedford Park, South Australia, 5042, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, 6009, Australia|SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, AL, 15121, Italy|Humanitas Gavazzeni, Bergamo, BG, 24125, Italy|Ospedale Villa Scassi, Genova, GE, 16149, Italy|Azienda Ospedaliera San Gerardo – Monza, Chirurgia Toracica, Monza, MB, 20900, Italy|European Institute of Oncology, Milano, MI, 20141, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, PV, 27100, Italy|Fondazione IRCCS – Istituto Nazionale dei Tumori Milano, Milan, 20133, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, 43126, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56124, Italy|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Chang Gung Medical Foundation Kaohsiung, Kaohsiung, 83301, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 112, Taiwan|Chang Gung Memorial Foundation LinKou Branch, Taoyuan, 33305, Taiwan|Addenbrooke’s Hospital, Cambridge, Cambridgeshire, CB20QQ, United Kingdom|Plymouth Hospitals (Derriford Hospital), Plymouth, Devon, PL6 8DH, United Kingdom|Centre for Experimental Cancer Medicine (CECM), London, England, EC1M 6BQ, United Kingdom|Southampton General Hospital, Southampton, Hampshire, SO16 6YD, United Kingdom|University Hospitals Leicester, Leicester, Leicestershire, LE1 5WW, United Kingdom|Scunthorpe General Hospital, Scunthorpe, North Lincolnshire, DN15 7BH, United Kingdom|Wansbeck General Hospital, Ashington, Northumberland, NE63 9JJ, United Kingdom|Oxford Cancer and Haematology Centre, The Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Edinburgh Cancer Centre, Edinburgh, EH4 2XU, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|St James’s University Hospital, Leeds, LS9 7TF, United Kingdom|St Bartholomew’s Hospital, London, EC1A 7BE, United Kingdom|University Hospital of South Manchester, Manchester, M23 9LT, United Kingdom | |
| NCT05375825 | Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin | https://clinicaltrials.gov/study/NCT05375825 | RECRUITING | PROCEDURE: Cytoreductive surgery|DRUG: LMB-100|DIAGNOSTIC_TEST: Immunohistochemical Assay for Mesothelin | National Cancer Institute (NCI) | 42 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | https://clinicaltrials.gov/study/NCT01521325 | COMPLETED | DRUG: Amatuximab | Morphotek | 6 | INTERVENTIONAL | National Cacner Institue, Bethesda, Maryland, 20892′, United States | ||
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | https://clinicaltrials.gov/study/NCT06034860 | RECRUITING | DRUG: MT-8421|DRUG: Nivolumab | Molecular Templates, Inc. | 200 | INTERVENTIONAL | The Angeles Clinic, Los Angeles, California, 90025, United States|Horizon Oncology Research, LLC, Lafayette, Indiana, 47905, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|Weill Cornell Medicine, New York, New York, 10065, United States|NEXT Oncology, Fairfax, Virginia, 22031, United States | ||
| NCT00365053 | PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | https://clinicaltrials.gov/study/NCT00365053 | COMPLETED | DRUG: belinostat|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 13 | INTERVENTIONAL | City of Hope, Duarte, California, 91010, United States | ||
| NCT02613312 | Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02613312 | RECRUITING | Mayo Clinic | 200 | OBSERVATIONAL | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | |||
| NCT00281125 | Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer | https://clinicaltrials.gov/study/NCT00281125 | TERMINATED | DRUG: PTK787 and Pemetrexed with or without Cisplatin | Nevada Cancer Institute | 20 | INTERVENTIONAL | Nevada Cancer Institute, Las Vegas, Nevada, 89135, United States | ||
| NCT04836429 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | https://clinicaltrials.gov/study/NCT04836429 | RECRUITING | DRUG: Porfimer Sodium|PROCEDURE: Video-Assisted Thoracic Surgery|DRUG: Photodynamic Therapy|DEVICE: Intraoperative PDT | Roswell Park Cancer Institute | 16 | INTERVENTIONAL | Roswell Park Cancer Institute, Buffalo, New York, 14263, United States | ||
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | https://clinicaltrials.gov/study/NCT03652077 | COMPLETED | DRUG: INCAGN02390 | Incyte Corporation | 40 | INTERVENTIONAL | The Angeles Clinical and Research Institute, Los Angeles, California, 90025, United States|University of Mississippi, Jackson, Mississippi, 39216, United States|Hackensack Medical Center, Hackensack, New Jersey, 07601, United States|Carolina BioOncology, Huntsville, North Carolina, 28078, United States | ||
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers | https://clinicaltrials.gov/study/NCT05544929 | RECRUITING | DRUG: KFA115|DRUG: tislelizumab | Novartis Pharmaceuticals | 220 | INTERVENTIONAL | Massachusetts General Hospital ., Boston, Massachusetts, 02114, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Shatin New Territories, Hong Kong|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Taipei, 10002, Taiwan | ||
| NCT01503177 | Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01503177 | COMPLETED | BIOLOGICAL: oncolytic measles virus encoding thyroidal sodium iodide symporter|OTHER: laboratory biomarker analysis|PROCEDURE: single photon emission computed tomography|PROCEDURE: computed tomography | Mayo Clinic | National Cancer Institute (NCI) | 15 | INTERVENTIONAL | Mayo Clinic, Rochester, Minnesota, 55905, United States | |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | https://clinicaltrials.gov/study/NCT03881488 | RECRUITING | DRUG: CTX-471|DRUG: pembrolizumab | Compass Therapeutics | Iqvia Pty Ltd|Merck, Sharp & Dohme, LLC, Rahway, NJ USA | 157 | INTERVENTIONAL | Ocala Oncology Center, Ocala, Florida, 34474, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, 34952, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Mt Sinai, New York, New York, 10029, United States|Duke University School of Medicine, Durham, North Carolina, 27705, United States|Institute for Translational Oncology Research (ITOR), Greenville, South Carolina, 29605, United States|Mary Crowley Cancer Research, Dallas, Texas, 75251, United States | |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT05538572 | RECRUITING | DRUG: PRT3645 | Prelude Therapeutics | 61 | INTERVENTIONAL | Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, 06511, United States|AdventHealth Medical Group Oncology Research at Celebration, Celebration, Florida, 34747, United States|Miami Cancer Institute, Miami, Florida, 33176, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|Laura and Isaac Perlmutter Cancer Center/ NYU Langone Health, New York, New York, 10016, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, 19107, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, 78229, United States|NEXT Virginia, Fairfax, Virginia, 22031, United States|National Cancer Centre Singapore, Singapore, 168583, Singapore | ||
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | https://clinicaltrials.gov/study/NCT01655225 | COMPLETED | DRUG: LY3023414|DRUG: Midazolam|DRUG: Fulvestrant|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Abemaciclib|DRUG: Letrozole | Eli Lilly and Company | 156 | INTERVENTIONAL | UCLA Medical Center, Los Angeles, California, 90095, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, 19104, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Azienda Ospedaliero – Universitaria S. Luigi Gonzaga, Orbassano, Torino, 10043, Italy|Fundacion de Investigacion de Diego, San Juan, 00927, Puerto Rico | ||
| NCT00019825 | Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura | https://clinicaltrials.gov/study/NCT00019825 | COMPLETED | DRUG: decitabine | National Cancer Institute (NCI) | INTERVENTIONAL | Warren Grant Magnuson Clinical Center – NCI Clinical Studies Support, Bethesda, Maryland, 20892-1182, United States|Center for Cancer Research, Bethesda, Maryland, 20892, United States | |||
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | https://clinicaltrials.gov/study/NCT05086692 | ABILITY-1 | RECRUITING | DRUG: MDNA11|DRUG: Pembrolizumab | Medicenna Therapeutics, Inc. | Merck Sharp & Dohme LLC | 115 | INTERVENTIONAL | Providence Saint John’s Health Center, Santa Monica, California, 90404, United States|Boca Raton Regional Hospital, Boca Raton, Florida, 33486, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Emory – Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Scientia Clinical Research, Randwick, New South Wales, 2031, Australia|Macquarie University, Sydney, New South Wales, 2109, Australia|Gallipoli Medical Research Foundation, Greenslopes, Queensland, 4120, Australia|Princess Margaret Cancer Center, Toronto, Ontario, M4W 3E2, Canada |
| NCT03126630 | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT03126630 | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Anetumab Ravtansine|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab|OTHER: Pharmacological Study | National Cancer Institute (NCI) | 46 | INTERVENTIONAL | University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, 35233, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, 85054, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, 85259, United States|City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Los Angeles County-USC Medical Center, Los Angeles, California, 90033, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, 92663, United States|UCHealth University of Colorado Hospital, Aurora, Colorado, 80045, United States|UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, 33180, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, 33146, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, 33442, United States|Mayo Clinic in Florida, Jacksonville, Florida, 32224-9980, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, 33176, United States|UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, 33324, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, 63141, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, 63129, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, 63376, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada | ||
| NCT00040625 | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. | https://clinicaltrials.gov/study/NCT00040625 | APPROVED_FOR_MARKETING | DRUG: Pemetrexed|DRUG: Cisplatin | Eli Lilly and Company | EXPANDED_ACCESS | For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Basking Ridge, New Jersey, United States|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Porto Alegre, RS, Brazil|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Sao Paulo, Brazil|”For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.”, Cairo, Egypt|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Cairo, Egypt|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Jeddah, Saudi Arabia | |||
| NCT01950572 | Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT01950572 | RECRUITING | National Cancer Institute (NCI) | 1000 | OBSERVATIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | |||
| NCT03834272 | Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies | https://clinicaltrials.gov/study/NCT03834272 | RECRUITING | COMBINATION_PRODUCT: LUM Imaging System | Lumicell, Inc. | 30 | INTERVENTIONAL | Massachusetts General Hospital, Boston, Massachusetts, 02114, United States | ||
| NCT00061477 | Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT00061477 | COMPLETED | DRUG: Pemetrexed|DRUG: Gemcitabine | Eli Lilly and Company | 48 | INTERVENTIONAL | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States | ||
| NCT02153229 | Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02153229 | MPM-PDT | RECRUITING | RADIATION: Photodynamic Therapy|PROCEDURE: Radical Pleurectomy|RADIATION: Chemotherapy|DRUG: Photofrin 2.0 mg/kg | Abramson Cancer Center at Penn Medicine | 102 | INTERVENTIONAL | Rosewell Park, Buffalo, New York, 14263, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | |
| NCT00325494 | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | https://clinicaltrials.gov/study/NCT00325494 | COMPLETED | DRUG: MORAb-009 | Morphotek | 24 | INTERVENTIONAL | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231, United States|National Cancer Institute, Bethesda, Maryland, 20892-1922, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States | ||
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | https://clinicaltrials.gov/study/NCT01098266 | COMPLETED | DRUG: NGR-hTNF plus Best Investigator’s Choice (BIC)|DRUG: Placebo plus Best Investigator’s Choice (BIC) | AGC Biologics S.p.A. | 400 | INTERVENTIONAL | Wilshire Oncology Medical Group, Corona, California, 92879, United States|City of Hope-Comprehensive Cancer Cente, Duarte, California, 91010, United States|H. Lee Moffitt ancer Center and Research Institute, Tampa, Florida, 33612, United States|Johns Hopkins, Baltimore, Maryland, 21231, United States|Columbia University, New York, New York, 10032, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|UTsouthwestern medical center, Dallas, Texas, 75390, United States|Antwerp University Hospital, Edegem, Antwerp, B-2650, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Liege, 4000, Belgium|Institut Jules Bordet, Bruxelles, 1000, Belgium|Cliniques Universitarie St. Luc, Bruxelles, 1200, Belgium|Universitair Ziekenhuis, Gent, 9000, Belgium|UAB – Alberta Cancer Board – Cross Cancer Institute, Edmonton, Alberta, T6G1Z2, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, M5G2C4, Canada|National Cancer Institute, Cairo, 11796, Egypt|Hôpitaux de Marseille Hôpital Nord, Marseille, Cedex 20, France|St James’s Hospital, Dublin, Ireland|Ospedale Santo Spirito, Casale Monferrato, Alessandria, 15033, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Torino, 10043, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria, 15100, Italy|Centro di Riferimento Oncologico, Aviano, Italy|Ospedale Valduce, Como, Italy|Azienda Ospedaliero-Universitaria Careggi di Firenze, Firenze, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genoa, 16132, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST, Meldola, 47014, Italy|Fondazione San Raffaele del Monte Tabor, Milan, 20132, Italy|Azienda Ospedaliera San Gerardo, Monza, 20052, Italy|Istituto Oncologico Veneto, Padova, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Unità Sanitaria locale di Ravenna, Ravenna, 48100, Italy|A.O. Salvini Garbagnate, Ospedale di Rho, Rho, Italy|Azienda Ospedaliera Senese, Siena, 53100, Italy|St. Jansdal Hospital, Harderwijk, Gelderland, 3840, Netherlands|St. Antonius Hospital, Nieuwegein, Utrecht, 3435, Netherlands|Medical University of Gdansk, Gdansk, 80211, Poland|Maria Sklodowska Memorial Cancer Center and Institute of Oncology, Warsaw, 02-781, Poland|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital Vall d’Hebron, Barcelona, 08035, Spain|The University Hospital, Linkoping, 581 85, Sweden|Chest Clinic, Wythenshawe Hospital, Manchester, Greater Manchester, M23 9LT, United Kingdom|Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, ME16 9QQ, United Kingdom|University Hospitals of Leicester, Leicester, Leicestershire, LE0116, United Kingdom|Mount Vernon Cancer Centre, Middlesex, Northwood, HA6 2RN, United Kingdom|Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, EH4 2XU, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, G12, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Castle Hill Hospital, Cottingham, Yorkshire, HU16 5JQ, United Kingdom|Guy’s Hospital, London, SE1 9RT, United Kingdom|The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom | ||
| NCT02707666 | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02707666 | RECRUITING | DRUG: Pembrolizumab|DRUG: Cisplatin and Pemetrexed | University of Chicago | 15 | INTERVENTIONAL | University of Chicago, Chicago, Illinois, 60637, United States | ||
| NCT04926948 | Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma | https://clinicaltrials.gov/study/NCT04926948 | RECRUITING | OTHER: Immunotherapy|OTHER: Quality-of-Life Assessment|RADIATION: Stereotactic Body Radiation Therapy | Mayo Clinic | National Cancer Institute (NCI) | 20 | INTERVENTIONAL | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | |
| NCT02151448 | αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies | https://clinicaltrials.gov/study/NCT02151448 | COMPLETED | BIOLOGICAL: DC vaccine|DRUG: Celecoxib|DRUG: Interferon Alfa-2b|BIOLOGICAL: rintatolimod | David Bartlett | National Cancer Institute (NCI) | 64 | INTERVENTIONAL | UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States | |
| NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) | https://clinicaltrials.gov/study/NCT02357147 | ARTEMIS | TERMINATED | DRUG: Placebo|DRUG: Amatuximab|DRUG: Pemetrexed|DRUG: Cisplatin | Morphotek | 124 | INTERVENTIONAL | La Jolla, California, United States|Newark, Delaware, United States|Bethesda, Maryland, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Spokane, Washington, United States|Camperdown, New South Wales, Australia|Auchenflower, Queensland, Australia|Richmond, Victoria, 3121, Australia|Perth, Western Australia, Australia|Caen, France|Creteil, France|La Tronche, France|Lille, France|Lyon Cedex, France|Marseille, France|Rennes, France|Toulouse, France|Berlin, Germany|Esslingen, Germany|Frankfurt am Main, Germany|Gauting, Germany|Hamburg, Germany|Hanover, Germany|Löwenstein, Germany|Ulm, Germany|Wöhrendamm, Germany|Rozzano, Milano, Italy|Pisa, Paradisa 2, 56124, Italy|Alessandria, Italy|Aviano, Italy|Bari, Italy|Bergamo, Italy|Genoa, Italy|Genova, Italy|Monza, Italy|Orbassano, Italy|Parma, Italy|Maidstone, Kent, United Kingdom|Dundee, United Kingdom|Hereford, United Kingdom|Leicester, United Kingdom|London, United Kingdom|Middlesex, United Kingdom|Preston, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom|Taunton, United Kingdom | |
| NCT03975387 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | https://clinicaltrials.gov/study/NCT03975387 | ACTIVE_NOT_RECRUITING | DRUG: ASTX295 | Astex Pharmaceuticals, Inc. | 250 | INTERVENTIONAL | City of Hope Comprehensive Cancer Center Site#114, Duarte, California, 91010, United States|Cedars-Sinai Medical Center Site #105, Los Angeles, California, 90048, United States|Hoag Hospital Site#110, Newport Beach, California, 92663, United States|Holden Comprehensive Cancer Center Site#108, Iowa City, Iowa, 52242, United States|University of Michigan Rogel Cancer Center Site#109, Ann Arbor, Michigan, 48109, United States|Regions Cancer Center Site #115, Saint Paul, Minnesota, 55101, United States|Columbia University Irving Medical Center – Herbert Irving Pavilion Site#104, New York, New York, 10032, United States|University of Pennsylvania-Abramson Cancer Center Site#113, Philadelphia, Pennsylvania, 19104, United States|The University of Texas MD Anderson Cancer Center Site #102, Houston, Texas, 77030, United States|NEXT Oncology Site #101, San Antonio, Texas, 78229, United States|Virgnia Cancer Specialists Site #103, Fairfax, Virginia, 22031, United States | ||
| NCT01912547 | Thromboelastography During Surgery for Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01912547 | UNKNOWN | PROCEDURE: Blood draw for TEG analysis | Brigham and Women’s Hospital | 100 | OBSERVATIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States | ||
| NCT05579366 | PRO1184 for Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT05579366 | PRO1184-001 | RECRUITING | DRUG: PRO1184 | ProfoundBio US Co. | 134 | INTERVENTIONAL | University of California Los Angeles Medical Center, Los Angeles, California, 90095, United States|University of California, San Diego; Moores Cancer Center, San Diego, California, 92093, United States|Providence Medical Foundation, Santa Rosa, California, 95403, United States|University of Kansas Medical Center (KUMC), Westwood, Kansas, 66205, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Karmanos Cancer Institute, Detroit, Michigan, 48085, United States|University of Oklahoma – Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, 37203, United States|Mary Crowley Cancer Research, Dallas, Texas, 75521, United States|START Mountain Region, West Valley City, Utah, 84119, United States|Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Hunan Cancer Hospital – Phase 1, Changsha, Hunan, China|Hunan Cancer Hospital – Thoracic Medicine Dept II, Changsha, Hunan, China|Jilin Cancer Hospital, Chang chun, Jilin, China|Fudan University Shanghai Cancer Center- Gynecology Onc, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai, China | |
| NCT01188486 | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | https://clinicaltrials.gov/study/NCT01188486 | TERMINATED | RADIATION: Stereotactic Body Radiation Therapy (SBRT)|RADIATION: Computed Tomography (CT)|DEVICE: Cyberknife|DEVICE: Trilogy|DEVICE: True Beam|DRUG: Iohexol|DRUG: Iodixanol | Stanford University | 12 | INTERVENTIONAL | Stanford University School of Medicine, Stanford, California, 94305, United States | ||
| NCT00053885 | PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00053885 | COMPLETED | DRUG: PTK787/ZK 222584 | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 47 | INTERVENTIONAL | Northeast Alabama Regional Medical Center, Anniston, Alabama, 36207, United States|Veterans Affairs Medical Center – Birmingham, Birmingham, Alabama, 35233-1996, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States|Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Naval Medical Center – San Diego, San Diego, California, 92134-3202, United States|Veterans Affairs Medical Center – San Diego, San Diego, California, 92161, United States|UCSF Comprehensive Cancer Center, San Francisco, California, 94115, United States|Veterans Affairs Medical Center – San Francisco, San Francisco, California, 94121, United States|CCOP – Christiana Care Health Services, Newark, Delaware, 19713, United States|Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Walter Reed Army Medical Center, Washington, District of Columbia, 20307-5001, United States|Veterans Affairs Medical Center – Washington, DC, Washington, District of Columbia, 20422, United States|Broward General Medical Center, Fort Lauderdale, Florida, 33316, United States|Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, 33021, United States|CCOP – Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|MBCCOP – University of Illinois at Chicago, Chicago, Illinois, 60612, United States|Veterans Affairs Medical Center – Chicago (Westside Hospital), Chicago, Illinois, 60612, United States|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States|CCOP – Illinois Oncology Research Association, Peoria, Illinois, 61615-7828, United States|West Suburban Center for Cancer Care, River Forest, Illinois, 60305, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, 46885-5099, United States|CCOP – Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, 52242-1009, United States|Baptist Hospital East – Louisville, Louisville, Kentucky, 40207, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|UMASS Memorial Cancer Center – University Campus, Worcester, Massachusetts, 01655, United States|Lakeland Cancer Care Center at Lakeland Hospital – St. Joseph, Saint Joseph, Michigan, 49085, United States|Veterans Affairs Medical Center – Minneapolis, Minneapolis, Minnesota, 55417, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455, United States|Veterans Affairs Medical Center – Columbia (Truman Memorial), Columbia, Missouri, 65201, United States|Ellis Fischel Cancer Center at University of Missouri – Columbia, Columbia, Missouri, 65203, United States|CCOP – Kansas City, Kansas City, Missouri, 64131, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, 63131, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-7680, United States|CCOP – Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, 89106, United States|Veterans Affairs Medical Center – Las Vegas, Las Vegas, Nevada, 89106, United States|New Hampshire Oncology-Hematology, PA – Hooksett, Hooksett, New Hampshire, 03106, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0002, United States|Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, 08103, United States|Veterans Affairs Medical Center – Buffalo, Buffalo, New York, 14215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States|CCOP – Syracuse Hematology-Oncology Associates of Central New York, P.C., East Syracuse, New York, 13057, United States|Elmhurst Hospital Center, Elmhurst, New York, 11373, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, 11432, United States|CCOP – North Shore University Hospital, Manhasset, New York, 11030, United States|North Shore University Hospital, Manhasset, New York, 11030, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, 10021, United States|Mount Sinai Medical Center, New York, New York, 10029, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States|Veterans Affairs Medical Center – Syracuse, Syracuse, New York, 13210, United States|Veterans Affairs Medical Center – Asheville, Asheville, North Carolina, 28805, United States|Lineberger Comprehensive Cancer Center at University of North Carolina – Chapel Hill, Chapel Hill, North Carolina, 27599-7295, United States|NorthEast Oncology Associates – Concord, Concord, North Carolina, 28025, United States|Veterans Affairs Medical Center – Durham, Durham, North Carolina, 27705, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, 28302-2000, United States|CCOP – Southeast Cancer Control Consortium, Goldsboro, North Carolina, 27534-9479, United States|Lenoir Memorial Cancer Center, Kinston, North Carolina, 28503-1678, United States|Comprehensive Cancer Center at Moore Regional Hospital, Pinehurst, North Carolina, 28374, United States|Zimmer Cancer Center at New Hanover Regional Medical Center, Wilmington, North Carolina, 28402-9025, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, 27157-1082, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, 43210-1240, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, 15224, United States|Lifespan: The Miriam Hospital, Providence, Rhode Island, 02906, United States|University of Tennessee Cancer Institute at Methodist Central Hospital, Memphis, Tennessee, 38104, United States|Veterans Affairs Medical Center – Memphis, Memphis, Tennessee, 38104, United States|Veterans Affairs Medical Center – Dallas, Dallas, Texas, 75219, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center – Dallas, Dallas, Texas, 75390-8852, United States|Vermont Cancer Center at University of Vermont, Burlington, Vermont, 05401-3498, United States|Martha Jefferson Hospital, Charlottesville, Virginia, 22902, United States|Virginia Oncology Associates – Norfolk, Norfolk, Virginia, 23502, United States|MBCCOP – Massey Cancer Center, Richmond, Virginia, 23298-0037, United States|Oncology and Hematology Associates of Southwest Virginia, Incorporated – Roanoke, Roanoke, Virginia, 24014, United States|St. Mary’s Medical Center, Huntington, West Virginia, 25701, United States | |
| NCT00402766 | Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00402766 | COMPLETED | DRUG: Cisplatin|DRUG: Imatinib Mesylate|DRUG: Pemetrexed|DRUG: Dexamethasone | M.D. Anderson Cancer Center | Novartis | 19 | INTERVENTIONAL | University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | https://clinicaltrials.gov/study/NCT02349412 | COMPLETED | OTHER: Early palliative care | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 405 | INTERVENTIONAL | UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Queen’s Medical Center, Honolulu, Hawaii, 96813, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, 60201, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, 60026, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, 60035, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Mercy Health Saint Mary’s, Grand Rapids, Michigan, 49503, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Park Nicollet Clinic – Saint Louis Park, Saint Louis Park, Minnesota, 55416, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|North Shore-LIJ Health System/Center for Advanced Medicine, New Hyde Park, New York, 11040, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, 10032, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Altru Cancer Center, Grand Forks, North Dakota, 58201, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, 23298, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, 54601, United States|Marshfield Clinic, Marshfield, Wisconsin, 54449, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States | |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | https://clinicaltrials.gov/study/NCT01773655 | COMPLETED | OTHER: tumor specimens | Memorial Sloan Kettering Cancer Center | United States Department of Defense | 196 | OBSERVATIONAL | Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | https://clinicaltrials.gov/study/NCT02688166 | TERMINATED | OTHER: Complete Cardiac Magnetic Resonance Imaging (MRI) | University of Maryland, Baltimore | 6 | OBSERVATIONAL | Ummc Msgccc, Baltimore, Maryland, 21201, United States | ||
| NCT00017186 | Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00017186 | COMPLETED | DRUG: epirubicin hydrochloride|DRUG: gemcitabine hydrochloride | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 69 | INTERVENTIONAL | MBCCOP – Gulf Coast, Mobile, Alabama, 36607, United States|CCOP – Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, 85259-5404, United States|Mayo Clinic – Jacksonville, Jacksonville, Florida, 32224, United States|CCOP – Illinois Oncology Research Association, Peoria, Illinois, 61602, United States|CCOP – Carle Cancer Center, Urbana, Illinois, 61801, United States|CCOP – Cedar Rapids Oncology Project, Cedar Rapids, Iowa, 52403-1206, United States|CCOP – Iowa Oncology Research Association, Des Moines, Iowa, 50309-1016, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, 51101-1733, United States|CCOP – Wichita, Wichita, Kansas, 67214-3882, United States|CCOP – Ochsner, New Orleans, Louisiana, 70121, United States|CCOP – Michigan Cancer Research Consortium, Ann Arbor, Michigan, 48106, United States|CCOP – Duluth, Duluth, Minnesota, 55805, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States|Coborn Cancer Center, Saint Cloud, Minnesota, 56303, United States|CCOP – Metro-Minnesota, Saint Louis Park, Minnesota, 55416, United States|CCOP – Missouri Valley Cancer Consortium, Omaha, Nebraska, 68106, United States|Medcenter One Health System, Bismarck, North Dakota, 58501-5505, United States|CCOP – Merit Care Hospital, Fargo, North Dakota, 58122, United States|CCOP – Toledo Community Hospital, Toledo, Ohio, 43623-3456, United States|CCOP – Geisinger Clinic and Medical Center, Danville, Pennsylvania, 17822-2001, United States|CCOP – Upstate Carolina, Spartanburg, South Carolina, 29303, United States|Rapid City Regional Hospital, Rapid City, South Dakota, 57709, United States|CCOP – Sioux Community Cancer Consortium, Sioux Falls, South Dakota, 57104, United States|CCOP – St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, 54301, United States | |
| NCT04981119 | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | https://clinicaltrials.gov/study/NCT04981119 | BASECAMP-1 | RECRUITING | OTHER: Apheresis|DIAGNOSTIC_TEST: Next Generation Sequencing (NGS)|DIAGNOSTIC_TEST: Long Range NGS HLA typing | A2 Biotherapeutics Inc. | Tempus Labs | 200 | OBSERVATIONAL | Banner Health, Gilbert, Arizona, 85234, United States|City of Hope, Duarte, California, 90101, United States|University of California San Diego, La Jolla, California, 92093, United States|Stanford University, Palo Alto, California, 94305, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States|Moffitt Cancer Center, Tampa, Florida, 33136, United States|Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, 02114, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Washington University, Saint Louis, Missouri, 63110, United States|NYU Langone Medical Center, New York, New York, 10016, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States |
| NCT01356251 | Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma | https://clinicaltrials.gov/study/NCT01356251 | COMPLETED | BEHAVIORAL: Questionnaires & online virtual support group|BEHAVIORAL: Questionnaires & online virtual support group | Memorial Sloan Kettering Cancer Center | 107 | INTERVENTIONAL | Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | ||
| NCT01064648 | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01064648 | ACTIVE_NOT_RECRUITING | DRUG: Cediranib Maleate|DRUG: Cisplatin|OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium|OTHER: Placebo Administration | National Cancer Institute (NCI) | 117 | INTERVENTIONAL | Highlands Oncology Group – Rogers, Rogers, Arkansas, 72758, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, 94531, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, 91505, United States|Kaiser Permanente-Fremont, Fremont, California, 94538, United States|Kaiser Permanente-Fresno, Fresno, California, 93720, United States|Los Angeles County-USC Medical Center, Los Angeles, California, 90033, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Kaiser Permanente-Modesto, Modesto, California, 95356, United States|Kaiser Permanente-Oakland, Oakland, California, 94611, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Kaiser Permanente-Redwood City, Redwood City, California, 94063, United States|Kaiser Permanente-Richmond, Richmond, California, 94801, United States|Kaiser Permanente-Roseville, Roseville, California, 95661, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|Kaiser Permanente-South Sacramento, Sacramento, California, 95823, United States|Kaiser Permanente – Sacramento, Sacramento, California, 95825, United States|Kaiser Permanente-San Francisco, San Francisco, California, 94115, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, 95119, United States|Kaiser Permanente San Leandro, San Leandro, California, 94577, United States|Kaiser Permanente-San Rafael, San Rafael, California, 94903, United States|Kaiser Permanente Medical Center – Santa Clara, Santa Clara, California, 95051, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, 95403, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, 94080, United States|Kaiser Permanente-Stockton, Stockton, California, 95210, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, 95688, United States|Kaiser Permanente-Vallejo, Vallejo, California, 94589, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, 94596, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, 06105, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, 30501, United States|Pali Momi Medical Center, ‘Aiea, Hawaii, 96701, United States|Queen’s Cancer Center – Pearlridge, ‘Aiea, Hawaii, 96701, United States|Hawaii Cancer Care Inc – Waterfront Plaza, Honolulu, Hawaii, 96813, United States|Queen’s Medical Center, Honolulu, Hawaii, 96813, United States|Straub Clinic and Hospital, Honolulu, Hawaii, 96813, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, 96813, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, 96817, United States|Kuakini Medical Center, Honolulu, Hawaii, 96817, United States|Queen’s Cancer Center – Kuakini, Honolulu, Hawaii, 96817, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, 96819, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States|Castle Medical Center, Kailua, Hawaii, 96734, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, 96766, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, 83706, United States|Kootenai Health – Coeur d’Alene, Coeur d’Alene, Idaho, 83814, United States|Kootenai Clinic Cancer Services – Post Falls, Post Falls, Idaho, 83854, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, 83864, United States|Saint Joseph Medical Center, Bloomington, Illinois, 61701, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, 61704, United States|Illinois CancerCare-Canton, Canton, Illinois, 61520, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, 62902, United States|Illinois CancerCare-Carthage, Carthage, Illinois, 62321, United States|Centralia Oncology Clinic, Centralia, Illinois, 62801, United States|Cancer Care Specialists of Illinois – Decatur, Decatur, Illinois, 62526, United States|Decatur Memorial Hospital, Decatur, Illinois, 62526, United States|Heartland Cancer Research NCORP, Decatur, Illinois, 62526, United States|Crossroads Cancer Center, Effingham, Illinois, 62401, United States|Illinois CancerCare-Eureka, Eureka, Illinois, 61530, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, 61401, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, 61401, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, 61443, United States|Illinois CancerCare-Macomb, Macomb, Illinois, 61455, United States|Cancer Care Center of O’Fallon, O’Fallon, Illinois, 62269, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, 61350, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, 61350, United States|Illinois CancerCare-Pekin, Pekin, Illinois, 61554, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, 61554, United States|Illinois CancerCare-Peoria, Peoria, Illinois, 61615, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, 61615, United States|Methodist Medical Center of Illinois, Peoria, Illinois, 61636, United States|OSF Saint Francis Medical Center, Peoria, Illinois, 61637, United States|Illinois CancerCare-Peru, Peru, Illinois, 61354, United States|Valley Radiation Oncology, Peru, Illinois, 61354, United States|Illinois CancerCare-Princeton, Princeton, Illinois, 61356, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, 62702, United States|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States|Springfield Clinic, Springfield, Illinois, 62702, United States|Memorial Medical Center, Springfield, Illinois, 62781, United States|Franciscan Saint Francis Health-Beech Grove, Beech Grove, Indiana, 46107, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, 46237, United States|Reid Health, Richmond, Indiana, 47374, United States|Cotton O’Neil Cancer Center / Stormont Vail Health, Topeka, Kansas, 66606, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, 41017, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, 48106, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Beaumont Hospital – Dearborn, Dearborn, Michigan, 48124, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Ascension Saint John Hospital, Detroit, Michigan, 48236, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, 48334, United States|Genesys Hurley Cancer Institute, Flint, Michigan, 48503, United States|Hurley Medical Center, Flint, Michigan, 48503, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, 48532, United States|Allegiance Health, Jackson, Michigan, 49201, United States|Sparrow Hospital, Lansing, Michigan, 48912, United States|Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan, 48154, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, 48341, United States|Lake Huron Medical Center, Port Huron, Michigan, 48060, United States|Ascension Saint Mary’s Hospital, Saginaw, Michigan, 48601, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, 48093, United States|Singing River Hospital, Pascagoula, Mississippi, 39581, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, 63628, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, 63703, United States|Southeast Cancer Center, Cape Girardeau, Missouri, 63703, United States|Capital Region Southwest Campus, Jefferson City, Missouri, 65109, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, 63670, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, 63080, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, 63127, United States|Community Hospital of Anaconda, Anaconda, Montana, 59711, United States|Billings Clinic Cancer Center, Billings, Montana, 59101, United States|Saint Vincent Healthcare, Billings, Montana, 59101, United States|Montana Cancer Consortium NCORP, Billings, Montana, 59102, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Bozeman Deaconess Hospital, Bozeman, Montana, 59715, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, 59701, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, 59405, United States|Great Falls Clinic, Great Falls, Montana, 59405, United States|Saint Peter’s Community Hospital, Helena, Montana, 59601, United States|Glacier Oncology PLLC, Kalispell, Montana, 59901, United States|Kalispell Regional Medical Center, Kalispell, Montana, 59901, United States|Montana Cancer Specialists, Missoula, Montana, 59802, United States|Saint Patrick Hospital – Community Hospital, Missoula, Montana, 59802, United States|Community Medical Hospital, Missoula, Montana, 59804, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, 28204, United States|Novant Health Carolina Surgical – Randolph, Charlotte, North Carolina, 28207, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, 28207, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, 28262, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, 28791, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, 28791, United States|Novant Health Cancer Institute – Huntersville, Huntersville, North Carolina, 28078, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, 28078, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, 28105, United States|Novant Health Cancer Institute – Matthews, Matthews, North Carolina, 28105, United States|Novant Health Cancer Institute – Mooresville, Mooresville, North Carolina, 28117, United States|Iredell Memorial Hospital, Statesville, North Carolina, 28677, United States|Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Carolina, 27104, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, 45714, United States|Adena Regional Medical Center, Chillicothe, Ohio, 45601, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, 45202, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, 45211, United States|Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio, 45230, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, 45236, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, 45242, United States|Mount Carmel East Hospital, Columbus, Ohio, 43213, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, 43214, United States|Riverside Methodist Hospital, Columbus, Ohio, 43214, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, 43215, United States|Grant Medical Center, Columbus, Ohio, 43215, United States|The Mark H Zangmeister Center, Columbus, Ohio, 43219, United States|Mount Carmel Health Center West, Columbus, Ohio, 43222, United States|Doctors Hospital, Columbus, Ohio, 43228, United States|Grandview Hospital, Dayton, Ohio, 45405, United States|Good Samaritan Hospital – Dayton, Dayton, Ohio, 45406, United States|Miami Valley Hospital, Dayton, Ohio, 45409, United States|Miami Valley Hospital North, Dayton, Ohio, 45415, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, 45459, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, 43015, United States|Delaware Radiation Oncology, Delaware, Ohio, 43015, United States|Grady Memorial Hospital, Delaware, Ohio, 43015, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, 45014, United States|Blanchard Valley Hospital, Findlay, Ohio, 45840, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, 45005-1066, United States|Wayne Hospital, Greenville, Ohio, 45331, United States|Kettering Medical Center, Kettering, Ohio, 45429, United States|Fairfield Medical Center, Lancaster, Ohio, 43130, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, 44903, United States|Marietta Memorial Hospital, Marietta, Ohio, 45750, United States|OhioHealth Marion General Hospital, Marion, Ohio, 43302, United States|Knox Community Hospital, Mount Vernon, Ohio, 43050, United States|Licking Memorial Hospital, Newark, Ohio, 43055, United States|Newark Radiation Oncology, Newark, Ohio, 43055, United States|Southern Ohio Medical Center, Portsmouth, Ohio, 45662, United States|Springfield Regional Medical Center, Springfield, Ohio, 45505, United States|Upper Valley Medical Center, Troy, Ohio, 45373, United States|Saint Ann’s Hospital, Westerville, Ohio, 43081, United States|Greene Memorial Hospital, Xenia, Ohio, 45385, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, 43701, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, 97015, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, 97222, United States|Providence Newberg Medical Center, Newberg, Oregon, 97132, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, 97045, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Providence Saint Vincent Medical Center, Portland, Oregon, 97225, United States|Prisma Health Cancer Institute – Spartanburg, Boiling Springs, South Carolina, 29316, United States|Prisma Health Cancer Institute – Easley, Easley, South Carolina, 29640, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, 29601, United States|Prisma Health Cancer Institute – Butternut, Greenville, South Carolina, 29605, United States|Prisma Health Cancer Institute – Faris, Greenville, South Carolina, 29605, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, 29605, United States|Prisma Health Cancer Institute – Eastside, Greenville, South Carolina, 29615, United States|Prisma Health Cancer Institute – Greer, Greer, South Carolina, 29650, United States|Prisma Health Cancer Institute – Seneca, Seneca, South Carolina, 29672, United States|Bristol Regional Medical Center, Bristol, Tennessee, 37620, United States|Wellmont Medical Associates Oncology and Hematology-Bristol, Bristol, Tennessee, 37620, United States|Wellmont Medical Associates Oncology and Hematology-Johnson City, Johnson City, Tennessee, 37604, United States|Ballad Health Cancer Care – Kingsport, Kingsport, Tennessee, 37660, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, 37660, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Danville Regional Medical Center, Danville, Virginia, 24541, United States|Southwest VA Regional Cancer Center, Norton, Virginia, 24273, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, 98221, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, 98225, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, 98310, United States|Highline Medical Center-Main Campus, Burien, Washington, 98166, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, 98026, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, 98029, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, 99336, United States|Seattle Cancer Care Alliance at EvergreenHealth, Kirkland, Washington, 98034, United States|PeaceHealth Saint John Medical Center, Longview, Washington, 98632, United States|Skagit Valley Hospital, Mount Vernon, Washington, 98274, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, 98370, United States|Harborview Medical Center, Seattle, Washington, 98104, United States|Minor and James Medical PLLC, Seattle, Washington, 98104, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, 98107, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Kaiser Permanente Washington, Seattle, Washington, 98112, United States|Swedish Medical Center-First Hill, Seattle, Washington, 98122, United States|University of Washington Medical Center – Montlake, Seattle, Washington, 98195, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, 98284, United States|Cancer Care Northwest – Spokane South, Spokane, Washington, 99202, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, 99218, United States|Rockwood Clinic, Spokane, Washington, 99220, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, 98664, United States|Compass Oncology Vancouver, Vancouver, Washington, 98684, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, 98801, United States|Rocky Mountain Oncology, Casper, Wyoming, 82609, United States|Big Horn Basin Cancer Center, Cody, Wyoming, 82414, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States | ||
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | https://clinicaltrials.gov/study/NCT04088786 | COMPLETED | DRUG: nanoliposomal irinotecan | Stony Brook University | Ipsen|Barbara Ann Karmanos Cancer Institute|University of Iowa | 18 | INTERVENTIONAL | University of Kentucky, Lexington, Kentucky, 40536, United States|Stony Brook University Cancer Center, Stony Brook, New York, 11794, United States | |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT03023319 | COMPLETED | DRUG: Bosutinib|DRUG: Pemetrexed | Nagla Abdel Karim | 6 | INTERVENTIONAL | Augusta University Georgia Cancer Center, Augusta, Georgia, 30912, United States | ||
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02611037 | ACTIVE_NOT_RECRUITING | DRUG: Cisplatin|DRUG: Methotrexate|DRUG: Gemcitabine|OTHER: Lung Cancer Symptom Scale for Mesothelioma Questionnaire | H. Lee Moffitt Cancer Center and Research Institute | 34 | INTERVENTIONAL | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 22612, United States | ||
| NCT01265433 | WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | https://clinicaltrials.gov/study/NCT01265433 | COMPLETED | BIOLOGICAL: WT-1-vaccine Montanide + GM-CSF|BIOLOGICAL: Montanide adjuvant + GM-CSF (This arm is closed) | Sellas Life Sciences Group | United States Department of Defense | 31 | INTERVENTIONAL | Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | https://clinicaltrials.gov/study/NCT01413451 | TERMINATED | DRUG: Amatuximab (MORab-009) | National Cancer Institute (NCI) | 7 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | https://clinicaltrials.gov/study/NCT02535312 | ACTIVE_NOT_RECRUITING | DRUG: Cisplatin|DRUG: Methoxyamine|DRUG: Pemetrexed Disodium | National Cancer Institute (NCI) | 30 | INTERVENTIONAL | City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|Los Angeles County-USC Medical Center, Los Angeles, California, 90033, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Keck Medical Center of USC Pasadena, Pasadena, California, 91105, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|UCHealth University of Colorado Hospital, Aurora, Colorado, 80045, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37204, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, 53792, United States | ||
| NCT00165555 | Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00165555 | COMPLETED | DRUG: Cisplatin|DRUG: Sodium Thiosulfate | Dana-Farber Cancer Institute | Brigham and Women’s Hospital | 70 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States | |
| NCT04162015 | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | https://clinicaltrials.gov/study/NCT04162015 | RECRUITING | DRUG: Nivolumab|DRUG: Pemetrexed|DRUG: Cisplatin or Carboplatin | Memorial Sloan Kettering Cancer Center | Bristol-Myers Squibb | 35 | INTERVENTIONAL | Memoiral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States | |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | https://clinicaltrials.gov/study/NCT02859415 | TERMINATED | DRUG: Mithramycin | National Cancer Institute (NCI) | 3 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | https://clinicaltrials.gov/study/NCT05703854 | RECRUITING | DRUG: CAR.70/IL15-transduced CB-derived NK cells|DRUG: Fludarabine phosphate|DRUG: Cyclophosphamide | M.D. Anderson Cancer Center | 50 | INTERVENTIONAL | M D Anderson Cancer Center, Houston, Texas, 77030, United States | ||
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | https://clinicaltrials.gov/study/NCT00423254 | COMPLETED | BIOLOGICAL: PSMA/PRAME|BIOLOGICAL: PSMA/PRAME | Mannkind Corporation | 12 | INTERVENTIONAL | Arizona Cancer Center, Tuscon, Arizona, 85724-5024, United States|Lombardi Comprehensive Cancer Center at Georgetown, Washington, District of Columbia, 20057, United States|H Lee Moffitt Cancer Center University of So Florida, Tampa, Florida, 33612, United States|Nevada Cancer Institute, Sparks, Nevada, 89431, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States | ||
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00738582 | Amatuximab | COMPLETED | DRUG: MORAb-009 (Amatuximab)|DRUG: Pemetrexed|DRUG: Cisplatin | Morphotek | 89 | INTERVENTIONAL | University of Alabama, Birmingham, Birmingham, Alabama, 35294, United States|University of California, San Diego, La Jolla, California, 92093, United States|UCLA Medical Hematology & Oncology, Los Angeles, California, 90095, United States|University of California, San Francisco, San Francisco, California, 94115, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Christiana Care Health System, Newark, Delaware, 19713, United States|Emory University School of Medicine, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Johns Hopkins University–Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|NIH/National Cancer Institute, Bethesda, Maryland, 20892, United States|Columbia University Medical Center, New York, New York, 10032, United States|Mary Babb Randolph Cancer Center, Morgantown, West Virginia, 26506, United States|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|Hopital Laval, Quebec, PQ, G1V 3E6, Canada|HELIOS Klinikum Emil von Behring, Berlin, 14165, Germany|Asklepios Fachkliniken Müchen-Gauting, Gauting, 82131, Germany|Krankenhaus Großhansdorf, Großhansdorf, 22927, Germany|Asklepios Klinik Harburg, Hamburg, 21075, Germany|Medizinsche Hochschule Hannover, Hannover, 30625, Germany|Fachklinik für Lungenerkrankungen Immenhausen, Immenhausen, 34376, Germany|Medizinische Klinik (Hämatologie/Onkologie), München, 81657, Germany|Medisch Spectrum Twente, Enschede, 7513 ER, Netherlands|Erasmus MC, Rotterdam, 3015 CE, Netherlands|H. de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Consorci Sanitari Parc Taulí, Barcelona, 08208, Spain|H. Son Dureta, Palma de Mallorca, 07014, Spain|Clínica Universitaria de Navarra, Pamplona, 31008, Spain|H. Virgen del Rocío, Sevilla, 41013, Spain | |
| NCT00165516 | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate | https://clinicaltrials.gov/study/NCT00165516 | COMPLETED | DRUG: Cisplatin|DRUG: Sodium Thiosulfate | Dana-Farber Cancer Institute | Brigham and Women’s Hospital | 85 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States | |
| NCT00375245 | Rapamycin With Grapefruit Juice for Advanced Malignancies | https://clinicaltrials.gov/study/NCT00375245 | COMPLETED | DRUG: Rapamycin (sirolimus)|OTHER: Grapefruit Juice | University of Chicago | 41 | INTERVENTIONAL | University of Chicago Hospitals, Chicago, Illinois, 60637, United States | ||
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | https://clinicaltrials.gov/study/NCT04670445 | UPLIFT | ACTIVE_NOT_RECRUITING | OTHER: Educational Video and QPL List|OTHER: Usual Care | Massachusetts General Hospital | Conquer Cancer Foundation | 210 | INTERVENTIONAL | Massachusetts General Hospital, Boston, Massachusetts, 02115, United States |
| NCT01258868 | Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas | https://clinicaltrials.gov/study/NCT01258868 | TERMINATED | DRUG: Celebrex|BIOLOGICAL: Tumor cell vaccine | National Cancer Institute (NCI) | 44 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | https://clinicaltrials.gov/study/NCT02159716 | COMPLETED | BIOLOGICAL: CART-meso | University of Pennsylvania | 19 | INTERVENTIONAL | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT05730816 | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI | https://clinicaltrials.gov/study/NCT05730816 | MAGIC-AKI | RECRUITING | DRUG: Magnesium sulfate|DRUG: Normal Saline | Brigham and Women’s Hospital | National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 130 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02130, United States |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | https://clinicaltrials.gov/study/NCT02408016 | TERMINATED | BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|DRUG: Cyclophosphamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Therapeutic Conventional Surgery | Fred Hutchinson Cancer Center | National Cancer Institute (NCI) | 11 | INTERVENTIONAL | Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States | |
| NCT04537715 | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | https://clinicaltrials.gov/study/NCT04537715 | COMPLETED | DRUG: Tazemetostat|DRUG: Itraconazole|DRUG: Tazemetostat|DRUG: Rifampin | Epizyme, Inc. | 42 | INTERVENTIONAL | California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, 92024, United States|The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, 60611, United States|South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, 49546, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45267, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|Onkologikoa, Donostia, Gipuzkoa, 20014, Spain|Hospital Universitario Vall d’Hebron, Barcelona, 08035, Spain|Hospital Fundacion Jimenez Diaz, Madrid, 28040, Spain | ||
| NCT03717415 | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT03717415 | UNKNOWN | DRUG: rebastinib|DRUG: Carboplatin | Deciphera Pharmaceuticals LLC | 117 | INTERVENTIONAL | University of California San Francisco (UCSF), San Francisco, California, 94115, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|The Ohio State University, Columbus, Ohio, 43210, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, San Antonio, Texas, 78240, United States | ||
| NCT03678350 | Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | https://clinicaltrials.gov/study/NCT03678350 | RECRUITING | DEVICE: Light Dosimetry for Intranoperative Therapy|PROCEDURE: Photodynamic Therapy|DRUG: Porfimer Sodium | Roswell Park Cancer Institute | Lumeda,Inc. | 12 | INTERVENTIONAL | Roswell Park Cancer Institute, Buffalo, New York, 14263, United States | |
| NCT04840615 | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT04840615 | RECRUITING | BIOLOGICAL: LMB-100|DRUG: ipilimumab | National Cancer Institute (NCI) | 20 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT04214015 | A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma | https://clinicaltrials.gov/study/NCT04214015 | UNKNOWN | OTHER: No intervention | ProgenaBiome | 100 | OBSERVATIONAL | ProgenaBiome, Ventura, California, 93003, United States | ||
| NCT00538850 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | https://clinicaltrials.gov/study/NCT00538850 | COMPLETED | DRUG: Fentanyl sublingual spray|DRUG: Placebo | INSYS Therapeutics Inc | National Cancer Institute (NCI) | 130 | INTERVENTIONAL | InSys Therapeutics, Incorporated, Chandler, Arizona, 85224, United States | |
| NCT03644550 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT03644550 | TERMINATED | DRUG: LMB-100|BIOLOGICAL: Pembrolizumab | National Cancer Institute (NCI) | 18 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | https://clinicaltrials.gov/study/NCT03760575 | RECRUITING | DRUG: Pembrolizumab|PROCEDURE: Indocyanine Green (ICG) Image-Guided Surgery|DRUG: Cisplatin|DRUG: Pemetrexed | Abramson Cancer Center at Penn Medicine | 20 | INTERVENTIONAL | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT01271959 | A Study of ChemoFx® Chemoresponse Assay in Solid Tumors – ChemoFx® Registry Study | https://clinicaltrials.gov/study/NCT01271959 | TERMINATED | Precision Therapeutics | 167 | OBSERVATIONAL | Cardio-Thoracic Surgeons, P.C., Birmingham, Alabama, 35213, United States|Hematology Oncology Associates, Oakland, California, 94609, United States|Collaborative Research Group, Boynton Beach, Florida, 33435, United States|Broward Oncology Associates, P.A., Fort Lauderdale, Florida, 33308, United States|The Center For Gynecologic Oncology, Hollywood, Florida, 33021, United States|GYN Oncology of Miami, Miami, Florida, 33143, United States|Miami International Surgical Services, Miami, Florida, 33173, United States|Orlando Cardiovascular Institute PA, Orlando, Florida, 32804, United States|Edward H. Kaplan, M.D. & Associates, Skokie, Illinois, 60076, United States|Iowa Clinic, Des Moines, Iowa, 50309, United States|Central Baptist Hospital Clinical Research Center, Lexington, Kentucky, 40503, United States|Oncology Associates of West Kentucky, Paducah, Kentucky, 42003, United States|Grand Blanc Surgical Specialist, Grand Blanc, Michigan, 48439, United States|Albany Thoracic & Esophageal Surgery, Albany, New York, 12208, United States|North Shore Hematology Oncology, East Setauket, New York, 11733, United States|The New York Hospital Medical Center of Queens, Flushing, New York, 11355, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Center for Clinical Research and Technology University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States|The Regional Cancer Center, Erie, Pennsylvania, 16505, United States|Barry S Siller MD, Houston, Texas, 77024, United States|Colorectal Surgical Associates, Houston, Texas, 77054, United States|Northwest Cancer Center, Houston, Texas, 77090, United States|Cancer Care Centers of South Texas, San Antonio, Texas, 78229, United States|Cancer Care Northwest, Spokane, Washington, 99202, United States|Heiskell, King, Burns & Tallman Surgical Associates, Inc., Morgantown, West Virginia, 26508, United States | |||
| NCT04525859 | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT04525859 | RECRUITING | BIOLOGICAL: Safety|BIOLOGICAL: Expansion Cohort | Oncovir, Inc. | Icahn School of Medicine at Mount Sinai | 19 | INTERVENTIONAL | Icahn School of Medicine Mount Sinai, New York, New York, 10029, United States | |
| NCT04115254 | Stereotactic Magnetic Resonance Guided Radiation Therapy | https://clinicaltrials.gov/study/NCT04115254 | RECRUITING | RADIATION: MR-guided Linac | Dana-Farber Cancer Institute | 397 | INTERVENTIONAL | Brigham & Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States | ||
| NCT00037817 | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | https://clinicaltrials.gov/study/NCT00037817 | COMPLETED | DRUG: Decitabine|BIOLOGICAL: Depsipeptide|DRUG: Celecoxib | National Cancer Institute (NCI) | 34 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT05228015 | RECRUITING | DRUG: IK-930 | Ikena Oncology | 158 | INTERVENTIONAL | Massachusetts General Hospital, Boston, Massachusetts, 02215, United States|Start Midwest, Grand Rapids, Michigan, 49546, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Next Oncology, San Antonio, Texas, 78229, United States | ||
| NCT00027703 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00027703 | COMPLETED | DRUG: gemcitabine hydrochloride|DRUG: cisplatin|BIOLOGICAL: bevacizumab|OTHER: placebo|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 106 | INTERVENTIONAL | University of Chicago, Chicago, Illinois, 60637, United States | ||
| NCT01204203 | Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) | https://clinicaltrials.gov/study/NCT01204203 | UAB0901 | COMPLETED | DRUG: Zometa | University of Alabama at Birmingham | Novartis Pharmaceuticals | 8 | INTERVENTIONAL | University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States |
| NCT04450043 | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance | https://clinicaltrials.gov/study/NCT04450043 | ACTIVE_NOT_RECRUITING | BEHAVIORAL: Run-In Sessions 1-5|BEHAVIORAL: RCT Transitions Program Sessions 1-5|BEHAVIORAL: RCT Control Session | Massachusetts General Hospital | 21 | INTERVENTIONAL | Massachusetts General Hospital, Boston, Massachusetts, 02115, United States | ||
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT04201145 | WITHDRAWN | DRUG: Pembrolizumab|DRUG: Defactinib | Raphael Bueno, MD | Merck Sharp & Dohme LLC | 0 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States | |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | https://clinicaltrials.gov/study/NCT01143545 | TERMINATED | BIOLOGICAL: Allogeneic Tumor Cell Vaccine (K562)|DRUG: Celecoxib|DRUG: cyclophosphamide | National Cancer Institute (NCI) | 10 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT03399552 | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT03399552 | COMPLETED | DRUG: Avelumab|RADIATION: Stereotactic Body Radiation Therapy | Memorial Sloan Kettering Cancer Center | Pfizer | 15 | INTERVENTIONAL | Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, 11570, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States | |
| NCT00025207 | Gefitinib in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00025207 | COMPLETED | DRUG: gefitinib|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 40 | INTERVENTIONAL | Cancer and Leukemia Group B, Chicago, Illinois, 60606, United States | ||
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT05238883 | RECRUITING | DRUG: HFB200301|DRUG: Tislelizumab | HiFiBiO Therapeutics | 170 | INTERVENTIONAL | Mayo Clinic, Scottsdale, Arizona, 85259, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Hospital Universitario Vall d’Hebron, Barcelona, 08035, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain | ||
| NCT02672033 | Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02672033 | TERMINATED | RADIATION: Hypofractionated Radiation Therapy|RADIATION: Intensity-Modulated Radiation Therapy|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Therapeutic Conventional Surgery | Jonsson Comprehensive Cancer Center | 2 | INTERVENTIONAL | UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States | ||
| NCT00101283 | Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00101283 | COMPLETED | DRUG: pemetrexed disodium|DRUG: gemcitabine hydrochloride|DRUG: carboplatin | Eastern Cooperative Oncology Group | National Cancer Institute (NCI)|North Central Cancer Treatment Group | 32 | INTERVENTIONAL | Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, 06360, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, 19958, United States|CCOP – Christiana Care Health Services, Newark, Delaware, 19713, United States|Mayo Clinic – Jacksonville, Jacksonville, Florida, 32224, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, 60504, United States|St. Joseph Medical Center, Bloomington, Illinois, 61701, United States|Graham Hospital, Canton, Illinois, 61520, United States|Memorial Hospital, Carthage, Illinois, 62321, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, 62526, United States|Eureka Community Hospital, Eureka, Illinois, 61530, United States|Galesburg Clinic, PC, Galesburg, Illinois, 61401, United States|Galesburg Cottage Hospital, Galesburg, Illinois, 61401, United States|Mason District Hospital, Havana, Illinois, 62644, United States|Hopedale Medical Complex, Hopedale, Illinois, 61747, United States|Joliet Oncology-Hematology Associates, Limited – West, Joliet, Illinois, 60435, United States|Kewanee Hospital, Kewanee, Illinois, 61443, United States|McDonough District Hospital, Macomb, Illinois, 61455, United States|Trinity Cancer Center at Trinity Medical Center – 7th Street Campus, Moline, Illinois, 61265, United States|BroMenn Regional Medical Center, Normal, Illinois, 61761, United States|Community Cancer Center, Normal, Illinois, 61761, United States|Community Hospital of Ottawa, Ottawa, Illinois, 61350, United States|Oncology Hematology Associates of Central Illinois, PC – Ottawa, Ottawa, Illinois, 61350, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, 61554, United States|Proctor Hospital, Peoria, Illinois, 61614, United States|CCOP – Illinois Oncology Research Association, Peoria, Illinois, 61615, United States|Oncology Hematology Associates of Central Illinois, PC – Peoria, Peoria, Illinois, 61615, United States|Methodist Medical Center of Illinois, Peoria, Illinois, 61636, United States|OSF St. Francis Medical Center, Peoria, Illinois, 61637, United States|Illinois Valley Community Hospital, Peru, Illinois, 61354, United States|Perry Memorial Hospital, Princeton, Illinois, 61356, United States|St. Margaret’s Hospital, Spring Valley, Illinois, 61362, United States|Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, 62781-0001, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, 61801, United States|CCOP – Carle Cancer Center, Urbana, Illinois, 61801, United States|Elkhart General Hospital, Elkhart, Indiana, 46515, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202-5289, United States|Veterans Affairs Medical Center – Indianapolis, Indianapolis, Indiana, 46202, United States|William N. Wishard Memorial Hospital, Indianapolis, Indiana, 46202, United States|Howard Community Hospital, Kokomo, Indiana, 46904, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, 46350, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, 46360, United States|CCOP – Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States|Memorial Hospital of South Bend, South Bend, Indiana, 46601, United States|Saint Joseph Regional Medical Center, South Bend, Indiana, 46617, United States|McFarland Clinic, PC, Ames, Iowa, 50010, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, 52403, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, 51101, United States|Mercy Medical Center – Sioux City, Sioux City, Iowa, 51104, United States|St. Luke’s Regional Medical Center, Sioux City, Iowa, 51104, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231-2410, United States|Union Hospital Cancer Program at Union Hospital, Elkton, Maryland, 21921, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, 48106-0995, United States|CCOP – Michigan Cancer Research Consortium, Ann Arbor, Michigan, 48106, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, 48123-2500, United States|Genesys Hurley Cancer Institute, Flint, Michigan, 48503, United States|Hurley Medical Center, Flint, Michigan, 48503, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, 48236, United States|Foote Memorial Hospital, Jackson, Michigan, 49201, United States|Borgess Medical Center, Kalamazoo, Michigan, 49001, United States|West Michigan Cancer Center, Kalamazoo, Michigan, 49007-3731, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States|Sparrow Regional Cancer Center, Lansing, Michigan, 48912-1811, United States|Seton Cancer Institute at Saint Mary’s – Saginaw, Saginaw, Michigan, 48601, United States|Lakeland Regional Cancer Care Center – St. Joseph, Saint Joseph, Michigan, 49085, United States|St. John Macomb Hospital, Warren, Michigan, 48093, United States|Fairview Ridges Hospital, Burnsville, Minnesota, 55337, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, 55433, United States|Duluth Clinic Cancer Center – Duluth, Duluth, Minnesota, 55805-1983, United States|CCOP – Duluth, Duluth, Minnesota, 55805, United States|Miller – Dwan Medical Center, Duluth, Minnesota, 55805, United States|Fairview Southdale Hospital, Edina, Minnesota, 55435, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, 55432, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, 55350, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, 55355, United States|HealthEast Cancer Care at St. John’s Hospital, Maplewood, Minnesota, 55109, United States|Minnesota Oncology Hematology, PA – Maplewood, Maplewood, Minnesota, 55109, United States|Virginia Piper Cancer Institute at Abbott – Northwestern Hospital, Minneapolis, Minnesota, 55407, United States|Hennepin County Medical Center – Minneapolis, Minneapolis, Minnesota, 55415, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, 55422-2900, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States|CCOP – Metro-Minnesota, Saint Louis Park, Minnesota, 55416, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, 55416, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, 55101, United States|HealthEast Cancer Care at St. Joseph’s Hospital, Saint Paul, Minnesota, 55102, United States|United Hospital, Saint Paul, Minnesota, 55102, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, 55379, United States|Ridgeview Medical Center, Waconia, Minnesota, 55387, United States|HealthEast Cancer Care at Woodwinds Health Campus, Woodbury, Minnesota, 55125, United States|Minnesota Oncology Hematology, PA – Woodbury, Woodbury, Minnesota, 55125, United States|Veterans Affairs Medical Center – East Orange, East Orange, New Jersey, 07018-1095, United States|CCOP – Northern New Jersey, Hackensack, New Jersey, 07601, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton, Marlton, New Jersey, 08053, United States|Cancer Institute of New Jersey at UMDNJ – Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08903, United States|Cancer Institute of New Jersey at Cooper – Voorhees, Voorhees, New Jersey, 08043, United States|Fox Chase Virtua Health Cancer Program at Virtua West Jersey, Voorhees, New Jersey, 08043, United States|Bismarck Cancer Center, Bismarck, North Dakota, 58501, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, 58501, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, 58501, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, 58502, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, 44309-2090, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, 44710-1799, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, 44106-5065, United States|St. Rita’s Medical Center, Lima, Ohio, 45801, United States|Morgan Cancer Center at Lehigh Valley Hospital – Cedar Crest, Allentown, Pennsylvania, 18105, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033-0850, United States|Lewistown Hospital, Lewistown, Pennsylvania, 17044, United States|Fox Chase Cancer Center – Philadelphia, Philadelphia, Pennsylvania, 19111-2497, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, 19141, United States|Mount Nittany Medical Center, State College, Pennsylvania, 16803, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, 57105, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, 57117-5039, United States|Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, 54601, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, 53792-6164, United States | |
| NCT02639767 | Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02639767 | WITHDRAWN | DRUG: Pemetrexed/Cisplatin|RADIATION: Pleural Intensity Modulated Radiation Therapy|DEVICE: MRI | Memorial Sloan Kettering Cancer Center | 0 | INTERVENTIONAL | Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, 11725, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, 10591, United States|Memorial Sloan Kettering West Harrison, West Harrison, New York, 10604, United States | ||
| NCT01212367 | Intrapleural Gene Transfer for Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01212367 | IFN-alpha | COMPLETED | BIOLOGICAL: SCH 721015|BIOLOGICAL: SCH 721015 | Abramson Cancer Center at Penn Medicine | National Cancer Institute (NCI) | 13 | INTERVENTIONAL | University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States |
| NCT00603356 | Phase I Study of OSI-930 and Erlotinib in Cancer Tumors | https://clinicaltrials.gov/study/NCT00603356 | COMPLETED | DRUG: OSI-930 and erlotinib | Astellas Pharma Inc | OSI Pharmaceuticals | 60 | INTERVENTIONAL | H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom | |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | https://clinicaltrials.gov/study/NCT05647265 | RECRUITING | BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|PROCEDURE: Surgical Procedure|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 26 | INTERVENTIONAL | Kingman Regional Medical Center, Kingman, Arizona, 86401, United States|PCR Oncology, Arroyo Grande, California, 93420, United States|Beebe South Coastal Health Campus, Frankford, Delaware, 19945, United States|Beebe Medical Center, Lewes, Delaware, 19958, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, 19713, United States|Helen F Graham Cancer Center, Newark, Delaware, 19713, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, 19713, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, 19718, United States|Beebe Health Campus, Rehoboth Beach, Delaware, 19971, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, 19801, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, 60115, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, 60134, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, 60045, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, 60555, United States|Christiana Care – Union Hospital, Elkton, Maryland, 21921, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, 89703, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada – Henderson, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, 89052, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, 89052, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, 89074, United States|GenesisCare USA – Henderson, Henderson, Nevada, 89074, United States|Las Vegas Urology – Green Valley, Henderson, Nevada, 89074, United States|Las Vegas Urology – Pebble, Henderson, Nevada, 89074, United States|Urology Specialists of Nevada – Green Valley, Henderson, Nevada, 89074, United States|Las Vegas Urology – Pecos, Las Vegas, Nevada, 89074, United States|OptumCare Cancer Care at Charleston, Las Vegas, Nevada, 89102, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, 89102, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, 89103, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, 89106, United States|Urology Specialists of Nevada – Central, Las Vegas, Nevada, 89106, United States|GenesisCare USA – Las Vegas, Las Vegas, Nevada, 89109, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, 89109, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, 89113, United States|Las Vegas Urology – Sunset, Las Vegas, Nevada, 89113, United States|Urology Specialists of Nevada – Southwest, Las Vegas, Nevada, 89113, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, 89119, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, 89128, United States|Comprehensive Cancer Centers of Nevada – Northwest, Las Vegas, Nevada, 89128, United States|GenesisCare USA – Vegas Tenaya, Las Vegas, Nevada, 89128, United States|Las Vegas Urology – Cathedral Rock, Las Vegas, Nevada, 89128, United States|Las Vegas Urology – Smoke Ranch, Las Vegas, Nevada, 89128, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, 89128, United States|Urology Specialists of Nevada – Northwest, Las Vegas, Nevada, 89128, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States|Comprehensive Cancer Centers of Nevada – Town Center, Las Vegas, Nevada, 89144, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, 89144, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, 89144, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, 89148-2405, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|GenesisCare USA – Fort Apache, Las Vegas, Nevada, 89148, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, 89148, United States|Comprehensive Cancer Centers of Nevada – Central Valley, Las Vegas, Nevada, 89169, United States|University Cancer Center, Las Vegas, Nevada, 89169, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, 89048, United States|Renown Regional Medical Center, Reno, Nevada, 89502, United States|Saint Mary’s Regional Medical Center, Reno, Nevada, 89503, United States|Radiation Oncology Associates, Reno, Nevada, 89509, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, 19317, United States|Overlake Medical Center, Bellevue, Washington, 98004, United States|Valley Medical Center, Renton, Washington, 98055, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, 98902, United States | |
| NCT00004033 | Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00004033 | COMPLETED | DRUG: liposomal NDDP|PROCEDURE: therapeutic thoracoscopy | NYU Langone Health | National Cancer Institute (NCI) | 30 | INTERVENTIONAL | NYU School of Medicine’s Kaplan Comprehensive Cancer Center, New York, New York, 10016, United States|University of Texas – MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States | |
| NCT01770665 | Validation of the MiCK Assay | https://clinicaltrials.gov/study/NCT01770665 | MiCK Assay | TERMINATED | Pierian Biosciences | 21 | OBSERVATIONAL | Mayo Validation Support Services 3050 Superior Drive NW, Rochester, Minnesota, 55901, United States | ||
| NCT02040142 | Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C | https://clinicaltrials.gov/study/NCT02040142 | COMPLETED | PROCEDURE: HIPEC|DRUG: Mitomycin C | Albert Einstein College of Medicine | 51 | INTERVENTIONAL | Department of Surgery, Montefiore Medical Center- Weiler Division, Bronx, New York, 10461, United States | ||
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | https://clinicaltrials.gov/study/NCT00897442 | COMPLETED | OTHER: Laboratory Biomarker Analysis | Gynecologic Oncology Group | National Cancer Institute (NCI) | 275 | OBSERVATIONAL | Highlands Oncology Group PA – Fayetteville, Fayetteville, Arkansas, 72703, United States|Washington Regional Medical Center – Fayetteville, Fayetteville, Arkansas, 72703, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, 91505, United States|Long Beach Memorial Medical Center-Todd Cancer Institute, Long Beach, California, 90806, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Stanford Cancer Institute, Palo Alto, California, 94304, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|UCSF Medical Center-Mount Zion, San Francisco, California, 94115, United States|Olive View-University of California Los Angeles Medical Center, Sylmar, California, 91342, United States|Colorado Gynecologic Oncology Group, Aurora, Colorado, 80010, United States|University of Colorado Cancer Center – Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Danbury Hospital, Danbury, Connecticut, 06810, United States|Hartford Hospital, Hartford, Connecticut, 06102, United States|The Hospital of Central Connecticut, New Britain, Connecticut, 06050, United States|Yale University, New Haven, Connecticut, 06520, United States|MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States|Holy Cross Hospital, Fort Lauderdale, Florida, 33308, United States|Florida Gynecologic Oncology, Fort Myers, Florida, 33905, United States|Jupiter Medical Center, Jupiter, Florida, 33458, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Augusta University Medical Center, Augusta, Georgia, 30912, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Memorial University Medical Center, Savannah, Georgia, 31404, United States|Northwestern University, Chicago, Illinois, 60611, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Illinois, Chicago, Illinois, 60612, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, 60453-2699, United States|Memorial Medical Center, Springfield, Illinois, 62781, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, 46260, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, 46628, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, 50325, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, 50325, United States|Iowa Methodist Medical Center, Des Moines, Iowa, 50309, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, 50309, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, 50309, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, 50314, United States|Mercy Medical Center – Des Moines, Des Moines, Iowa, 50314, United States|Iowa Lutheran Hospital, Des Moines, Iowa, 50316, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|Methodist West Hospital, West Des Moines, Iowa, 50266-7700, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, 50266, United States|Our Lady Bellefonte Hospital, Ashland, Kentucky, 41101, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, 41017, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, 40202, United States|Woman’s Hospital, Baton Rouge, Louisiana, 70817, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, 70112, United States|CHRISTUS Highland Medical Center, Shreveport, Louisiana, 71105, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, 04102, United States|The Union Memorial Hospital, Baltimore, Maryland, 21218, United States|MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, 21237, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, 20889-5600, United States|Baystate Medical Center, Springfield, Massachusetts, 01199, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, 01605, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Hurley Medical Center, Flint, Michigan, 48502, United States|Gynecologic Oncology of West Michigan PLLC, Grand Rapids, Michigan, 49546, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, 55455, United States|Saint Dominic-Jackson Memorial Hospital, Jackson, Mississippi, 39216, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|Keesler Medical Center, Kessler AFB, Mississippi, 39534, United States|University of Missouri – Ellis Fischel, Columbia, Missouri, 65212, United States|Saint Louis University Hospital, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, 65804, United States|Mercy Hospital Springfield, Springfield, Missouri, 65804, United States|CoxHealth South Hospital, Springfield, Missouri, 65807, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, 89109, United States|Women’s Cancer Center of Nevada, Las Vegas, Nevada, 89169, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Cooper Hospital University Medical Center, Camden, New Jersey, 08103, United States|Hackensack University Medical CCOP, Hackensack, New Jersey, 07601, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Rutgers New Jersey Medical School, Newark, New Jersey, 07101, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87102, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Mount Sinai Medical Center, New York, New York, 10029, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, 10032, United States|Stony Brook University Medical Center, Stony Brook, New York, 11794, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27599, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, 28203, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, 28204, United States|Gynecologic Oncology Network, Greenville, North Carolina, 27834, United States|Pitt County Memorial Hosp Inc., Greenville, North Carolina, 27834, United States|East Carolina University, Greenville, North Carolina, 27858, United States|FirstHealth of the Carolinas-Moore Regional Hosiptal, Pinehurst, North Carolina, 28374, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Akron General Medical Center, Akron, Ohio, 44307, United States|Good Samaritan Hospital – Cincinnati, Cincinnati, Ohio, 45220, United States|University of Cincinnati, Cincinnati, Ohio, 45267, United States|Case Western Reserve University, Cleveland, Ohio, 44106, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Riverside Methodist Hospital, Columbus, Ohio, 43214, United States|Lake University Ireland Cancer Center, Mentor, Ohio, 44060, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Cancer Care Associates-Midtown, Tulsa, Oklahoma, 74104, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, 74146, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, 97210, United States|Compass Oncology Rose Quarter, Portland, Oregon, 97227, United States|Abington Memorial Hospital, Abington, Pennsylvania, 19001, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, 18103, United States|Saint Luke’s University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, 18015, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Temple University Hospital, Philadelphia, Pennsylvania, 19140, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|West Penn Hospital, Pittsburgh, Pennsylvania, 15224, United States|Geisinger Medical Group, State College, Pennsylvania, 16801, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, 18711, United States|Women and Infants Hospital, Providence, Rhode Island, 02905, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, 29605, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, 29307, United States|Black Hills Obstetrics and Gynecology, Rapid City, South Dakota, 57701, United States|Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, 57104, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Sanford USD Medical Center – Sioux Falls, Sioux Falls, South Dakota, 57117-5134, United States|Chattanooga’s Program in Women’s Oncology, Chattanooga, Tennessee, 37403, United States|East Tennessee State University, Johnson City, Tennessee, 37614-0054, United States|Southeast Gynecologic Oncology Associates, Knoxville, Tennessee, 37917, United States|University of Tennessee Health Science Center, Memphis, Tennessee, 38163, United States|Meharry Medical College, Nashville, Tennessee, 37208, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, 79106, United States|University Medical Center Brackenridge, Austin, Texas, 78701, United States|Parkland Memorial Hospital, Dallas, Texas, 75235, United States|Zale Lipshy University Hospital, Dallas, Texas, 75235, United States|Clements University Hospital, Dallas, Texas, 75390, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, 78234, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States|The Methodist Hospital System, Houston, Texas, 77030, United States|Wilford Hall Medical Center, Lackland AFB, Texas, 78236, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, 79410, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States|Scott and White Memorial Hospital, Temple, Texas, 76508, United States|Virginia Oncology Associates-Hampton, Hampton, Virginia, 23666, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, 24016, United States|MultiCare Auburn Medical Center, Auburn, Washington, 98001, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, 98531, United States|Saint Francis Hospital, Federal Way, Washington, 98003, United States|Saint Clare Hospital, Lakewood, Washington, 98499, United States|Providence – Saint Peter Hospital, Olympia, Washington, 98506-5166, United States|Capital Medical Center, Olympia, Washington, 98507, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, 98372, United States|Virginia Mason CCOP, Seattle, Washington, 98101, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Pacific Gynecology Specialists, Seattle, Washington, 98104, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Swedish Medical Center-First Hill, Seattle, Washington, 98122-4307, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|MultiCare Allenmore Hospital, Tacoma, Washington, 98405, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, 98405, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, 98405, United States|Northwest NCI Community Oncology Research Program, Tacoma, Washington, 98405, United States|Saint Joseph Medical Center, Tacoma, Washington, 98405, United States|Multicare Health System, Tacoma, Washington, 98415, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, 54729, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, 54701, United States|Sacred Heart Hospital, Eau Claire, Wisconsin, 54701, United States|Marshfield Clinic – Ladysmith Center, Ladysmith, Wisconsin, 54848, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 53792, United States|Marshfield Clinic, Marshfield, Wisconsin, 54449, United States|Saint Joseph’s Hospital, Marshfield, Wisconsin, 54449, United States|Aurora Saint Luke’s Medical Center, Milwaukee, Wisconsin, 53215, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, 53233, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, 54548, United States|Marshfield Clinic at James Beck Cancer Center, Rhinelander, Wisconsin, 54501, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, 54868, United States|Marshfield Clinic Cancer Care at Saint Michael’s Hospital, Stevens Point, Wisconsin, 54481, United States|Saint Michael’s Hospital, Stevens Point, Wisconsin, 54481, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, 54401, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, 53227, United States|Diagnostic and Treatment Center, Weston, Wisconsin, 54476, United States|Marshfield Clinic – Weston Center, Weston, Wisconsin, 54476, United States|Marshfield Clinic – Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States | |
| NCT00002465 | High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma | https://clinicaltrials.gov/study/NCT00002465 | UNKNOWN | DRUG: megestrol acetate | St. Vincent Medical Center – Los Angeles | INTERVENTIONAL | St. Vincent Medical Center – Los Angeles, Los Angeles, California, 90057, United States | |||
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | https://clinicaltrials.gov/study/NCT04491942 | RECRUITING | DRUG: Cisplatin|DRUG: Elimusertib|DRUG: Gemcitabine Hydrochloride | National Cancer Institute (NCI) | 74 | INTERVENTIONAL | University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, 20892, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, 53792, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada | ||
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT02903914 | COMPLETED | DRUG: INCB001158|DRUG: Pembrolizumab | Incyte Corporation | 260 | INTERVENTIONAL | University of South Alabama, Mobile, Alabama, 36604, United States|Honor Health/Pinnacle Oncology Hematology, Scottsdale, Arizona, 85258, United States|University of Arizona, Tucson, Arizona, 85719, United States|Georgetown, Washington, District of Columbia, 20007, United States|Johns Hopkins, Baltimore, Maryland, 21287, United States|BIDMC, Boston, Massachusetts, 02215, United States|DFCI, Boston, Massachusetts, 02215, United States|Henry Ford, Detroit, Michigan, 48202, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, 37203, United States|Vanderbilt, Nashville, Tennessee, 37232, United States|MD Anderson, Houston, Texas, 77230-1402, United States|MD Anderson, Houston, Texas, 77230, United States|START, San Antonio, Texas, 78229, United States|Ospedale San Raffaele, Milan, 20132, Italy|Oncologica Azienda Ospedaliera Universitaria Senese, Siena, 53100, Italy|NKI, Amsterdam, 1066 CX, Netherlands|Radboudumc, Nijmegen, HP 452, Netherlands|Hospital Universitari Vall d’Hebron, Barcelona, 8035, Spain|Institut Catala d’Oncologia, Barcelona, 8908, Spain|START Madrid-HM CIOCC, Madrid, 28050, Spain | ||
| NCT02860286 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT02860286 | COMPLETED | DRUG: Tazemetostat | Epizyme, Inc. | 74 | INTERVENTIONAL | University of California, Los Angeles, Los Angeles, California, 90025, United States|City of Hope National Medical Center, Los Angeles, California, 90301, United States|University of California San Francisco, San Francisco, California, 94143, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic – Rochester, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Institut Bergonie, Bordeaux Cedex, 33076, France|CHRU de Lille, Lille, 59037, France|Institut Gustave Roussy, Villejuif cedex, 94805, France|University of Leicester & Leicester University Hospitals, Leicester, LE1 9HN, United Kingdom|St. Bartholomew’s Hospital, London, EC1M 6BQ, United Kingdom|University College Hospital, London, NW1 2PG, United Kingdom|Royal Marsden Hospital – Chelsea, London, SW3 6JJ, United Kingdom|University Hospital of South Manchester, Manchester, M23 9LT, United Kingdom|Royal Marsden Hospital – Surrey, Sutton, SM2 5PT, United Kingdom | ||
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | https://clinicaltrials.gov/study/NCT02637531 | ACTIVE_NOT_RECRUITING | DRUG: IPI-549 (eganelisib)|DRUG: Nivolumab | Infinity Pharmaceuticals, Inc. | 219 | INTERVENTIONAL | UCSD, San Diego, California, 92093, United States|UCLA, Santa Monica, California, 90404, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, 34952, United States|Emory University, Atlanta, Georgia, 30322, United States|Massachusetts General Hospital, Boston, Massachusetts, 02116, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|South Texas Accelerated Research and Treatment (START), San Antonio, Texas, 78229, United States | ||
| NCT02592551 | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02592551 | COMPLETED | DRUG: MEDI4736|DRUG: Tremelimumab|OTHER: no other name | Baylor College of Medicine | 24 | INTERVENTIONAL | Baylor St Lukes, Houston, Texas, 77030, United States | ||
| NCT00996385 | Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT00996385 | UNKNOWN | DRUG: Velcade (bortezomib) plus Eloxatin (oxaliplatin) | Columbia University | 29 | INTERVENTIONAL | Columbia University Medical Center, New York, New York, 10032, United States | ||
| NCT01355965 | Autologous Redirected RNA Meso-CIR T Cells | https://clinicaltrials.gov/study/NCT01355965 | COMPLETED | BIOLOGICAL: Autologous T cells | University of Pennsylvania | 18 | INTERVENTIONAL | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT03007030 | Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery | https://clinicaltrials.gov/study/NCT03007030 | RECRUITING | DRUG: Brentuximab Vedotin|OTHER: Laboratory Biomarker Analysis | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | 55 | INTERVENTIONAL | M D Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT03556228 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | https://clinicaltrials.gov/study/NCT03556228 | RECRUITING | DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete) | VM Oncology, LLC | 74 | INTERVENTIONAL | City of Hope National Medical Center, Duarte, California, 91010, United States|Memorial Cancer Institute at Memorial Healthcare Systems, Pembroke Pines, Florida, 33028, United States|Atlantic Health System, Morristown Medical Center, Morristown, New Jersey, 07962, United States|Weill Cornell Medicine, Cornell University, New York, New York, 10065, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|Erlanger Health System (Hospital); University of Tennessee College of Medicine, Chattanooga, Chattanooga, Tennessee, 37403, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States | ||
| NCT04158141 | Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT04158141 | RECRUITING | DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Decortication|RADIATION: Intensity-Modulated Radiation Therapy|DRUG: Pemetrexed|DRUG: Pemetrexed Disodium|RADIATION: Pencil Beam Scanning|PROCEDURE: Pleurectomy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration | NRG Oncology | National Cancer Institute (NCI) | 150 | INTERVENTIONAL | UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, 33146, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, 33442, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, 33607, United States|Moffitt Cancer Center – McKinley Campus, Tampa, Florida, 33612, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Mount Sinai Hospital, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|MD Anderson in The Woodlands, Conroe, Texas, 77384, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|MD Anderson West Houston, Houston, Texas, 77079, United States|MD Anderson League City, League City, Texas, 77573, United States|MD Anderson in Sugar Land, Sugar Land, Texas, 77478, United States|Swedish Medical Center-First Hill, Seattle, Washington, 98122, United States|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, H3H 2R9, Canada | |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | https://clinicaltrials.gov/study/NCT02004028 | TERMINATED | DRUG: VS-6063 | Verastem, Inc. | 35 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States | ||
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | https://clinicaltrials.gov/study/NCT03538028 | COMPLETED | BIOLOGICAL: INCAGN02385 | Incyte Biosciences International Sàrl | 22 | INTERVENTIONAL | The Angeles Clinic and Research Center, Los Angeles, California, 90025, United States|Hackensack Medical Center, Hackensack, New Jersey, 07601, United States|Carolina BioOncology Institute, Huntersville, North Carolina, 28078, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States | ||
| NCT00003723 | S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery | https://clinicaltrials.gov/study/NCT00003723 | COMPLETED | DRUG: gemcitabine hydrochloride | SWOG Cancer Research Network | National Cancer Institute (NCI) | 57 | INTERVENTIONAL | MBCCOP – University of South Alabama, Mobile, Alabama, 36688, United States|CCOP – Greater Phoenix, Phoenix, Arizona, 85006-2726, United States|Veterans Affairs Medical Center – Phoenix (Hayden), Phoenix, Arizona, 85012, United States|Veterans Affairs Medical Center – Tucson, Tucson, Arizona, 85723, United States|Arizona Cancer Center, Tucson, Arizona, 85724, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Veterans Affairs Medical Center – Little Rock (McClellan), Little Rock, Arkansas, 72205, United States|Veterans Affairs Medical Center – Long Beach, Long Beach, California, 90822, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033-0800, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States|Beckman Research Institute, City of Hope, Los Angeles, California, 91010, United States|Veterans Affairs Outpatient Clinic – Martinez, Martinez, California, 94553, United States|CCOP – Bay Area Tumor Institute, Oakland, California, 94609-3305, United States|University of California Davis Medical Center, Sacramento, California, 95817, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94115-0128, United States|CCOP – Santa Rosa Memorial Hospital, Santa Rosa, California, 95403, United States|David Grant Medical Center, Travis Air Force Base, California, 94535, United States|Veterans Affairs Medical Center – Denver, Denver, Colorado, 80220, United States|University of Colorado Cancer Center, Denver, Colorado, 80262, United States|CCOP – Atlanta Regional, Atlanta, Georgia, 30342-1701, United States|Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, 30905-5650, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, 96813, United States|CCOP – Central Illinois, Decatur, Illinois, 62526, United States|Veterans Affairs Medical Center – Hines (Hines Junior VA Hospital), Hines, Illinois, 60141, United States|Loyola University Medical Center, Maywood, Illinois, 60153, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160-7357, United States|CCOP – Wichita, Wichita, Kansas, 67214-3882, United States|Veterans Affairs Medical Center – Wichita, Wichita, Kansas, 67218, United States|Veterans Affairs Medical Center – Lexington, Lexington, Kentucky, 40511-1093, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, 40536-0084, United States|MBCCOP – LSU Medical Center, New Orleans, Louisiana, 70112, United States|Tulane University School of Medicine, New Orleans, Louisiana, 70112, United States|Veterans Affairs Medical Center – New Orleans, New Orleans, Louisiana, 70112, United States|Louisiana State University Health Sciences Center – Shreveport, Shreveport, Louisiana, 71130-3932, United States|Veterans Affairs Medical Center – Shreveport, Shreveport, Louisiana, 71130, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Veterans Affairs Medical Center – Boston (Jamaica Plain), Jamaica Plain, Massachusetts, 02130, United States|Veterans Affairs Medical Center – Ann Arbor, Ann Arbor, Michigan, 48105, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0752, United States|Veterans Affairs Medical Center – Detroit, Detroit, Michigan, 48201-1932, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|CCOP – Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, 49503, United States|Providence Hospital – Southfield, Southfield, Michigan, 48075-9975, United States|Veterans Affairs Medical Center – Biloxi, Biloxi, Mississippi, 39531-2410, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216-4505, United States|Veterans Affairs Medical Center – Jackson, Jackson, Mississippi, 39216, United States|Keesler Medical Center – Keesler AFB, Keesler AFB, Mississippi, 39534-2576, United States|Veterans Affairs Medical Center – Kansas City, Kansas City, Missouri, 64128, United States|CCOP – Kansas City, Kansas City, Missouri, 64131, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, 63110-0250, United States|CCOP – St. Louis-Cape Girardeau, Saint Louis, Missouri, 63141, United States|CCOP – Cancer Research for the Ozarks, Springfield, Missouri, 65807, United States|CCOP – Montana Cancer Consortium, Billings, Montana, 59101, United States|Veterans Affairs Medical Center – Albuquerque, Albuquerque, New Mexico, 87108-5138, United States|MBCCOP – University of New Mexico HSC, Albuquerque, New Mexico, 87131, United States|Veterans Affairs Medical Center – Brooklyn, Brooklyn, New York, 11209, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, 45219, United States|Veterans Affairs Medical Center – Cincinnati, Cincinnati, Ohio, 45220-2288, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, 44195, United States|CCOP – Columbus, Columbus, Ohio, 43206, United States|Veterans Affairs Medical Center – Dayton, Dayton, Ohio, 45428, United States|CCOP – Dayton, Kettering, Ohio, 45429, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, United States|Veterans Affairs Medical Center – Oklahoma City, Oklahoma City, Oklahoma, 73104, United States|Oregon Cancer Center at Oregon Health Sciences University, Portland, Oregon, 97201-3098, United States|Veterans Affairs Medical Center – Portland, Portland, Oregon, 97207, United States|CCOP – Columbia River Program, Portland, Oregon, 97213, United States|CCOP – Greenville, Greenville, South Carolina, 29615, United States|CCOP – Upstate Carolina, Spartanburg, South Carolina, 29303, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, 78234, United States|University of Texas Medical Branch, Galveston, Texas, 77555-1329, United States|Texas Tech University Health Science Center, Lubbock, Texas, 79423, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78284-7811, United States|Veterans Affairs Medical Center – San Antonio (Murphy), San Antonio, Texas, 78284, United States|Veterans Affairs Medical Center – Temple, Temple, Texas, 76504, United States|CCOP – Scott and White Hospital, Temple, Texas, 76508, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84132, United States|Veterans Affairs Medical Center – Salt Lake City, Salt Lake City, Utah, 84148, United States|CCOP – Virginia Mason Research Center, Seattle, Washington, 98101, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Veterans Affairs Medical Center – Seattle, Seattle, Washington, 98108, United States|CCOP – Northwest, Tacoma, Washington, 98405-0986, United States | |
| NCT06037941 | Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT06037941 | RECRUITING | DIAGNOSTIC_TEST: E-Nose testing|DIAGNOSTIC_TEST: Research blood | Memorial Sloan Kettering Cancer Center | UNIVERSITY CAMPUS BIO-MEDICO, ITALY | 20 | INTERVENTIONAL | Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Consent Only ), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York, 11553, United States | |
| NCT00509041 | Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00509041 | COMPLETED | DRUG: dasatinib | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 46 | INTERVENTIONAL | Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94115, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, 19958, United States|CCOP – Christiana Care Health Services, Newark, Delaware, 19713, United States|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, 32803-1273, United States|Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, 31403-3089, United States|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States|Elkhart General Hospital, Elkhart, Indiana, 46515, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, 46845, United States|Howard Community Hospital, Kokomo, Indiana, 46904, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, 46350, United States|CCOP – Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States|Memorial Hospital of South Bend, South Bend, Indiana, 46601, United States|Saint Joseph Regional Medical Center, South Bend, Indiana, 46617, United States|South Bend Clinic, South Bend, Indiana, 46617, United States|Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, Maryland, 21237, United States|Union Hospital Cancer Program at Union Hospital, Elkton MD, Maryland, 21921, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Lakeland Regional Cancer Care Center – St. Joseph, St. Joseph, Michigan, 49085, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, 55455, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, 63131, United States|Arch Medical Services, Incorporated at Center for Cancer Care and Research, Saint Louis, Missouri, 63141, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, 68114, United States|Cancer Institute of New Jersey at Cooper – Voorhees, Voorhees, New Jersey, 08043, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, 27534, United States|Kinston Medical Specialists, Kinston, North Carolina, 28501, United States|Iredell Memorial Hospital, Statesville, North Carolina, 28677, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157-1096, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, 43210-1240, United States|CCOP – Greenville, Greenville, South Carolina, 29615, United States|Mountainview Medical, Berlin, Vermont, 05602, United States|Fletcher Allen Health Care – University Health Center Campus, Burlington, Vermont, 05401, United States|Danville Regional Medical Center, Danville, Virginia, 24541, United States | |
| NCT02798536 | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT02798536 | COMPLETED | DRUG: LMB-100|DRUG: nab-paclitaxel | National Cancer Institute (NCI) | 21 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT05047536 | KZR-261 in Subjects With Advanced Solid Malignancies | https://clinicaltrials.gov/study/NCT05047536 | RECRUITING | DRUG: KZR-261 | Kezar Life Sciences, Inc. | 225 | INTERVENTIONAL | Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|University of California Los Angeles, Los Angeles, California, 90095, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Sara Cannon Research Institution (SCRI) – Tennessee Oncology Nashville, Nashville, Tennessee, 37203, United States|START (South Texas Accelerated Research Therapeutics), San Antonio, Texas, 78229, United States|Virginia Cancer Specialists (VCS), Fairfax, Virginia, 22031, United States | ||
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT04515836 | RECRUITING | DRUG: Olaparib | University of Chicago | AstraZeneca | 56 | INTERVENTIONAL | University of Chicago Medical Center, Chicago, Illinois, 60615, United States | |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | https://clinicaltrials.gov/study/NCT00094978 | TERMINATED | DRUG: Depsipeptide|DRUG: Flavopiridol (alvocidib) | National Cancer Institute (NCI) | 23 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT04042480 | TERMINATED | DRUG: SGN-CD228A | Seagen Inc. | 88 | INTERVENTIONAL | University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem, North Carolina, 27157, United States|Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Sanford Cancer Center, Sioux Falls, South Dakota, 57104, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, 77030, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States|Institut Gustave Roussy, Villejuif Cedex, 94805, France|Istituto Europeo di Oncologia, Milano, 20141, Italy|Hospital Universitario Vall d’Hebron, Barcelona, 08035, Spain|The Royal Marsden Hospital (Surrey), Sutton, SM2 5PT, United Kingdom | ||
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT05311618 | RECRUITING | DRUG: NGM438|DRUG: Pembrolizumab | NGM Biopharmaceuticals, Inc | Merck Sharp & Dohme LLC | 71 | INTERVENTIONAL | Yale Cancer Center, New Haven, Connecticut, 06520, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|START Midwest, Grand Rapids, Michigan, 49546, United States|Mount Sinai Hospital, New York, New York, 10029, United States|MD Anderson, Houston, Texas, 77030, United States | |
| NCT00604461 | Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) | https://clinicaltrials.gov/study/NCT00604461 | TERMINATED | DRUG: Carboplatin, Bevacizumab and Pemetrexed | H. Lee Moffitt Cancer Center and Research Institute | Genentech, Inc. | 13 | INTERVENTIONAL | H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States | |
| NCT01861301 | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT01861301 | TERMINATED | OTHER: Laboratory Biomarker Analysis|DRUG: Tivantinib | National Cancer Institute (NCI) | 18 | INTERVENTIONAL | City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|City of Hope South Pasadena, South Pasadena, California, 91030, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Decatur Memorial Hospital, Decatur, Illinois, 62526, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, 60201, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Illinois CancerCare-Peoria, Peoria, Illinois, 61615, United States|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, 46845, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, 63141, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, 17033-0850, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States | ||
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT04013334 | ACTIVE_NOT_RECRUITING | DRUG: MTG201|DRUG: Nivolumab Injection [Opdivo] | Momotaro-Gene Inc. | Baylor College of Medicine|Synteract, Inc. | 12 | INTERVENTIONAL | Baylor College of Medicine, Houston, Texas, 77030, United States | |
| NCT01675765 | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01675765 | COMPLETED | BIOLOGICAL: Immunotherapy plus chemotherapy|BIOLOGICAL: Immunotherapy with cyclophosphamide plus chemotherapy | Aduro Biotech, Inc. | 60 | INTERVENTIONAL | University of California at San Francisco, San Francisco, California, 94115, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|National Cancer Institute, Bethesda, Maryland, 20892, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | https://clinicaltrials.gov/study/NCT05732831 | RECRUITING | DRUG: TNG462 | Tango Therapeutics, Inc. | 159 | INTERVENTIONAL | Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|New York University Langone Health, New York, New York, 10016, United States|Sarah Cannon Tennessee Oncology, Nashville, Tennessee, 37203, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, 84112, United States|Institute Gustav Roussy, Villejuif, 94805, France|Hospital Universitario Fundacion Jimenez Diaz, Madrid, 28040, Spain|Hospital de Sanchinarro, Madrid, 28050, Spain | ||
| NCT04040231 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | https://clinicaltrials.gov/study/NCT04040231 | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Galinpepimut-S|DRUG: Nivolumab|BIOLOGICAL: Sargramostim | Memorial Sloan Kettering Cancer Center | 10 | INTERVENTIONAL | Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan – Kettering Cancer Center, New York, New York, 10021, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States | ||
| NCT00003034 | ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen | https://clinicaltrials.gov/study/NCT00003034 | UNKNOWN | DRUG: doxorubicin hydrochloride|DRUG: ranpirnase | Alfacell | 300 | INTERVENTIONAL | CCOP – Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201, United States|Spectrum Health Hospital – Butterworth Campus, Grand Rapids, Michigan, 49503, United States|CCOP – Duluth, Duluth, Minnesota, 55805-1983, United States|Missouri Cancer Care, PC at St. Joseph Health Center – St. Charles, St. Charles, Missouri, 63301, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, 68114-4199, United States|University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, 87131-5636, United States|Asklepios Fachkliniken Muenchen-Gauting, Gauting, D-82131, Germany|Hospital Grosshansdorf, Grosshansdorf, D-22927, Germany|Asklepios Klinik St. Georg, Hamburg, D-20099, Germany|Asklepios Klinik Harburg, Hamburg, D-21075, Germany|Klinikum Rechts Der Isar – Technische Universitaet Muenchen, Munich, D-81675, Germany|Istituto Nazionale per la Ricerca sul Cancro, Genoa, 16132, Italy|Ospedale San Martino, Genoa, 16132, Italy|Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, 27100, Italy|Medical University of Gdansk, Gdansk, 80-211, Poland|University School of Medical Sciences, Poznan, PL-60 569, Poland|Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, 02-781, Poland|Klinika Chrorob Pluc I Gruzlicy, Zabrze, 41-803, Poland | ||
| NCT03867578 | Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT03867578 | ACTIVE_NOT_RECRUITING | DIAGNOSTIC_TEST: HR-MRI|DIAGNOSTIC_TEST: Standard CT Imaging|DIAGNOSTIC_TEST: Ultrasound | University of Chicago | 26 | INTERVENTIONAL | University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, 60637, United States | ||
| NCT00107432 | Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. | https://clinicaltrials.gov/study/NCT00107432 | COMPLETED | DRUG: sorafenib tosylate|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 44 | INTERVENTIONAL | Cancer and Leukemia Group B, Chicago, Illinois, 60606, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States | ||
| NCT03000257 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT03000257 | COMPLETED | DRUG: Venetoclax|DRUG: Rovalpituzumab Tesirine|DRUG: ABBV-181 | AbbVie | 182 | INTERVENTIONAL | Moores Cancer Center at UC San Diego /ID# 157374, La Jolla, California, 92093, United States|The University of Chicago Medical Center /ID# 157375, Chicago, Illinois, 60637-1443, United States|Carolina BioOncology Institute /ID# 157376, Huntersville, North Carolina, 28078, United States|South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, 78229, United States|Virginia Cancer Specialists – Fairfax /ID# 157377, Fairfax, Virginia, 22031, United States|Blacktown Hospital /ID# 167386, Blacktown, New South Wales, 2148, Australia|St Vincent’s Hospital Melbourne /ID# 167552, Fitzroy Melbourne, Victoria, 3065, Australia|Linear Clinical Research /ID# 170797, Nedlands, Western Australia, 6000, Australia|Medizinische Universitaet Graz /ID# 168752, Graz, Steiermark, 8036, Austria|Universitair Ziekenhuis Antwerpen /ID# 170702, Edegem, Antwerpen, 2650, Belgium|UZ Gent /ID# 170881, Gent, Oost-Vlaanderen, 9000, Belgium|Cross Cancer Institute /ID# 167603, Edmonton, Alberta, T6G 1Z2, Canada|Tampere University Hospital /ID# 166839, Tampere, Pirkanmaa, 33520, Finland|Docrates Cancer Center /ID# 166838, Helsinki, 00180, Finland|Institut Bergonie /ID# 162662, Bordeaux, Gironde, 33000, France|Institut du Cancer de Montpellier – Val d’Aurelle /ID# 163999, Montpellier CEDEX 5, Herault, 34298, France|Centre Leon Berard /ID# 162660, Lyon CEDEX 08, Rhone, 69373, France|Institut Gustave Roussy /ID# 162753, Villejuif Cedex, Val-de-Marne, 94805, France|National Cancer Center Hospital East /ID# 166433, Kashiwa-shi, Chiba, 277-8577, Japan|National Hospital Organization Kyushu Cancer Center /ID# 206229, Fukuoka-shi, Fukuoka, 811-1395, Japan|National Cancer Center Hospital /ID# 166279, Chuo-ku, Tokyo, 104-0045, Japan|Hospital Universitario Fundacion Jimenez Diaz /ID# 163862, Madrid, 28040, Spain|Hospital Universitario HM Sanchinarro /ID# 163861, Madrid, 28050, Spain|Hospital Clinico Universitario de Valencia /ID# 163925, Valencia, 46010, Spain|National Taiwan University Hospital /ID# 163997, Taipei City, 100, Taiwan|Taipei Medical University Hospital /ID# 163998, Taipei City, 11031, Taiwan | ||
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study | https://clinicaltrials.gov/study/NCT04213794 | RECRUITING | DRUG: Cisplatin|PROCEDURE: Cytoreductive Surgery|DRUG: Doxorubicin|DRUG: Hyperthermic Intraperitoneal Chemotherapy|DRUG: Sodium Thiosulfate | Mayo Clinic | National Cancer Institute (NCI) | 43 | INTERVENTIONAL | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | https://clinicaltrials.gov/study/NCT00700336 | COMPLETED | DRUG: pemetrexed, cisplatin and CBP501|DRUG: pemetrexed and cisplatin|DRUG: pemetrexed, cisplatin and CBP501, dose finding | CanBas Co. Ltd. | 69 | INTERVENTIONAL | Mayo Clinic, Scottsdale, Arizona, 85259, United States|Arizona Cancer Center, Tucson, Arizona, 85719-1454, United States|City of Hope, Duarte, California, 91010, United States|University of Chicago, Chicago, Illinois, 60637, United States|Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, 48201, United States|Nevada Cancer Institute, Las Vegas, Nevada, 89135, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87131, United States|Memorial-Sloan Kettering Cancer Center, New York, New York, 10022, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Penn State Milton S. Hershey Medical Ctr., Hershey, Pennsylvania, 17033, United States|Cancer Therapy & Research Center, San Antonio, Texas, 78229, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States | ||
| NCT04672434 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | https://clinicaltrials.gov/study/NCT04672434 | ACTIVE_NOT_RECRUITING | DRUG: Sym021|DRUG: Sym024 | Symphogen A/S | 100 | INTERVENTIONAL | START Midwest, Grand Rapids, Michigan, 49545, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, San Antonio, Texas, 78229, United States|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 1Z5, Canada | ||
| NCT01416714 | Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy | https://clinicaltrials.gov/study/NCT01416714 | SUSPENDED | University of Chicago | 1000 | OBSERVATIONAL | The University of Chicago, Chicago, Illinois, 60637, United States | |||
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | https://clinicaltrials.gov/study/NCT01907100 | TERMINATED | DRUG: Nintedanib|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Placebo | Boehringer Ingelheim | 545 | INTERVENTIONAL | University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|University of California San Francisco, San Francisco, California, 94115, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, 80120-4413, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89052, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|Greenville Health System, Greenville, South Carolina, 29615, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Texas Oncology – McAllen, McAllen, Texas, 78503, United States|Texas Oncology-San Antonio Northeast, San Antonio, Texas, 78217, United States|Cancer Care Northwest Centers, PS, Spokane Valley, Washington, 99216, United States|Sanatorio Güemes, Ciudad Autónoma de Bs As, C1180AAX, Argentina|Instituto Medico Especializado Alexander Fleming, Ciudad Autónoma de Bs As, C1426ANZ, Argentina|Clínica Universitaria Reina Fabiola, Ciudad de Cordoba, X5004FHP, Argentina|Northern Cancer Institute, St Leonards, New South Wales, 2065, Australia|Calvary Mater Newcastle Hospital, Waratah, New South Wales, 2298, Australia|The Prince Charles Hospital, Chermside, Queensland, 4032, Australia|Mater Cancer Care Centre, South Brisbane, Queensland, 4101, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Peninsula Haematology & Oncology, Frankston, Victoria, 3199, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Border Onclogy Research, Wodonga, Victoria, 3690, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Perth Oncology, Perth, Western Australia, 6000, Australia|LKH Leoben, Leoben, 8700, Austria|AKH – Medical University of Vienna, Vienna, 1090, Austria|Klinikum Wels – Grieskirchen GmbH, Wels, 4600, Austria|Brussels – UNIV Saint-Luc, Bruxelles, 1200, Belgium|Edegem – UNIV UZ Antwerpen, Edegem, 2650, Belgium|UNIV UZ Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|AZ Sint-Maarten, Mechelen, 2800, Belgium|QEII Health Sciences Centre (Dalhousie University), Halifax, Nova Scotia, B3H 1V7, Canada|Health Sciences North, Sudbury, Ontario, P3E 5J1, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|IUCPQ (Laval University), Quebec, GLV 4G5, Canada|Centro Internacional de Estudios Clínicos – CIEC, Recoleta, 8420383, Chile|Orlandi Oncologia, Vitacura, 7630372, Chile|University Clinic for Pulmonary Diseases, Zagreb, 10000, Croatia|University Hospital Brno, Brno, 625 00, Czechia|University Hospital Olomouc, Olomouc, 779 00, Czechia|Rigshospitalet, København, Onkologisk afdeling, Købenahvn Ø, 2100, Denmark|Clinical Research Center Alexandria, Alexandria, 21131, Egypt|Medical Research Institute, Alexandria, 21648, Egypt|National Cancer Institute, Cairo University, Cairo, 11796, Egypt|Nasser Institute, Cairo, 12655, Egypt|CLI Bordeaux Nord Aquitaine, Bordeaux, 33000, France|HOP Morvan, Brest, 29609, France|HOP Côte de Nacre, Caen, 14033, France|HOP Calmette, Lille, 59000, France|HOP Nord, Marseille, 13015, France|HOP Lyon Sud, Pierre-Bénite, 69230, France|HOP HIA Saint-Anne, Toulon, 83800, France|HOP Larrey, Toulouse, 31059, France|INS Gustave Roussy, Villejuif, 94805, France|Vivantes Netzwerk für Gesundheit GmbH, Berlin, 12351, Germany|Helios Klinikum Emil von Behring, Berlin, 14165, Germany|Klinik Schillerhöhe GmbH, Gerlingen, 70839, Germany|Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, 22927, Germany|Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg, 69126, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, 66421, Germany|Klinik, Löwenstein, Löwenstein, 74245, Germany|Rambam Medical Center, Haifa, 31096, Israel|Rabin Medical Center Beilinson, Petach Tikva, 49100, Israel|Sourasky Medical Center, Tel-Aviv, 64239, Israel|Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, 15121, Italy|Centro di riferimento Oncologico, Aviano (PN), 33081, Italy|Humanitas Gavazzeni, Bergamo, 24125, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genova, 16132, Italy|Azienda Sanitaria Ospedale S. Luigi Gonzaga, Orbassano (TO), 10043, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, 53100, Italy|University Hospital of Occupational and Environmental Health, Fukuoka, Kitakyushu, 807-8556, Japan|Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Amagasaki, 660-8550, Japan|Hyogo College of Medicine Hospital, Hyogo, Nishinomiya, 663-8501, Japan|Yokosuka Kyosai Hospital, Kanagawa , Yokosuka, 238-8558, Japan|Japan Labour Health and Safety Organization Okayama Rosai Hospital, Okayama, Okayama, 702-8055, Japan|Kindai University Hospital, Osaka, OsakaSayama, 589-8511, Japan|Otemae Hospital, Osaka, Osaka, 540-0008, Japan|Juntendo University Hospital, Tokyo, Bunkyo-ku, 113-8431, Japan|Centro Oncologico de Chihuahua, Chihuahua, 31217, Mexico|Instituto Nacional de Cancerologia, Mexico, 14080, Mexico|Centro Oncologico Estatal ISSEMYM, Toluca, 50180, Mexico|Medisch Spectrum Twente, Enschede, 7513 ER, Netherlands|Zuyderland Medisch Centrum, Heerlen, 6419 PC, Netherlands|Erasmus Medisch Centrum, Rotterdam, 3015 CE, Netherlands|Oslo Universitetssykehus HF, Radiumhospitalet, Oslo, N-0310, Norway|St. Olavs Hospital, Universitetssykehuset i Trondheim, Trondheim, N-7006, Norway|University Clinical Center, Gdansk, Gdansk, 80-952, Poland|Clin.Hosp.Med.Univ.Marcinkowski in Poznan, Poznan, 60-569, Poland|Greater PL Cent.Pulmo.&Thor.Surg.Eugenia&Janusz Zeyland, Poznan, 60-569, Poland|Onco.Cent. – Instit. of Maria Sklodowskiej-Curie, Warsaw, 02-781, Poland|Centro Hospitalar Lisboa Norte Hospital Pulido Valente, Lisboa, 1769-001, Portugal|Hospital CUF Porto, Porto, 4100-180, Portugal|St.Budg.Heal.Inst.”Chelyabinsk Reg.Clin.Cen.Onc&Nucl.Med”, Chelyabinsk, 454087, Russian Federation|St.Auton.Heal.Inst.”Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan”, Kazan, 420029, Russian Federation|FSBI “N.N Blokhin Med.Res.Cent.Onc.”MoH of RF, Moscow, 115478, Russian Federation|1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., Saint-Petersburg, 197022, Russian Federation|FSBI “N.N. Petrov National Medical Research Center of Oncology” of MoH of RF, Saint-Petersburg, 197758, Russian Federation|SBI HC-Rep.Clin.Onc.Disp.MoH.Rep.Bashkortostan, Ufa, 450054, Russian Federation|Wilgers Oncology Centre, Pretoria, 0041, South Africa|Hospital Universitario de Cruces, Barakaldo (Vizcaya), 48903, Spain|Hospital Vall d’Hebron, Barcelona, 08035, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Donostia, Donostia (Gipuzkoa), 20080, Spain|Hospital Duran i Reynals, L’Hospitalet de Llobregat, 08907, Spain|Hospital Ramón y Cajal, Madrid, 28034, Spain|Hospital Virgen de la Victoria, Malaga, 29010, Spain|Hospital Virgen del Rocío, Sevilla, 41013, Spain|Hospital Clínico de Valencia, Valencia, 46010, Spain|Sahlgrenska US, Göteborg, Göteborg, 413 45, Sweden|Universitetssjukhuset, Linköping, Linköping, 581 85, Sweden|Skånes universitetssjukhus, Lund, Lund, 221 85, Sweden|Karolinska Univ. sjukhuset, Stockholm, 171 76, Sweden|Akademiska sjukhuset, Uppsala, 751 85, Sweden|Eskisehir Osmangazi Üni. Sag. Uygulama ve Arastirma Has., Eskisehir, 26950, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi, Istanbul, 34899, Turkey|Dr.Suat Seren EAH, Izmir, 35120, Turkey|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Guy’s Hospital, London, SE1 9RT, United Kingdom|The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom|The Royal Marsden Hospital, Sutton, SM2 5PT, United Kingdom|Wythenshawe Hospital, Wythenshawe, M23 9LT, United Kingdom | ||
| NCT03228537 | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT03228537 | ACTIVE_NOT_RECRUITING | DRUG: Atezolizumab|DRUG: Cisplatin|PROCEDURE: Extrapleural Pneumonectomy|DRUG: Pemetrexed Disodium|PROCEDURE: Pleurectomy|RADIATION: Radiation Therapy | National Cancer Institute (NCI) | 29 | INTERVENTIONAL | Mayo Clinic Hospital in Arizona, Phoenix, Arizona, 85054, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, 85259, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, 71913, United States|PCR Oncology, Arroyo Grande, California, 93420, United States|City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, 80907, United States|Porter Adventist Hospital, Denver, Colorado, 80210, United States|Mercy Medical Center, Durango, Colorado, 81301, United States|Southwest Oncology PC, Durango, Colorado, 81301, United States|Mountain Blue Cancer Care Center, Golden, Colorado, 80401, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, 80228, United States|Saint Anthony Hospital, Lakewood, Colorado, 80228, United States|Littleton Adventist Hospital, Littleton, Colorado, 80122, United States|Longmont United Hospital, Longmont, Colorado, 80501, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, 80501, United States|Parker Adventist Hospital, Parker, Colorado, 80138, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, 80138, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, 81004, United States|Rocky Mountain Cancer Centers – Pueblo, Pueblo, Colorado, 81008, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, 80260, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, 32207, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, 83706, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, 83605, United States|Kootenai Health – Coeur d’Alene, Coeur d’Alene, Idaho, 83814, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, 83642, United States|Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, 83687, United States|Kootenai Clinic Cancer Services – Post Falls, Post Falls, Idaho, 83854, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, 83864, United States|Rush – Copley Medical Center, Aurora, Illinois, 60504, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, 61704, United States|Illinois CancerCare-Canton, Canton, Illinois, 61520, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, 62902, United States|SIH Cancer Institute, Carterville, Illinois, 62918, United States|Illinois CancerCare-Carthage, Carthage, Illinois, 62321, United States|Centralia Oncology Clinic, Centralia, Illinois, 62801, United States|Carle at The Riverfront, Danville, Illinois, 61832, United States|Cancer Care Specialists of Illinois – Decatur, Decatur, Illinois, 62526, United States|Decatur Memorial Hospital, Decatur, Illinois, 62526, United States|Carle Physician Group-Effingham, Effingham, Illinois, 62401, United States|Crossroads Cancer Center, Effingham, Illinois, 62401, United States|Illinois CancerCare-Eureka, Eureka, Illinois, 61530, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, 61401, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, 61401, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, 61443, United States|Illinois CancerCare-Macomb, Macomb, Illinois, 61455, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, 61938, United States|Cancer Care Center of O’Fallon, O’Fallon, Illinois, 62269, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, 61350, United States|Illinois CancerCare-Pekin, Pekin, Illinois, 61554, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, 61554, United States|Illinois CancerCare-Peoria, Peoria, Illinois, 61615, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, 61615, United States|Methodist Medical Center of Illinois, Peoria, Illinois, 61636, United States|OSF Saint Francis Medical Center, Peoria, Illinois, 61637, United States|Illinois CancerCare-Peru, Peru, Illinois, 61354, United States|Valley Radiation Oncology, Peru, Illinois, 61354, United States|Illinois CancerCare-Princeton, Princeton, Illinois, 61356, United States|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States|Springfield Clinic, Springfield, Illinois, 62702, United States|Memorial Medical Center, Springfield, Illinois, 62781, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, 62226, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|The Carle Foundation Hospital, Urbana, Illinois, 61801, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, 60560, United States|Mary Greeley Medical Center, Ames, Iowa, 50010, United States|McFarland Clinic – Ames, Ames, Iowa, 50010, United States|McFarland Clinic – Boone, Boone, Iowa, 50036, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, 50325, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, 50325, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, 51503, United States|Greater Regional Medical Center, Creston, Iowa, 50801, United States|Mercy Medical Center – Des Moines, Des Moines, Iowa, 50314, United States|Mission Cancer and Blood – Laurel, Des Moines, Iowa, 50314, United States|McFarland Clinic – Trinity Cancer Center, Fort Dodge, Iowa, 50501, United States|McFarland Clinic – Jefferson, Jefferson, Iowa, 50129, United States|McFarland Clinic – Marshalltown, Marshalltown, Iowa, 50158, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, 50266, United States|Lawrence Memorial Hospital, Lawrence, Kansas, 66044, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, 67208, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, 67214, United States|Cancer Center of Kansas – Wichita, Wichita, Kansas, 67214, United States|Flaget Memorial Hospital, Bardstown, Kentucky, 40004, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, 40701, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, 40504, United States|Saint Joseph Hospital East, Lexington, Kentucky, 40509, United States|Saint Joseph London, London, Kentucky, 40741, United States|Jewish Hospital, Louisville, Kentucky, 40202, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, 40215, United States|UofL Health Medical Center Northeast, Louisville, Kentucky, 40245, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, 40165, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, 70121, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, 48183, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, 48038, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Allegiance Health, Jackson, Michigan, 49201, United States|Henry Ford Macomb Health Center – Shelby Township, Shelby, Michigan, 48315, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, 48322, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, 63628, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, 63703, United States|Southeast Cancer Center, Cape Girardeau, Missouri, 63703, United States|Capital Region Southwest Campus, Jefferson City, Missouri, 65109, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, 63670, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, 63080, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, 63127, United States|Community Hospital of Anaconda, Anaconda, Montana, 59711, United States|Billings Clinic Cancer Center, Billings, Montana, 59101, United States|Bozeman Deaconess Hospital, Bozeman, Montana, 59715, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, 59405, United States|Great Falls Clinic, Great Falls, Montana, 59405, United States|Saint Peter’s Community Hospital, Helena, Montana, 59601, United States|Kalispell Regional Medical Center, Kalispell, Montana, 59901, United States|Community Medical Hospital, Missoula, Montana, 59804, United States|CHI Health Saint Francis, Grand Island, Nebraska, 68803, United States|Heartland Hematology and Oncology, Kearney, Nebraska, 68845, United States|CHI Health Good Samaritan, Kearney, Nebraska, 68847, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, 68510, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, 68122, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, 68122, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, 68124, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, 68130, United States|Creighton University Medical Center, Omaha, Nebraska, 68131, United States|Midlands Community Hospital, Papillion, Nebraska, 68046, United States|Comprehensive Cancer Centers of Nevada – Henderson, Henderson, Nevada, 89052, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, 89052, United States|OptumCare Cancer Care at Charleston, Las Vegas, Nevada, 89102, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, 89106, United States|GenesisCare USA – Las Vegas, Las Vegas, Nevada, 89109, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, 89119, United States|Comprehensive Cancer Centers of Nevada – Northwest, Las Vegas, Nevada, 89128, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, 89128, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, 89144, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, 89148, United States|Comprehensive Cancer Centers of Nevada – Central Valley, Las Vegas, Nevada, 89169, United States|Renown Regional Medical Center, Reno, Nevada, 89502, United States|Saint Mary’s Regional Medical Center, Reno, Nevada, 89503, United States|Radiation Oncology Associates, Reno, Nevada, 89509, United States|Good Samaritan Hospital – Cincinnati, Cincinnati, Ohio, 45220, United States|Bethesda North Hospital, Cincinnati, Ohio, 45242, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, 45247, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, 45255, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, 73505, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Memorial Hospital, Chattanooga, Tennessee, 37404, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, 37343, United States|Memorial GYN Plus, Ooltewah, Tennessee, 37363, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, 77802, United States|MD Anderson in The Woodlands, Conroe, Texas, 77384, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, 77026-1967, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|MD Anderson West Houston, Houston, Texas, 77079, United States|MD Anderson League City, League City, Texas, 77573, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, 75080, United States|MD Anderson in Sugar Land, Sugar Land, Texas, 77478, United States|University of Virginia Cancer Center, Charlottesville, Virginia, 22908, United States|Overlake Medical Center, Bellevue, Washington, 98004, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, 98310, United States|Harrison Medical Center, Bremerton, Washington, 98310, United States|Highline Medical Center-Main Campus, Burien, Washington, 98166, United States|Saint Elizabeth Hospital, Enumclaw, Washington, 98022, United States|Saint Francis Hospital, Federal Way, Washington, 98003, United States|Saint Clare Hospital, Lakewood, Washington, 98499, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, 98370, United States|Valley Medical Center, Renton, Washington, 98055, United States|FHCC South Lake Union, Seattle, Washington, 98109, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|University of Washington Medical Center – Montlake, Seattle, Washington, 98195, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, 98405, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, 98405, United States|Billings Clinic-Cody, Cody, Wyoming, 82414, United States|Welch Cancer Center, Sheridan, Wyoming, 82801, United States | ||
| NCT04913337 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | https://clinicaltrials.gov/study/NCT04913337 | RECRUITING | DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707 plus pembrolizumab | NGM Biopharmaceuticals, Inc | Merck Sharp & Dohme LLC | 179 | INTERVENTIONAL | University of Southern California, Los Angeles, California, 90033, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists – Sarasota – SCRI, Sarasota, Florida, 34232, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|START Midwest, LLC, Grand Rapids, Michigan, 49546, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|Prisma Health – Upstate, Greenville, South Carolina, 29605, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 78701, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, San Antonio, Texas, 78229, United States|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|China Medical University Hospital, Taichung, 404327, Taiwan|National Taiwan University Hospital, Taipei, 100225, Taiwan | |
| NCT00413322 | Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT00413322 | COMPLETED | DRUG: belinostat|DRUG: 5-Fluorouracil (5-FU) | Onxeo | 35 | INTERVENTIONAL | Mayo Clinic Arizona, Scottsdale, Arizona, 85259, United States|University of Nebraska, Omaha, Nebraska, 68198-7680, United States|Portsmouth Regional Hospital Hematology/Oncology Clinic, Portsmouth, New Hampshire, 03801, United States | ||
| NCT01385722 | Molecular Analysis of Thoracic Malignancies | https://clinicaltrials.gov/study/NCT01385722 | ENROLLING_BY_INVITATION | Stanford University | 1000 | OBSERVATIONAL | Stanford University School of Medicine, Stanford, California, 94305, United States | |||
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | https://clinicaltrials.gov/study/NCT03207347 | COMPLETED | DRUG: Niraparib | University of Florida | GlaxoSmithKline | 37 | INTERVENTIONAL | University of Florida, Gainesville, Florida, 32610, United States|University of Miami, Miami, Florida, 33136, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, 32806, United States | |
| NCT04897022 | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | https://clinicaltrials.gov/study/NCT04897022 | RECRUITING | DRUG: Pembrolizumab|RADIATION: IMPRINT | Memorial Sloan Kettering Cancer Center | 24 | INTERVENTIONAL | Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States | ||
| NCT00004547 | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | https://clinicaltrials.gov/study/NCT00004547 | COMPLETED | PROCEDURE: Surgery|PROCEDURE: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|DRUG: Postoperative dwell with paclitaxel and 5-FU | National Cancer Institute (NCI) | 188 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | https://clinicaltrials.gov/study/NCT01362790 | COMPLETED | DRUG: Pentostatin|DRUG: Cyclophosphamide|BIOLOGICAL: SS1(dsFv)PE38 – lot 073I0809|BIOLOGICAL: SS1(dsFv)PE38 – lot FIL129J01 | National Cancer Institute (NCI) | 55 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | https://clinicaltrials.gov/study/NCT02628067 | RECRUITING | BIOLOGICAL: pembrolizumab|BIOLOGICAL: pembrolizumab | Merck Sharp & Dohme LLC | 1609 | INTERVENTIONAL | Call for Information (Investigational Site 0202), Los Angeles, California, 90033, United States|Call for Information (Investigational Site 0017), Los Angeles, California, 90048, United States|Call for Information (Investigational Site 0010), Boston, Massachusetts, 02215, United States|Call for Information (Investigational Site 0008), New Brunswick, New Jersey, 08903, United States|MSD Australia, North Ryde, Australia|MSD Brasil, Sao Paulo, Brazil|Merck Canada, Kirkland, Quebec, H9H 4M7, Canada|Merck Sharp & Dohme (I.A.) Corp., Santiago, Chile|MDS Colombia SAS, Bogota, Colombia|MSD Denmark, Glostrup, Denmark|MSD France, Paris, France|MSD Sharp & Dohme GmbH, Haar, Germany|Merck Sharp & Dohme Co. Ltd., Hod Hasharon, Israel|MSD Italia S.r.l., Rome, Italy|MSD Korea LTD, Seoul, 4130, Korea, Republic of|MSD, Mexico City, Mexico|Merck Sharp & Dohme BV, Haarlem, Netherlands|MSD Norge A/S, Drammen, Norway|Merck Sharp & Dohme (I.A.) Corporation, Makati, Philippines|Merck Sharp & Dohme IDEA, Inc., Moscow, Russian Federation|MSD (Pty) LTD South Africa, Midrand, South Africa|Merck Sharp and Dohme de Espana S.A., Madrid, Spain|Merck Sharp & Dohme (I.A.) Corp., Taipei, Taiwan | ||
| NCT00295503 | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00295503 | COMPLETED | DRUG: bevacizumab|DRUG: cisplatin|DRUG: pemetrexed | University of Texas Southwestern Medical Center | University of Chicago|Columbia University|Duke University | 53 | INTERVENTIONAL | University of Texas Southwestern Medical Center, Dallas, Texas, 75390-8852, United States | |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin | https://clinicaltrials.gov/study/NCT02029690 | TRAP | TERMINATED | DRUG: ADI-PEG 20 | Polaris Group | 85 | INTERVENTIONAL | Mayo Clinic Rochester, Rochester, Minnesota, 55902, United States|Centre for Experimental Cancer Medicine (CECM), London, England, EC1M 6BQ, United Kingdom|Cambridge Hospital, Cambridge, CB2 0QQ, United Kingdom|Guys Hospital, London, SE1 7EH, United Kingdom | |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | https://clinicaltrials.gov/study/NCT01624090 | TERMINATED | DRUG: Mithramycin | National Cancer Institute (NCI) | 16 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | https://clinicaltrials.gov/study/NCT01997190 | MpeTK01 | COMPLETED | BIOLOGICAL: AdV-tk + valacyclovir | Candel Therapeutics, Inc. | University of Pennsylvania | 19 | INTERVENTIONAL | University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States |
| NCT04914897 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | https://clinicaltrials.gov/study/NCT04914897 | ACTIVE_NOT_RECRUITING | DRUG: THOR-707|DRUG: Pembrolizumab | Sanofi | Merck Sharp & Dohme LLC | 160 | INTERVENTIONAL | Hematology Oncology Clinic-Site Number:8400010, Baton Rouge, Louisiana, 70809, United States|Mount Sinai Medical Center-Site Number:8400006, New York, New York, 10021, United States|Cleveland Clinic Foundation-Site Number:8400004, Cleveland, Ohio, 44195, United States|Thomas Jefferson University Hospital-Site Number:8400009, Philadelphia, Pennsylvania, 19107, United States|Thomas Jefferson University – North East-Site Number:8401009, Philadelphia, Pennsylvania, 19114, United States|The Sarah Cannon Research Institute-Site Number:8400003, Nashville, Tennessee, 37203, United States|Investigational Site Number :0320002, Caba, Buenos Aires, 1430, Argentina|Investigational Site Number :0320001, Caba, Buenos Aires, C1019ABS, Argentina|Investigational Site Number :0360001, Macquarie Park, New South Wales, 2109, Australia|Investigational Site Number :0360002, Richmond, Victoria, 3121, Australia|Investigational Site Number :1520005, Santaigo, Reg Metropolitana De Santiago, 8241470, Chile|Investigational Site Number :1520004, Santiago, Reg Metropolitana De Santiago, 7500713, Chile|Investigational Site Number :1520002, Santiago, Reg Metropolitana De Santiago, 7500921, Chile|Investigational Site Number :1520001, Santiago, Reg Metropolitana De Santiago, 8420383, Chile|Investigational Site Number :1520003, Temuco, 4800827, Chile|Investigational Site Number :2500006, Bordeaux Cedex, France|Investigational Site Number :2500001, Nantes, 44093, France|Investigational Site Number :2500005, Paris, 75018, France|Investigational Site Number :2500003, Toulouse, 31059, France|Investigational Site Number :3800005, Aviano (PN), Friuli-Venezia Giulia, 33081, Italy|Investigational Site Number :3800003, Roma, Lazio, 00144, Italy|Investigational Site Number :3800001, Rozzano, Milano, 20089, Italy|Investigational Site Number :3800002, Orbassano, Torino, 10043, Italy|Investigational Site Number :3800006, Bologna, 40138, Italy|Investigational Site Number :3800004, Milano, 20133, Italy|Investigational Site Number :3800008, Padova, 35128, Italy|Investigational Site Number :3920005, Nagoya-shi, Aichi, 460-0001, Japan|Investigational Site Number :3920004, Matsuyama-shi, Ehime, 791-0280, Japan|Investigational Site Number :3920001, Sapporo-shi, Hokkaido, 003-0804, Japan|Investigational Site Number :3920002, Ube-shi, Yamaguchi, 755-0241, Japan|Investigational Site Number :4100002, Seoul, Seoul-teukbyeolsi, 03080, Korea, Republic of|Investigational Site Number :4100003, Seoul, Seoul-teukbyeolsi, 05505, Korea, Republic of|Investigational Site Number :4100001, Seoul, Seoul-teukbyeolsi, 06351, Korea, Republic of|Investigational Site Number :6160001, Warszawa, Mazowieckie, 02-781, Poland|Investigational Site Number :6160002, Poznan, Wielkopolskie, 60-693, Poland|Oncology Health Group-Site Number:8400001, Hato Rey, 00917, Puerto Rico|Investigational Site Number :7240006, Barcelona, Barcelona [Barcelona], 08035, Spain|Investigational Site Number :7240005, Barcelona / Sabadell, Catalunya [Cataluña], 08208, Spain|Investigational Site Number :7240003, Girona, Girona [Gerona], 17007, Spain|Investigational Site Number :7240001, Madrid, Madrid, Comunidad De, 28041, Spain|Investigational Site Number :7240004, Madrid, Madrid, Comunidad De, 28046, Spain|Investigational Site Number :7240002, Madrid, 28034, Spain|Investigational Site Number :1580003, Taichung City, 404, Taiwan|Investigational Site Number :1580002, Tainan, 704, Taiwan|Investigational Site Number :1580005, Taipei, Taiwan | |
| NCT03319537 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | https://clinicaltrials.gov/study/NCT03319537 | COMPLETED | DRUG: pevonedistat|DRUG: Pemetrexed and cisplatin | Memorial Sloan Kettering Cancer Center | M.D. Anderson Cancer Center | 9 | INTERVENTIONAL | Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, 11570, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States | |
| NCT00006014 | SU5416 in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00006014 | COMPLETED | DRUG: semaxanib | National Cancer Institute (NCI) | 45 | INTERVENTIONAL | University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States|Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, 62526, United States|Evanston Northwestern Health Care, Evanston, Illinois, 60201, United States|Division of Hematology/Oncology, Park Ridge, Illinois, 60068, United States|Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, 61602, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, 62701, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46885-5099, United States|Michiana Hematology/Oncology P.C., South Bend, Indiana, 46617, United States | ||
| NCT05071014 | A Study of Pembrolizumab and Cryoablation in People With Mesothelioma | https://clinicaltrials.gov/study/NCT05071014 | RECRUITING | DRUG: Pembrolizumab|PROCEDURE: Image-guided cryoablation | Memorial Sloan Kettering Cancer Center | 10 | INTERVENTIONAL | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York, 11553, United States | ||
| NCT05245500 | Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | https://clinicaltrials.gov/study/NCT05245500 | RECRUITING | DRUG: MRTX1719 | Mirati Therapeutics Inc. | 370 | INTERVENTIONAL | Mayo Clinic, Phoenix, Arizona, 85054, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, 80218, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, 32827, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|NorthShore Hematology Oncology Associates P.C New York Cancer and Blood Specialists, Port Jefferson Station, New York, 11776, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Oncology Consultants, P.A., Houston, Texas, 77030, United States|START Center for Cancer Care, San Antonio, Texas, 78229, United States|NEXT Virginia, Fairfax, Virginia, 22031, United States|Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States | ||
| NCT00897247 | Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite | https://clinicaltrials.gov/study/NCT00897247 | COMPLETED | GENETIC: microarray analysis|GENETIC: protein expression analysis|GENETIC: proteomic profiling|OTHER: laboratory biomarker analysis | Barbara Ann Karmanos Cancer Institute | National Cancer Institute (NCI) | 494 | OBSERVATIONAL | Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201-1379, United States | |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT05070247 | RECRUITING | DRUG: TAK-500|DRUG: Pembrolizumab | Takeda | 118 | INTERVENTIONAL | City of Hope, Duarte, California, 91010, United States|University of California San Diego, La Jolla, California, 92093-1503, United States|University of Colorado – Anschutz Medical Campus – PPDS, Aurora, Colorado, 80045, United States|Sarah Cannon Research Institute, Denver, Colorado, 80218-1238, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215-5418, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111-2434, United States|START South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229-3307, United States | ||
| NCT00004183 | Capecitabine in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00004183 | COMPLETED | DRUG: capecitabine | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | 27 | INTERVENTIONAL | Veterans Affairs Medical Center – Birmingham, Birmingham, Alabama, 35233-1996, United States|University of California San Diego Cancer Center, La Jolla, California, 92093-0658, United States|Veterans Affairs Medical Center – San Francisco, San Francisco, California, 94121, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94143-0128, United States|CCOP – Christiana Care Health Services, Wilmington, Delaware, 19899, United States|Lombardi Cancer Center, Washington, District of Columbia, 20007, United States|Walter Reed Army Medical Center, Washington, District of Columbia, 20307-5000, United States|CCOP – Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, 60612, United States|Veterans Affairs Medical Center – Chicago (Westside Hospital), Chicago, Illinois, 60612, United States|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States|Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, 52722, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, 52242-1009, United States|Veterans Affairs Medical Center – Togus, Togus, Maine, 04330, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, 21201, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States|Veterans Affairs Medical Center – Minneapolis, Minneapolis, Minnesota, 55417, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455, United States|Veterans Affairs Medical Center – Columbia (Truman Memorial), Columbia, Missouri, 65201, United States|Ellis Fischel Cancer Center – Columbia, Columbia, Missouri, 65203, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-3330, United States|CCOP – Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, 89106, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756-0002, United States|Veterans Affairs Medical Center – Buffalo, Buffalo, New York, 14215, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States|CCOP – North Shore University Hospital, Manhasset, New York, 11030, United States|North Shore University Hospital, Manhasset, New York, 11030, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|New York Presbyterian Hospital – Cornell Campus, New York, New York, 10021, United States|Mount Sinai Medical Center, NY, New York, New York, 10029, United States|State University of New York – Upstate Medical University, Syracuse, New York, 13210, United States|Veterans Affairs Medical Center – Syracuse, Syracuse, New York, 13210, United States|CCOP – Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, 13217, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, 27599-7295, United States|Veterans Affairs Medical Center – Durham, Durham, North Carolina, 27705, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States|CCOP – Southeast Cancer Control Consortium, Winston-Salem, North Carolina, 27104-4241, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, 27157-1082, United States|Arthur G. James Cancer Hospital – Ohio State University, Columbus, Ohio, 43210-1240, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Medical University of South Carolina, Charleston, South Carolina, 29425-0721, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, 38103, United States|Veterans Affairs Medical Center – Memphis, Memphis, Tennessee, 38104, United States|CCOP – Southwestern Vermont Regional Cancer Center, Bennington, Vermont, 05201, United States|Vermont Cancer Center, Burlington, Vermont, 05401-3498, United States|Veterans Affairs Medical Center – White River Junction, White River Junction, Vermont, 05009, United States|Veterans Affairs Medical Center – Richmond, Richmond, Virginia, 23249, United States|MBCCOP – Massey Cancer Center, Richmond, Virginia, 23298-0037, United States | |
| NCT03926143 | A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | https://clinicaltrials.gov/study/NCT03926143 | TERMINATED | DRUG: BAY94-9343 (Anetumab ravtansine) | Bayer | 9 | INTERVENTIONAL | University of Chicago, Chicago, Illinois, 60637, United States|National Cancer Institute – Maryland, Bethesda, Maryland, 20892, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States|Mary Crowley Medical Research Center, Dallas, Texas, 75230, United States|Hôpital de la Timone – Marseille, Marseille, 13385, France|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, 20162, Italy|Samodzielny Publiczny Wojewodzki Szpital Zespolony, Szczecin-Zdunowo, 70-891, Poland | ||
| NCT00748085 | CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD) | https://clinicaltrials.gov/study/NCT00748085 | ICEtheMAD | TERMINATED | DEVICE: CryoSpray Ablation | CSA Medical, Inc. | 5 | INTERVENTIONAL | Franklin Square Hospital Center, Baltimore, Maryland, 21237, United States | |
| NCT03277352 | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | https://clinicaltrials.gov/study/NCT03277352 | TERMINATED | DRUG: INCAGN01876|DRUG: Epacadostat|DRUG: Pembrolizumab | Incyte Biosciences International Sàrl | 10 | INTERVENTIONAL | The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States | ||
| NCT02648763 | Staging Procedures to Diagnose Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02648763 | RECRUITING | Mayo Clinic | 200 | OBSERVATIONAL | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | |||
| NCT00066404 | Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions | https://clinicaltrials.gov/study/NCT00066404 | COMPLETED | BIOLOGICAL: recombinant adenovirus-hIFN-beta | Abramson Cancer Center at Penn Medicine | National Cancer Institute (NCI) | INTERVENTIONAL | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT00003263 | Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00003263 | COMPLETED | BIOLOGICAL: recombinant interferon alfa|DRUG: cisplatin|PROCEDURE: surgical procedure|RADIATION: radiation therapy | Fox Chase Cancer Center | National Cancer Institute (NCI) | 6 | INTERVENTIONAL | Office of S. Terry Kraus, Marrero, Louisiana, 70072, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Virginia Oncology Associates, Newport News, Virginia, 23606, United States | |
| NCT01604863 | A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies | https://clinicaltrials.gov/study/NCT01604863 | SUSPENDED | DRUG: HGS1036 + Paclitaxel + Carboplatin|DRUG: HGS1036 + Cisplatin + Etoposide|DRUG: HGS1036 + Docetaxel | Human Genome Sciences Inc., a GSK Company | 54 | INTERVENTIONAL | Scottsdale, Arizona, 85258, United States|Boston, Massachusetts, 02114, United States | ||
| NCT02959463 | Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT02959463 | ACTIVE_NOT_RECRUITING | OTHER: Laboratory Biomarker Analysis|RADIATION: Palliative Radiation Therapy|BIOLOGICAL: Pembrolizumab|RADIATION: Radiation Therapy | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | 24 | INTERVENTIONAL | M D Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | https://clinicaltrials.gov/study/NCT05451849 | RECRUITING | BIOLOGICAL: TC-510|DRUG: Fludarabine|DRUG: Cyclophosphamide | TCR2 Therapeutics | 140 | INTERVENTIONAL | University of California, San Francisco, San Francisco, California, 94143, United States|University of Miami, Miami, Florida, 33146, United States|National Cancer Institute, Bethesda, Maryland, 20814, United States|University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, 55455, United States|Montefiore Einstein Cancer Center, Bronx, New York, 10461, United States|University of Oklahoma, Oklahoma City, Oklahoma, 73104, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States | ||
| NCT00354393 | Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00354393 | COMPLETED | DRUG: Cisplatin|DRUG: Methotrexate|DRUG: Vinorelbine ditartrate|PROCEDURE: Adjuvant therapy|PROCEDURE: Conventional surgery|PROCEDURE: Neoadjuvant Therapy|RADIATION: 3-dimensional conformal radiation therapy|RADIATION: Intensity-modulated radiation therapy | The Cleveland Clinic | National Cancer Institute (NCI) | 9 | INTERVENTIONAL | Case Comprehensive Cancer Center, Cleveland, Ohio, 44106-5065, United States | |
| NCT04847063 | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | https://clinicaltrials.gov/study/NCT04847063 | RECRUITING | DRUG: Mitomycin C|DRUG: Cisplatin|PROCEDURE: Heated Intraperitonial Chemotherapy|DRUG: Doxorubicin|DRUG: Oxaliplatin|DRUG: 5-Fluorouracil|DRUG: Sodium Thiosulfate | National Cancer Institute (NCI) | 60 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | https://clinicaltrials.gov/study/NCT03420963 | RECRUITING | BIOLOGICAL: Cord Blood-derived Expanded Allogeneic Natural Killer Cells|DRUG: Cyclophosphamide|DRUG: Etoposide | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | 38 | INTERVENTIONAL | M D Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | https://clinicaltrials.gov/study/NCT04792463 | RECRUITING | Mohamed Abdel-Rahman | 500 | OBSERVATIONAL | The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States | |||
| NCT00132704 | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation | https://clinicaltrials.gov/study/NCT00132704 | COMPLETED | RADIATION: Ionizing radiation (IR) therapy|RADIATION: Ionizing radiation (IR) | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI) | 149 | OBSERVATIONAL | Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States | |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | https://clinicaltrials.gov/study/NCT03507452 | COMPLETED | DRUG: BAY2287411|DRUG: BAY2287411 | Bayer | 36 | INTERVENTIONAL | National Cancer Institute – Maryland, Bethesda, Maryland, 20892, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|HUS, Meilahden sairaala, Helsinki, 00290, Finland|Nederlands Kanker Instituut, Amsterdam, 1066 CX, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Skånes Universitetssjukhus, Lund, 221 85, Sweden|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, SM2 5PT, United Kingdom | ||
| NCT04429204 | Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma | https://clinicaltrials.gov/study/NCT04429204 | WITHDRAWN | PROCEDURE: Biospecimen Collection|PROCEDURE: Cryosurgery | Jonsson Comprehensive Cancer Center | 0 | INTERVENTIONAL | UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States | ||
| NCT00027508 | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00027508 | TERMINATED | DRUG: trabectedin | PharmaMar | National Cancer Institute (NCI) | INTERVENTIONAL | Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States | ||
| NCT02639091 | Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | https://clinicaltrials.gov/study/NCT02639091 | COMPLETED | DRUG: BAY 94-9343|DRUG: Pemetrexed|DRUG: Cisplatin | Bayer | 36 | INTERVENTIONAL | Chicago, Illinois, 60637, United States|Bethesda, Maryland, 20892, United States|Detroit, Michigan, 48202, United States|Charleston, South Carolina, 29425, United States|Milano, Lombardia, 20089, Italy|Milano, Lombardia, 20133, Italy | ||
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | https://clinicaltrials.gov/study/NCT05500508 | RECRUITING | DRUG: AMXT1501|DRUG: DFMO | Aminex Therapeutics, Inc. | 56 | INTERVENTIONAL | Mayo Clinic – Arizona, Phoenix, Arizona, 85054, United States|Mayo Clinic – Florida, Jacksonville, Florida, 32224, United States|Mayo Clinic – Minnesota, Rochester, Minnesota, 55905, United States|Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, 45229, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutch Cancer Center – Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Kids Cancer Centre, Sydney, New South Wales, Australia | ||
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01870609 | COMMAND | TERMINATED | DRUG: defactinib (VS-6063)|DRUG: Placebo | Verastem, Inc. | 344 | INTERVENTIONAL | University of California San Francisco Medical Center, San Francisco, California, United States|Cleveland Clinic Florida, Weston, Florida, 33331, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Jacobi Medical Center, Bronx, New York, 10461, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cleveland Clinic, Cleveland, Ohio, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|Peninsula Oncology Centre, Frankston, Victoria, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Chris O’Brien Lifehouse at RPA, Camperdown, Australia|Monash Cancer Center, East Bentlrigh, 3165, Australia|Epworth Hospital, Melbourne, Australia|Northern Cancer Institute, Sydney, Australia|Calvary Mater Newcastle, Waratah, Australia|Princess Alexandra Hospital +61(0)7 3176 5054, Woolloongabba, QLD 4102, Australia|UCL – St. Luc, Brussel, Belgium|Antwerp University Hospital, Edegem, Belgium|University Hopsital Ghent, Ghent, Belgium|Universitaire Ziekenhuizen Leuven (University Hospitals Leuven), Leuven, Belgium|CHU Liege – Sart Tilman, Liege, Belgium|Princess Margaret Hospital, Toronto, Ontario, Canada|CHRU, Lille, Lille, France|Hôpitaux de Marseille, Marseille, France|Gustave Roussy, Villejuif, France|Cliniche Humanitas Gavazzeni, Bergamo, Italy|Istituto Oncologico Veneto, Padova, Italy|Kyushu Cancer Center, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Hyogo College of Medicine, Hyogo, Japan|Okayama Rousai Hospital, Okayama, Japan|Kinki University Hospital, Osaka, Japan|Juntendo University, Tokyo, Japan|Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Medisch Spectrum Twente, Enschede, Enschede, Netherlands|Atrium MC, Heerlen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland Oncology Research Centre, Auckland, New Zealand|Canterbury Regional Cancer & Haematology Service, Christchurch, New Zealand|Norwegian Radium Hospital, Oslo, Norway|Centrum Pulmonologii Ii Torakochirurgii w Bystrej, Bystra, Poland|Iatros International / Bloemfontein Medi-Clinic, Bloemfontein, Free State, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Mary Potter Oncology Center, Little Company of Mary Hospital, Pretoria, South Africa|Institut Oncològic del Vallés Consorci Hospitalari Parc Tauli, Barcelona, Spain|Vall d’Hebron University Hospital, Barcelona, Spain|Ensayos Clínicos Oncología, Madrid, Spain|Hospital Madrid Norte- Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain|Skane University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Uppsala, Sweden|Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom|Southmead Hospital, Bristol, United Kingdom|Addenbrooke’s Hospital, Cambridge, United Kingdom|Velindre Hospital Cardiff, Cardiff, United Kingdom|Broomfield Hospital, Chelmsford, CM1 7ET, United Kingdom|Tayside Cancer Centre, Dundee, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Kent Oncology Centre, Maidstone Hospital, Kent, United Kingdom|University of Leicester, Leicester, United Kingdom|Guys Hospital, London, United Kingdom|St. Bartholomew’s Hospital, London, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom|Southampton General Hospital, Southampton, United Kingdom | |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations | https://clinicaltrials.gov/study/NCT04665206 | RECRUITING | DRUG: VT3989 | Vivace Therapeutics, Inc | 188 | INTERVENTIONAL | University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, San Antonio, Texas, 78229, United States|Monash Health, Clayton, Victoria, 3168, Australia|Peter MacCullum Cancer Centre, Melbourne, Victoria, 3000, Australia|Linear Clinical Research, Nedlands, Western Australia, 6009, Australia | ||
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT03685591 | TERMINATED | DRUG: PF-06952229|DRUG: Enzalutamide | Pfizer | 49 | INTERVENTIONAL | HonorHealth, Scottsdale, Arizona, 85258, United States|UCLA Dept of Medicine -Hematology/Oncology,Santa Monica, Santa Monica, California, 90404, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mass General/ North Shore Center for Outpatient Care, Danvers, Massachusetts, 01923, United States|Dana-Farber Cancer Institute – Chestnut Hill, Newton, Massachusetts, 02459, United States|OU Medical Center Presbyterian Tower, Oklahoma City, Oklahoma, 73104, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Sarah Cannon Research Institute – Pharmacy, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|The Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, San Antonio, Texas, 78229, United States | ||
| NCT00003508 | Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma | https://clinicaltrials.gov/study/NCT00003508 | TERMINATED | DRUG: Antineoplaston therapy (Atengenal + Astugenal) | Burzynski Research Institute | 8 | INTERVENTIONAL | Burzynski Clinic, Houston, Texas, 77055-6330, United States | ||
| NCT05185791 | ERAS® Guidelines Validation of CRS With or Without HIPEC | https://clinicaltrials.gov/study/NCT05185791 | RECRUITING | OTHER: Pre-ERAS® phase (current clinical practice)|OTHER: Post-ERAS® implementation phase | Hospices Civils de Lyon | 288 | OBSERVATIONAL | University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, Alberta, T2N 1N4, Canada|Lausanne University Hospital, Lausanne, 1011, Switzerland | ||
| NCT00137826 | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | https://clinicaltrials.gov/study/NCT00137826 | COMPLETED | DRUG: Erlotinib|DRUG: Bevacizumab | Dana-Farber Cancer Institute | Massachusetts General Hospital|University of Chicago | 37 | INTERVENTIONAL | The University of Chicago, Chicago, Illinois, 60637, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States | |
| NCT02464904 | Intrapleural Cryotherapy for Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02464904 | TERMINATED | PROCEDURE: Cryotherapy|OTHER: Control | Mayo Clinic | CSA Medical, Inc. | 17 | INTERVENTIONAL | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | |
| NCT00685204 | An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00685204 | TL139 | UNKNOWN | DRUG: Milataxel | Taxolog Inc. | 90 | INTERVENTIONAL | Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Chicago, Chicago, Illinois, 60637, United States|New York University Cancer Center, New York, New York, 10016, United States | |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | https://clinicaltrials.gov/study/NCT02568449 | COMPLETED | DRUG: Nintedanib | Barbara Ann Karmanos Cancer Institute | National Cancer Institute (NCI) | 20 | INTERVENTIONAL | University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | |
| NCT00055705 | PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer | https://clinicaltrials.gov/study/NCT00055705 | COMPLETED | BIOLOGICAL: PV701 | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL | Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States | ||
| NCT04577326 | Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma | https://clinicaltrials.gov/study/NCT04577326 | RECRUITING | DRUG: cyclophosphamide|BIOLOGICAL: CAR T cells | Memorial Sloan Kettering Cancer Center | Atara Biotherapeutics | 30 | INTERVENTIONAL | Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States | |
| NCT00733252 | Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease | https://clinicaltrials.gov/study/NCT00733252 | WITHDRAWN | PROCEDURE: bronchoscopic and lung imaging studies|PROCEDURE: diagnostic bronchoscopy|PROCEDURE: histopathologic examination|PROCEDURE: optical coherence tomography | Case Comprehensive Cancer Center | National Cancer Institute (NCI) | 0 | OBSERVATIONAL | Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, 44106-5065, United States | |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | https://clinicaltrials.gov/study/NCT03907852 | RECRUITING | BIOLOGICAL: gavo-cel|DRUG: fludarabine|DRUG: cyclophosphamide|DRUG: Nivolumab|DRUG: Ipilimumab | TCR2 Therapeutics | Bristol-Myers Squibb | 175 | INTERVENTIONAL | University of California, San Francisco, San Francisco, California, 94143, United States|University of Miami Sylvester Cancer Center, Miami, Florida, 33136, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|National Cancer Institute, Bethesda, Maryland, 20814, United States|Columbia University Medical Center, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Duke University, Durham, North Carolina, 27705, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2C1, Canada | |
| NCT04056026 | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma | https://clinicaltrials.gov/study/NCT04056026 | COMPLETED | BIOLOGICAL: Fecal Microbiota Transplant | ProgenaBiome | 1 | INTERVENTIONAL | ProgenaBiome, Ventura, California, 93003, United States | ||
| NCT00028782 | EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer | https://clinicaltrials.gov/study/NCT00028782 | TERMINATED | DRUG: etanidazole|PROCEDURE: therapeutic conventional surgery|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 80 | INTERVENTIONAL | Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT00039182 | Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung | https://clinicaltrials.gov/study/NCT00039182 | COMPLETED | DRUG: erlotinib hydrochloride|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 55 | INTERVENTIONAL | Southwest Oncology Group, San Antonio, Texas, 78245, United States | ||
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | https://clinicaltrials.gov/study/NCT01135849 | COMPLETED | Daniel Bernstein | 99 | OBSERVATIONAL | Stanford University School of Medicine, Stanford, California, 94305, United States | |||
| NCT00770120 | S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery | https://clinicaltrials.gov/study/NCT00770120 | COMPLETED | DRUG: everolimus | SWOG Cancer Research Network | National Cancer Institute (NCI) | 61 | INTERVENTIONAL | Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, 85724-5024, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, 90089-9181, United States|Tibotec Therapeutics – Division of Ortho Biotech Products, LP, Marysville, California, 95901, United States|Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, 92868, United States|Valley Medical Oncology Consultants – Pleasanton, Pleasanton, California, 94588, United States|University of California Davis Cancer Center, Sacramento, California, 95817, United States|San Luis Valley Regional Medical Center, Alamosa, Colorado, 81101, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, 80045, United States|Shaw Regional Cancer Center, Edwards, Colorado, 81632, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, 81601, United States|Montrose Memorial Hospital Cancer Center, Montrose, Colorado, 81401, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, 06105, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, 62526, United States|Edward Hospital Cancer Center, Naperville, Illinois, 60540, United States|Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, 62781-0001, United States|St. Francis Hospital and Health Centers – Beech Grove Campus, Beech Grove, Indiana, 46107, United States|Reid Hospital & Health Care Services, Richmond, Indiana, 47374, United States|Cancer Center of Kansas, PA – Chanute, Chanute, Kansas, 66720, United States|Cancer Center of Kansas, PA – Dodge City, Dodge City, Kansas, 67801, United States|Cancer Center of Kansas, PA – El Dorado, El Dorado, Kansas, 67042, United States|Cancer Center of Kansas – Fort Scott, Fort Scott, Kansas, 66701, United States|Cancer Center of Kansas-Independence, Independence, Kansas, 67301, United States|Cancer Center of Kansas, PA – Kingman, Kingman, Kansas, 67068, United States|Lawrence Memorial Hospital, Lawrence, Kansas, 66044, United States|Cancer Center of Kansas, PA – Liberal, Liberal, Kansas, 67905, United States|Cancer Center of Kansas, PA – Newton, Newton, Kansas, 67114, United States|Cancer Center of Kansas, PA – Parsons, Parsons, Kansas, 67357, United States|Cancer Center of Kansas, PA – Pratt, Pratt, Kansas, 67124, United States|Cancer Center of Kansas, PA – Salina, Salina, Kansas, 67401, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, 67401, United States|Cancer Center of Kansas, PA – Wellington, Wellington, Kansas, 67152, United States|Associates in Womens Health, PA – North Review, Wichita, Kansas, 67208, United States|Cancer Center of Kansas, PA – Medical Arts Tower, Wichita, Kansas, 67208, United States|Cancer Center of Kansas, PA – Wichita, Wichita, Kansas, 67214, United States|CCOP – Wichita, Wichita, Kansas, 67214, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, 67214, United States|Cancer Center of Kansas, PA – Winfield, Winfield, Kansas, 67156, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, 48106-0995, United States|CCOP – Michigan Cancer Research Consortium, Ann Arbor, Michigan, 48106, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0942, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, 48123-2500, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201-1379, United States|Genesys Hurley Cancer Institute, Flint, Michigan, 48503, United States|Hurley Medical Center, Flint, Michigan, 48503, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, 48236, United States|Foote Memorial Hospital, Jackson, Michigan, 49201, United States|Sparrow Regional Cancer Center, Lansing, Michigan, 48912-1811, United States|St. Mary Mercy Hospital, Livonia, Michigan, 48154, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, 48341-2985, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, 48060, United States|Seton Cancer Institute at Saint Mary’s – Saginaw, Saginaw, Michigan, 48601, United States|St. John Macomb Hospital, Warren, Michigan, 48093, United States|CCOP – Montana Cancer Consortium, Billings, Montana, 59101, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, 59101, United States|Hematology-Oncology Centers of the Northern Rockies – Billings, Billings, Montana, 59102, United States|Billings Clinic – Downtown, Billings, Montana, 59107-7000, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, 59715, United States|St. James Healthcare Cancer Care, Butte, Montana, 59701, United States|Great Falls Clinic – Main Facility, Great Falls, Montana, 59405, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, 59405, United States|Northern Montana Hospital, Havre, Montana, 59501, United States|St. Peter’s Hospital, Helena, Montana, 59601, United States|Glacier Oncology, PLLC, Kalispell, Montana, 59901, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, 59901, United States|Kalispell Regional Medical Center, Kalispell, Montana, 59901, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, 59807-7877, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, 59807, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, 87131-5636, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, 28233-3549, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, 27534, United States|Iredell Memorial Hospital, Statesville, North Carolina, 28677, United States|Mary Rutan Hospital, Bellefontaine, Ohio, 43311, United States|Adena Regional Medical Center, Chillicothe, Ohio, 45601, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, 43214-3998, United States|CCOP – Columbus, Columbus, Ohio, 43215, United States|Grant Medical Center Cancer Care, Columbus, Ohio, 43215, United States|Mount Carmel Health – West Hospital, Columbus, Ohio, 43222, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, 43228, United States|Grandview Hospital, Dayton, Ohio, 45405, United States|Good Samaritan Hospital, Dayton, Ohio, 45406, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, 45409, United States|Samaritan North Cancer Care Center, Dayton, Ohio, 45415, United States|CCOP – Dayton, Dayton, Ohio, 45420, United States|Grady Memorial Hospital, Delaware, Ohio, 43015, United States|Blanchard Valley Medical Associates, Findlay, Ohio, 45840, United States|Middletown Regional Hospital, Franklin, Ohio, 45005-1066, United States|Wayne Hospital, Greenville, Ohio, 45331, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, 45429, United States|Fairfield Medical Center, Lancaster, Ohio, 43130, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, 45750, United States|Knox Community Hospital, Mount Vernon, Ohio, 43050, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, 43055, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, 45505, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, 45373-1300, United States|Mount Carmel St. Ann’s Cancer Center, Westerville, Ohio, 43081, United States|Clinton Memorial Hospital, Wilmington, Ohio, 45177, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, 45385, United States|Genesis – Good Samaritan Hospital, Zanesville, Ohio, 43701, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, 97015, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, 97222, United States|Providence Newberg Medical Center, Newberg, Oregon, 97132, United States|Willamette Falls Hospital, Oregon City, Oregon, 97045, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, 97213-2967, United States|CCOP – Columbia River Oncology Program, Portland, Oregon, 97225, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center, Kingsport, Tennessee, 37662, United States|U.T. Medical Center Cancer Institute, Knoxville, Tennessee, 37920-6999, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, 77030-4009, United States|Danville Regional Medical Center, Danville, Virginia, 24541, United States|Southwest Virginia Regional Cancer Center at Wellmonth Health, Norton, Virginia, 24273, United States|St. Joseph Cancer Center, Bellingham, Washington, 98225, United States|Olympic Hematology and Oncology, Bremerton, Washington, 98310, United States|Columbia Basin Hematology, Kennewick, Washington, 99336, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, 98273, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, 98370, United States|Harborview Medical Center, Seattle, Washington, 98104, United States|Minor and James Medical, PLLC, Seattle, Washington, 98104, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Group Health Central Hospital, Seattle, Washington, 98112, United States|Swedish Cancer Institute at Swedish Medical Center – First Hill Campus, Seattle, Washington, 98122-4307, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, 98195, United States|Cancer Care Northwest – Spokane South, Spokane, Washington, 99202, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, 99218, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, 98668, United States|Northwest Cancer Specialists at Vancouver Cancer Center, Vancouver, Washington, 98684, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, 98801-2028, United States|Rocky Mountain Oncology, Casper, Wyoming, 82609, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, 82801, United States | |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT02399371 | ACTIVE_NOT_RECRUITING | BIOLOGICAL: Pembrolizumab|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacogenomic Study | University of Chicago | National Cancer Institute (NCI) | 65 | INTERVENTIONAL | University of Chicago, Chicago, Illinois, 60637, United States | |
| NCT00024271 | Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer | https://clinicaltrials.gov/study/NCT00024271 | UNKNOWN | BIOLOGICAL: recombinant interferon gamma|DRUG: cisplatin|DRUG: doxorubicin hydrochloride|DRUG: gemcitabine hydrochloride|DRUG: mitomycin C|PROCEDURE: conventional surgery|PROCEDURE: hyperthermia treatment|RADIATION: radiation therapy | Herbert Irving Comprehensive Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL | Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, 10032, United States | ||
| NCT00020579 | MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma | https://clinicaltrials.gov/study/NCT00020579 | COMPLETED | DRUG: entinostat | National Institutes of Health Clinical Center (CC) | National Cancer Institute (NCI) | 75 | INTERVENTIONAL | National Naval Medical Center, Bethesda, Maryland, 20889-5000, United States|Warren Grant Magnuson Clinical Center – NCI Clinical Studies Support, Bethesda, Maryland, 20892-1182, United States|NCI – Center for Cancer Research, Bethesda, Maryland, 20892, United States | |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment | https://clinicaltrials.gov/study/NCT04028479 | ROOT | RECRUITING | DIAGNOSTIC_TEST: Biomarker Testing (L)|DRUG: Systemic Treatment (T)|OTHER: Patient Reported Outcomes (P) | Taproot Health | 100000 | OBSERVATIONAL | Teton Cancer Institute, Idaho Falls, Idaho, 83404, United States|Oncology and Hematology of South Texas, Laredo, Texas, 78041, United States | |
| NCT01766739 | Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma | https://clinicaltrials.gov/study/NCT01766739 | ACTIVE_NOT_RECRUITING | BIOLOGICAL: GL-ONC1 | Memorial Sloan Kettering Cancer Center | Genelux Corporation | 18 | INTERVENTIONAL | Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States | |
| NCT05571839 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | https://clinicaltrials.gov/study/NCT05571839 | RECRUITING | DRUG: SGN-BB228 | Seagen Inc. | 275 | INTERVENTIONAL | University of California at San Francisco, San Francisco, California, 94158, United States|Sarah Cannon Research Institute at HealthONE – Denver, Denver, Colorado, 80218, United States|Northwestern University, Chicago, Illinois, 60611, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|NYU Langone Hospital, New York, New York, 10016, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, 98109, United States|Universitatsspital Zurich, Zurich, Other, 8091, Switzerland | ||
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT03918252 | RECRUITING | DRUG: Nivolumab Injection|DRUG: Ipilimumab Injection | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Bristol-Myers Squibb | 30 | INTERVENTIONAL | Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine, Baltimore, Maryland, 21201, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT02293005 | COMPLETED | DRUG: Alisertib | M.D. Anderson Cancer Center | Millennium Pharmaceuticals, Inc. | 28 | INTERVENTIONAL | University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01112293 | COMPLETED | DRUG: GC1008 | Abramson Cancer Center at Penn Medicine | 14 | INTERVENTIONAL | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT02372227 | TERMINATED | DRUG: VS-5584 and VS-6063 | Verastem, Inc. | 21 | INTERVENTIONAL | The University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Memorial Sloane Kettering Cancer Center, New York, New York, 10065, United States|University of Leicester, Leicester, United Kingdom|The Institute of Cancer Research, Sutton Surrey, United Kingdom | ||
| NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT03075527 | SUSPENDED | DRUG: Tremelimumab|DRUG: Durvalumab | Dana-Farber Cancer Institute | AstraZeneca | 19 | INTERVENTIONAL | Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States | |
| NCT00413075 | Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | https://clinicaltrials.gov/study/NCT00413075 | COMPLETED | DRUG: oral belinostat | Onxeo | Spectrum Pharmaceuticals, Inc | 121 | INTERVENTIONAL | Yale New Haven Hospital, New Haven, Connecticut, 06520, United States|Columbia University – Herbert Irving Cancer Center, New York, New York, 01132, United States|New York University Cancer Institute, New York, New York, 10016, United States|M.D. Anderson Cancer Center, Houston, Texas, 77230-1402, United States|Research Facility, Copenhagen, Denmark|Research Facility, London, Surrey, SW3 6JJ, United Kingdom | |
| NCT00002475 | Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | https://clinicaltrials.gov/study/NCT00002475 | COMPLETED | BIOLOGICAL: allogeneic tumor cell vaccine|BIOLOGICAL: autologous tumor cell vaccine|BIOLOGICAL: recombinant interferon alfa|BIOLOGICAL: recombinant interferon gamma|BIOLOGICAL: sargramostim|DRUG: cyclophosphamide | St. Vincent Medical Center – Los Angeles | 40 | INTERVENTIONAL | St. Vincent Medical Center – Los Angeles, Los Angeles, California, 90057-1901, United States | ||
| NCT04334759 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT04334759 | DREAM3R | RECRUITING | DRUG: Durvalumab|DRUG: Standard Chemotherapy|DRUG: Ipilimumab and Nivolumab | PrECOG, LLC. | AstraZeneca|Thoracic Oncology Group Australasia (TOGA)|University of Sydney | 480 | INTERVENTIONAL | University of California San Diego, La Jolla, California, 92093, United States|University of Miami, Miami, Florida, 33136, United States|Moffitt Cancer Center, Tampa, Florida, 18054, United States|Emory University, Atlanta, Georgia, 30322, United States|University of Chicago, Chicago, Illinois, 60637, United States|NorthShore University Health System/Kellogg Cancer Center, Evanston, Illinois, 60201, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States|Massaschusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55416, United States|Morristown Medical/Atlantic Health, Morristown, New Jersey, 07960, United States|Jersey Shore University Medical Center, Neptune, New Jersey, 07753, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Memorial Sloan Kettering, New York, New York, 10065, United States|University of Cincinnati, Cincinnati, Ohio, 45267, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|The Ohio State University, Columbus, Ohio, 43210, United States|Penn State Cancer Institute, Hershey, Pennsylvania, 17033, United States|Abramson Cancer Cener at Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15224, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|Canberra Hospital, Garran, Australian Capital Territory, 2605, Australia|Blacktown Hospital, Blacktown, New South Wales, 2148, Australia|Chris O’Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, 2450, Australia|Gosford Hospital, Gosford, New South Wales, 2250, Australia|Wyong Hospital, Hamlyn Terrace, New South Wales, 2259, Australia|Nepean Hospital, Kingswood, New South Wales, 2747, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Orange Health Service, Orange, New South Wales, 2800, Australia|Northern Cancer Institute (GenesisCare), Saint Leonards, New South Wales, 2065, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, 4066, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|Icon Cancer Care Chermside, Chermside, Queensland, 4032, Australia|The Prince Charles Hospital, Chermside, Queensland, 4032, Australia|Townsville University Hospital, Douglas, Queensland, 4814, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, 4101, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, 5011, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Launceston General Hospital, Launceston, Tasmania, 7250, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, 3199, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Epworth HealthCare – Richmond, Richmond, Victoria, 3121, Australia|Sunshine Hospital (Western Health), Saint Albans, Victoria, 3021, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Sir Charles Gairdner Hospital (SCGH), Nedlands, Western Australia, 6009, Australia|Auckland City Hospital, Grafton, Auckland, 1023, New Zealand |
| NCT02812875 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | https://clinicaltrials.gov/study/NCT02812875 | COMPLETED | DRUG: CA-170 | Curis, Inc. | 71 | INTERVENTIONAL | University of California San Francisco, San Francisco, California, 94143, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, 80218, United States|Sarah Cannon Research Institute, Sarasota, Florida, 34232, United States|Northwestern University, Chicago, Illinois, 60208, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Carolina BioOncology Institute, Huntersville, North Carolina, 28078, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15237, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Yonsei University Health System – Severance Hospital, Seoul, 3722, Korea, Republic of|Asan Medical Center, Seoul, 5505, Korea, Republic of|Hospital Clinic i Provincial, Barcelona, 08036, Spain|Catalan Institute of Oncology, Barcelona, 08907, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|Guy’s and St Thomas’ NHS Foundation Trust, London, SE1 9RT, United Kingdom | ||
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy | https://clinicaltrials.gov/study/NCT02661659 | WITHDRAWN | BIOLOGICAL: Multipeptide vaccine S-588210 | University of Chicago | 0 | INTERVENTIONAL | University of Chicago, Chicago, Illinois, 60637, United States | ||
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | https://clinicaltrials.gov/study/NCT03935893 | RECRUITING | BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Fludarabine + Cyclophosphamide combination | Udai Kammula | 240 | INTERVENTIONAL | UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States | ||
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | https://clinicaltrials.gov/study/NCT00165503 | TERMINATED | DRUG: Cisplatin|DRUG: Sodium Thiosulfate|DRUG: ALIMTA | Dana-Farber Cancer Institute | Brigham and Women’s Hospital | 16 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States | |
| NCT00006216 | Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma | https://clinicaltrials.gov/study/NCT00006216 | UNKNOWN | BIOLOGICAL: PA-1-STK ovarian carcinoma vaccine|DRUG: ganciclovir | Louisiana State University Health Sciences Center in New Orleans | INTERVENTIONAL | Louisiana State University School of Medicine, New Orleans, Louisiana, 70112-2822, United States | |||
| NCT02838745 | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM | https://clinicaltrials.gov/study/NCT02838745 | TERMINATED | DRUG: Pemetrexed|DRUG: Cisplatin | Baylor College of Medicine | 7 | INTERVENTIONAL | Baylor St Lukes, Houston, Texas, 77030, United States | ||
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment | https://clinicaltrials.gov/study/NCT00585845 | TERMINATED | BIOLOGICAL: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin | Anza Therapeutics, Inc. | 17 | INTERVENTIONAL | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, 21231, United States|National Cancer Institute, NCI, Bethesda, Maryland, 20892, United States|University of Pennsylvania Abramson Family Cancer Research Center, Philadelphia, Pennsylvania, 19104, United States|Hadassah Hebrew University Medical Center, Jerusalem, 91120, Israel | ||
| NCT00062283 | Alanosine in Treating Patients With Cancer | https://clinicaltrials.gov/study/NCT00062283 | COMPLETED | DRUG: L-alanosine | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL | University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35294-3300, United States|Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, 85724, United States|Wilshire Oncology Medical Group, Incorporated – La Verne, La Verne, California, 91750, United States|Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Lynn Regional Cancer Center West, Boca Raton, Florida, 33428, United States|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States|Midwest Cancer Research Group, Incorporated, Skokie, Illinois, 60077, United States|St. Vincent’s Comprehensive Cancer Center – Manhattan, New York, New York, 10011, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, 37232-6838, United States|MD Anderson Cancer Center at University of Texas, Houston, Texas, 77030, United States|U.S. Oncology, Incorporated, Houston, Texas, 77060, United States | ||
| NCT01401907 | Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | https://clinicaltrials.gov/study/NCT01401907 | COMPLETED | OTHER: early palliative care | Massachusetts General Hospital | 351 | INTERVENTIONAL | Massachusetts General Hospital, Boston, Massachusetts, 02114, United States | ||
| NCT00629343 | Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | https://clinicaltrials.gov/study/NCT00629343 | UNKNOWN | DRUG: Azacitidine In Combination With Temozolomide | Columbia University | Schering-Plough|Celgene Corporation | 28 | INTERVENTIONAL | Columbia University Medical Center, New York, New York, 10032, United States | |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT01592383 | COMPLETED | DRUG: erlotinib hydrochloride | University of Chicago | National Cancer Institute (NCI) | 2 | INTERVENTIONAL | University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637-1470, United States | |
| NCT02187783 | LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) | https://clinicaltrials.gov/study/NCT02187783 | SIGNATURE | COMPLETED | DRUG: LEE011 | Novartis Pharmaceuticals | 106 | INTERVENTIONAL | University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|Alaska Clinical Research, Anchorage, Alaska, 99503, United States|Arizona Oncology Associates Dept. Of Onc., Phoenix, Arizona, United States|University of Arkansas/ Arkansas Cancer Research Center UA Medical Sciences, Little Rock, Arkansas, 72205, United States|PCR Oncology, Pismo Beach, California, 93449, United States|University of California Davis Cancer Center UC Davis Cancer (3), Sacramento, California, 95817, United States|Sarah Cannon Research Institute, Denver, Colorado, 80218, United States|Danbury Hospital, Danbury, Connecticut, 06810, United States|Yale University School of Medicine Smilow Cancer Hospital, New Haven, Connecticut, 06520, United States|Whittingham Cancer Center Norwalk Hospital, Norwalk, Connecticut, 06856, United States|Stamford Hospital Med. Oncology Hematology Res., Stamford, Connecticut, 06902, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta, Georgia, 30060, United States|Harbin Clinic Medical Oncology Clin. Res., Rome, Georgia, 30165, United States|Queen’s Medical Center Queens Cancer Center, Honolulu, Hawaii, 96817, United States|Northwestern Medicine Developmental Therapeutics Institute, Chicago, Illinois, 60611, United States|Indiana University Indiana Univ. – Purdue Univ., Indianapolis, Indiana, 46202, United States|Northern Indiana Cancer Research Consortium No. Indiana Cancer Res., South Bend, Indiana, 46617, United States|University of Iowa Hospitals & Clinics Regulatory Contact 2, Iowa City, Iowa, 52242, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|St. Agnes Hospital St. Agnes Hospital (2), Baltimore, Maryland, 21229, United States|Michigan Medicine University of Michigan Int. Medicine Oncology, Ann Arbor, Michigan, 48109 5271, United States|Cancer and Hematology Centers of West Michigan Dept. of Oncology, Grand Rapids, Michigan, 49546, United States|Saint Luke’s Hospital/Marion Bloch Neuroscience Institute St. Luke’s Hospital (4), Kansas City, Missouri, 64111, United States|Research Medical Center Research Med Center (2), Kansas City, Missouri, 64132, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2), Las Vegas, Nevada, 89109, United States|Cooper Health System Cooper Health System (5), Camden, New Jersey, 08103, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, 87106, United States|Cancer Center at Presbyterian, Albuquerque, New Mexico, United States|Broome Oncology Broome Oncology (2), Johnson City, New York, 13790, United States|University of N C at Chapel Hill Physician Office Building, Chapel Hill, North Carolina, 27599-7600, United States|Carolina Oncology Specialists, PC, Hickory, North Carolina, 28602, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|Oncology Hematology Care Inc Oncology Hematology Care 2, Cincinnati, Ohio, 45242, United States|Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio, 44195, United States|Ohio State University Medical Center Comprehensive Cancer Center, Columbus, Ohio, 43221, United States|Oregon Health and Science University Oregon Health & Science U (56), Portland, Oregon, 97239, United States|Salem Health, Salem, Oregon, 97309, United States|Fox Chase Cancer Center Dept of Medical Oncology, Philadelphia, Pennsylvania, 19111, United States|Rhode Island Hospital Rhode Island Hosp. (2), Providence, Rhode Island, 02903, United States|Greenville Health System ITOR – Cancer Institute, Greenville, South Carolina, 29615, United States|Sanford University of South Dakota Medical Center Sanford Health, Sioux Falls, South Dakota, 57104, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, 37404, United States|The West Clinic Dept. of the West Clinic, Memphis, Tennessee, 38120, United States|Tennessee Oncology Tennessee Oncology (3), Nashville, Tennessee, 37203, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, 78404, United States|Oncology Consultants Oncology Group, Houston, Texas, 77024, United States|MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston, Texas, 77030, United States|University of Texas Health Science Center at San Antonio Cancer Therapy & Research Ctr., San Antonio, Texas, 78229, United States|Intermountain Medical Center Intermountain Healthcare, Murray, Utah, 84157, United States|Utah Cancer Specialists Utah Cancer Specialists (11), Salt Lake City, Utah, 84106, United States|Shenandoah Oncology Shenadoah Oncology (2), Winchester, Virginia, 22601, United States|Kadlec Clinic Hematology and Oncology Kadlec Clinic Hematology & Onc, Kennewick, Washington, 99336, United States|Vista Oncology Inc. PS, Olympia, Washington, 98502, United States|Multicare Research Institute, Tacoma, Washington, 98405, United States|Northwest Medical Specialties Rainier Physicians, PC, Tacoma, Washington, 98405, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, 98057, United States|Wenatchee Valley Medical Center Wenatchee Valley, Wenatchee, Washington, 98801, United States|Aurora Research Institute Aurora Health Care, Milwaukee, Wisconsin, 53226, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, 53226, United States | |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | https://clinicaltrials.gov/study/NCT03715933 | RECRUITING | DRUG: INBRX-109|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: 5-fluorouracil|DRUG: Irinotecan|DRUG: Temozolomide | Inhibrx, Inc. | 240 | INTERVENTIONAL | HonorHealth Research Institute, Scottsdale, Arizona, 85258, United States|City of Hope, Duarte, California, 91010, United States|Valkyrie Clinical Trials, Los Angeles, California, 90067, United States|University of California, San Diego (UCSD) – Moores Cancer Center, San Diego, California, 92093, United States|Sarcoma Oncology Center, Santa Monica, California, 90403, United States|University of Colorado Hospital, Aurora, Colorado, 80045, United States|Emory University – Winship Cancer Institute, Atlanta, Georgia, 30322, United States|The University of Chicago, Chicago, Illinois, 60637, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|START Midwest Michigan, PC, Grand Rapids, Michigan, 49546, United States|David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19106, United States|Vanderbilt University School of Medicine, Nashville, Tennessee, 37232, United States|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, San Antonio, Texas, 78229, United States|NEXT Oncology – Virginia, Fairfax, Virginia, 22031, United States | ||
| NCT03710876 | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT03710876 | INFINITE | ACTIVE_NOT_RECRUITING | BIOLOGICAL: rAd-IFN|DRUG: Celecoxib Oral Product|DRUG: Gemcitabine | Trizell Ltd | University of Pennsylvania | 53 | INTERVENTIONAL | University of California, Los Angeles (UCLA) – Medical Center, Los Angeles, California, 90059, United States|University of California, San Francisco (UCSF), San Francisco, California, 94158, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|University of Kansas Medical Center, Kansas City, Kansas, 66205, United States|University of Maryland Medical Center, Baltimore, Maryland, 21201, United States|Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Masonic Cancer Center – University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic – Rochester, Rochester, Minnesota, 55905, United States|New York University (NYU) Clinical Cancer Center, New York, New York, 10016, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Chris O’Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Québec, Sainte-Foy, G1V 4G5, Canada|CHU de Nantes – Hôpital Nord Laennec, Saint-Herblain, Nantes Cedex 1, 44093, France|Institut Bergonie, Bordeaux, 33076, France|CHRU de Brest – Hopital Augustin Morvan, Brest, 29200, France|CHU de Caen – Hopital Cote de Nacre, Caen, 14033, France|CHRU de Lille, Lille, 59037, France|Institut Curie – Oncologie Medicale, Paris, 75248, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Centre Hospitalier de Saint-Quentin, Saint-Quentin, 02 321, France|Ludwig-Maximilians-Universitaet Muenchen, Munich, Bavaria, 80336, Germany|Evangelisches Krankenhaus Hamm, Hamm, 59063, Germany|Universitatsklinikum Regensburg, Regensburg, 93053, Germany|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì-Cesena (FC), 47014, Italy|Azienda Ospedaliero Universitaria Senese, Cancer Immunotherapy, Siena, Tuscany, 53100, Italy|Med Polonia Sp. z o.o., Poznań, 60-693, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej – Curie, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, ul. Roentgena 5, Poland|Ogarev Mordovia State University, Saransk, The Republic Of Mordovia ;, 430005, Russian Federation|Kursk Regional Clinical Oncology Dispensary, Kursk, 305035, Russian Federation|Medicina 24/7, Moscow, 115280, Russian Federation|Budget Healthcare Institution of Omsk region Clinical Oncology Dispensary, Omsk, 644013, Russian Federation|State Budget Educational Institution of Higher Professional Education Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of Russian Federation, Saint Petersburg, 197022, Russian Federation|Petrov National Medical Research Center of Oncology, Saint Petersburg, 197758, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, 404130, Russian Federation|Derriford Hospital ; Derriford Hospital, Plymouth, Devon, PL6 8DH, United Kingdom|Beatson, West of Scotland Cancer Centre, Glasgow, Scotland, G12 0YN, United Kingdom|Royal Marsden Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom|Guy’s and St. Thomas’ NHS Trust, London, SE1 9RT, United Kingdom|Wythenshawe Hospital UHSM, Manchester, M23 9LT, United Kingdom|Churchill Hospital, Oxford, OX3 7LJ, United Kingdom |
| NCT01843374 | Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT01843374 | Tremelimumab | ACTIVE_NOT_RECRUITING | DRUG: Tremelimumab|DRUG: Placebo | MedImmune LLC | 571 | INTERVENTIONAL | Research Site, Scottsdale, Arizona, 85259, United States|Research Site, La Jolla, California, 92093, United States|Research Site, Los Angeles, California, 90025, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Santa Monica, California, 90404, United States|Research Site, New Haven, Connecticut, 06511, United States|Research Site, Newark, Delaware, 19718, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Augusta, Georgia, 30912, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Peoria, Illinois, 61615, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Baltimore, Maryland, 21231, United States|Research Site, Minneapolis, Minnesota, 55445, United States|Research Site, New York, New York, 10065, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Dallas, Texas, 75390, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Adelaide, 5000, Australia|Research Site, Auchenflower, 4066, Australia|Research Site, Box Hill, 3128, Australia|Research Site, Chermside, 4032, Australia|Research Site, East Bentleigh, 3165, Australia|Research Site, Gosford, 2250, Australia|Research Site, Heidelberg, 3084, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Saint Leonards, 2065, Australia|Research Site, Waratah, 2298, Australia|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Sainte Foy, Quebec, G1V 4G5, Canada|Research Site, Copenhagen, 2100, Denmark|Research Site, Caen Cedex, 14076, France|Research Site, Le Mans Cedex, 72037, France|Research Site, Lille Cedex, 59037, France|Research Site, Nice, 06189, France|Research Site, Rennes Cedex 9, 35033, France|Research Site, Toulouse, 31059, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Berlin, 13125, Germany|Research Site, Esslingen a.N., 73730, Germany|Research Site, Freiburg, 79106, Germany|Research Site, Gauting, 82131, Germany|Research Site, Grosshansdorf, 22927, Germany|Research Site, Hamburg, 21075, Germany|Research Site, Hemer, 58675, Germany|Research Site, Karlsruhe, 76137, Germany|Research Site, Lubeck, 23538, Germany|Research Site, Löwenstein, 74245, Germany|Research Site, Gyöngyös – Mátraháza, 3200, Hungary|Research Site, Törökbálint, 2045, Hungary|Research Site, Beer Sheva, 84101, Israel|Research Site, Alessandria, 15100, Italy|Research Site, Aviano, 33081, Italy|Research Site, Bergamo, 24125, Italy|Research Site, Bologna, 40138, Italy|Research Site, Candiolo, 10060, Italy|Research Site, Genova, 16132, Italy|Research Site, Meldola, 47014, Italy|Research Site, Milano, 20133, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Siena, 53100, Italy|Research Site, Jeonnam, 58128, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Breda, 4818 CK, Netherlands|Research Site, Eindhoven, 5623EJ, Netherlands|Research Site, Rotterdam, 3015 GD, Netherlands|Research Site, Gdansk, 80-952, Poland|Research Site, Poznan, 60-693, Poland|Research Site, Szczecin, 70-891, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Craiova, 200385, Romania|Research Site, Moscow, 115478, Russian Federation|Research Site, Nizhny Novgorod, 603006, Russian Federation|Research Site, Saint-Petersburg, 197022, Russian Federation|Research Site, Kraaifontein, 7570, South Africa|Research Site, Pretoria, 0081, South Africa|Research Site, Pretoria, 0181, South Africa|Research Site, Barcelona, 08035, Spain|Research Site, Madrid, 28040, Spain|Research Site, Sabadell (Barcelona), 08208, Spain|Research Site, San Sebastian, 20014, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Linkoping, 58185, Sweden|Research Site, Lund, 22185, Sweden|Research Site, Umea, SE90185, Sweden|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, Leicester, LE1 5WW, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Maidstone, ME16 9QQ, United Kingdom|Research Site, Manchester, M23 9LT, United Kingdom|Research Site, Plymouth, PL6 8DH, United Kingdom|Research Site, Southampton, SO16 6YD, United Kingdom|Research Site, Wirral, CH63 4JY, United Kingdom | |
| NCT00668499 | A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00668499 | WITHDRAWN | DRUG: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin | University of Southern California | Sponsor Name Pending | 0 | INTERVENTIONAL | USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States | |
| NCT02899299 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | https://clinicaltrials.gov/study/NCT02899299 | CheckMate743 | COMPLETED | BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin | Bristol-Myers Squibb | Ono Pharmaceutical Co. Ltd | 605 | INTERVENTIONAL | Ucsf, San Francisco, California, 94143, United States|Local Institution – 0014, New Haven, Connecticut, 06520, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, 33612, United States|Local Institution – 0002, Chicago, Illinois, 60637, United States|Univ Of Maryland Greenbaum Cancer Center, Baltimore, Maryland, 21201, United States|Local Institution – 0013, Detroit, Michigan, 48201, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, 49503, United States|Local Institution – 0004, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Nassau, New York, New York, 10065, United States|Local Institution – 0007, Cleveland, Ohio, 44195, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212, United States|Local Institution – 0005, Houston, Texas, 77030, United States|West Virginia University, Morgantown, West Virginia, 26506, United States|Local Institution – 0032, Sydney, New South Wales, 2139, Australia|Local Institution – 0031, Birtinya, Queensland, 4575, Australia|Local Institution – 0033, Clayton, Victoria, 3168, Australia|Local Institution – 0030, Malvern, Victoria, 3144, Australia|Local Institution – 0034, Nedlands, Western Australia, 6009, Australia|Local Institution – 0089, Brussels, 1090, Belgium|Local Institution – 0086, Edegem, 2650, Belgium|Local Institution – 0087, Liège, 4000, Belgium|Local Institution – 0088, Sint-Niklaas, 9100, Belgium|Local Institution, Barretos, Sao Paulo, 14784-400, Brazil|Local Institution – 0064, Sao Paulo, 05403-010, Brazil|Local Institution – 0018, Santiago, Metropolitana, 8420383, Chile|Local Institution – 0133, Harbin Shi, Heilongjiang, 150081, China|Local Institution, Changchun, Jilin, 130021, China|Local Institution, Shenyang, Liaoning, China|Local Institution – 0124, Kunming, 0, China|Local Institution – 0120, Shanghai, 200030, China|Local Institution – 0039, Bogota, 0, Colombia|Local Institution – 0040, Bogota, 0, Colombia|Local Institution – 0057, Caen, 14033, France|Local Institution – 0073, Creteil, 94010, France|Local Institution – 0074, La Tronche, 38700, France|Local Institution – 0067, Lille Cedex, 59037, France|Local Institution – 0069, Marseille Cedex 20, 13915, France|Local Institution – 0056, Paris, 75018, France|Local Institution – 0080, Saint Herblain, 44805, France|Local Institution – 0093, Strasbourg Cedex, 67091, France|Local Institution – 0058, Toulon Cedex, 83056, France|Local Institution – 0068, Toulouse Cedex 9, 31059, France|Local Institution – 0026, Cologne, 51109, Germany|Local Institution – 0054, Coswig, 01640, Germany|Local Institution – 0038, Essen, 45147, Germany|Local Institution, Essen, 45147, Germany|Local Institution – 0023, Gottingen, 37075, Germany|Local Institution – 0024, Grosshansdorf, 22927, Germany|Local Institution – 0027, Hamburg, 21075, Germany|Local Institution – 0037, Heidelberg, 69126, Germany|Local Institution – 0021, Homburg an d. Saar, 66421, Germany|Local Institution – 0022, Immenhausen, 34376, Germany|Local Institution – 0019, Moers, 47441, Germany|Local Institution – 0017, Athens, 11527, Greece|Local Institution – 0016, Thessaloniki, 57001, Greece|Local Institution – 0042, Ravenna, Emilia-Romagna, 48121, Italy|Local Institution – 0047, Aviano, 33081, Italy|Local Institution – 0044, Bari, 70124, Italy|Local Institution – 0046, Catania, 95124, Italy|Local Institution – 0045, Genova, 16132, Italy|Local Institution – 0043, Napoli, 80131, Italy|Local Institution – 0048, Rozzano, 20089, Italy|Local Institution – 0041, Siena, 53100, Italy|Local Institution – 0105, Nagoya-shi, Aichi, 4668560, Japan|Local Institution – 0097, Chiba-shi, Chiba, 2608677, Japan|Local Institution – 0108, Fukuyama-shi, Hiroshima, 7200001, Japan|Local Institution – 0114, Hiroshima-Shi, Hiroshima, 7348551, Japan|Local Institution – 0101, Sapporo-shi, Hokkaido, 0030804, Japan|Local Institution – 0106, Amagasaki-shi, Hyogo, 6608550, Japan|Local Institution – 0098, Nishinomiya-shi, Hyogo, 6638501, Japan|Local Institution – 0095, Yokohama-shi, Kanagawa, 2210855, Japan|Local Institution – 0104, Natori-shi, Miyagi, 9811293, Japan|Local Institution – 0107, Niigata-shi, Niigata, 9518520, Japan|Local Institution – 0100, Okayama-shi, Okayama, 7028055, Japan|Local Institution – 0096, Kitaadachi-gun, Saitama, 3620806, Japan|Local Institution – 0094, Chuo-ku, Tokyo, 1040045, Japan|Local Institution – 0099, Ube-shi, Yamaguchi, 7550241, Japan|Local Institution – 0113, Osakasayama-city, 5898511, Japan|Local Institution – 0079, Df, Distrito Federal, 06720, Mexico|Local Institution – 0053, Mexico, Distrito Federal, 14000, Mexico|Local Institution – 0050, Mexico, Distrito Federal, 14050, Mexico|Local Institution – 0051, Guadalajara, Jalisco, 44270, Mexico|Local Institution – 0118, Chihuahua, 31000, Mexico|Local Institution – 0092, Amsterdam, 1066 CX, Netherlands|Local Institution – 0091, Rotterdam, 3000 CA, Netherlands|Local Institution – 0078, Bytom, 41-902, Poland|Local Institution – 0076, Krakow, 31-202, Poland|Local Institution – 0077, Warszawa, 02-781, Poland|Local Institution – 0115, Bucharest, 020122, Romania|Local Institution – 0109, Bucuresti, 021389, Romania|Local Institution – 0102, Craiova, 200347, Romania|Local Institution – 0055, Romania, 400015, Romania|Local Institution – 0150, Moscow, 115478, Russian Federation|Local Institution – 0071, Moscow, 121309, Russian Federation|Local Institution – 0072, Saint Petersburg, 197758, Russian Federation|Local Institution – 0060, Pretoria, Gauteng, 0075, South Africa|Local Institution – 0059, Cape Town, Western Cape, 7570, South Africa|Local Institution – 0049, Bern, 3010, Switzerland|Local Institution – 0036, Lausanne, 1011, Switzerland|Local Institution – 0029, Zurich, 8091, Switzerland|Local Institution – 0111, Diyarbakır, 21280, Turkey|Local Institution – 0112, Istanbul, 34098, Turkey|Local Institution – 0110, Seyhan, 01130, Turkey|Local Institution – 0085, Truro, Cornwall, TR1 3LJ, United Kingdom|Local Institution – 0084, Edinburgh, Midlothian, EH4 2XU, United Kingdom|Local Institution – 0081, Leicester, LE1 5WW, United Kingdom|Local Institution – 0083, London, EC1A 7BE, United Kingdom|Local Institution – 0116, Manchester, M23 9LT, United Kingdom|Local Institution – 0090, Southampton, SO16 6YD, United Kingdom |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | https://clinicaltrials.gov/study/NCT01851395 | RECRUITING | National Cancer Institute (NCI) | 275 | OBSERVATIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | |||
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | https://clinicaltrials.gov/study/NCT04794699 | RECRUITING | DRUG: IDE397|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Nab paclitaxel|DRUG: Pemetrexed | IDEAYA Biosciences | 382 | INTERVENTIONAL | Honor Health Research Institute, Scottsdale, Arizona, 85258, United States|City of Hope, Duarte, California, 91010, United States|Indiana University Health Hospital, Indianapolis, Indiana, 46202, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Columbia University Medical Center – Herbert Irving Pavilion, New York, New York, 10032, United States|Weill Cornell Medical College, New York, New York, 10065, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, 37203, United States|MD Anderson, Houston, Texas, 77030, United States|Next Oncology, San Antonio, Texas, 78229, United States | ||
| NCT04104776 | A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | https://clinicaltrials.gov/study/NCT04104776 | RECRUITING | DRUG: CPI-0209 | Constellation Pharmaceuticals | 213 | INTERVENTIONAL | Emory University Hospital, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|University of Maryland – Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|START Midwest, Grand Rapids, Michigan, 49546, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Montefiore Einstein Center for Cancer Care, Bronx, New York, 10461, United States|NYU Langone Medical Center – Laura and Isaac Perlmutter Cancer Center, New York, New York, 10016, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45219, United States|START San Antonio, San Antonio, Texas, 78229, United States|University of Virginia Cancer Center, Charlottesville, Virginia, 22903, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Hospital Universitario de Salamanca, Salamanca, Castilla Y Leon, 37007, Spain|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom | ||
| NCT02613299 | Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT02613299 | RECRUITING | Mayo Clinic | 200 | OBSERVATIONAL | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | |||
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT04242199 | RECRUITING | DRUG: INCB099280 | Incyte Corporation | 203 | INTERVENTIONAL | Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Upmc Cancercenter, Pittsburgh, Pennsylvania, 15232, United States|Md Anderson Cancer Center, Houston, Texas, 77030, United States|University of Washington, Seattle, Washington, 98195, United States|Chris Obrien Lifehouse, Camperdown, New South Wales, 02050, Australia|Austin Hospital, Heidelberg, Victoria, 03084, Australia|Nucleus Network Pty Ltd, Melbourne, Victoria, 03004, Australia|Linear Clinical Research, Nedlands, Western Australia, 06009, Australia|Cliniques Universitaires Ucl Saint-Luc, Brussels, 01200, Belgium|Institut Jules Bordet Clinical Trials Conduct Unit, Brussels, B-1070, Belgium|Universitair Ziekenhuis Antwerpen (Uza), Edegem, 02650, Belgium|Ghent University Hospital, Ghent, 09000, Belgium|Universitaire Ziekenhuis Leuven – Gasthuisberg, Leuven, 03000, Belgium|Institut de Cancerologie de L Ouest – Site Paul Papin, Angers, 49000, France|Institut Bergonie, Bordeaux, 33000, France|Chu Hopital de La Timone, Marseille Cedex 5, 13385, France|Centre Eugene Marquis, Rennes, 35042, France|Institut Gustave Roussy, Villejuif, 94800, France|National Cancer Center Hospital East, Chiba, 277-8577, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan | ||
| NCT02899195 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma | https://clinicaltrials.gov/study/NCT02899195 | PrE0505 | COMPLETED | DRUG: Durvalumab | PrECOG, LLC. | AstraZeneca | 55 | INTERVENTIONAL | University San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, 90095, United States|Stanford Cancer Institute, Stanford, California, 94305, United States|University of Colorado, Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|University of Miami Hospital, Miami, Florida, 33136, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|NorthShore University HealthSystem, Evanston, Illinois, 60201, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55416, United States|Washington University in St Louis, Saint Louis, Missouri, 63110, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|New York University Laura and Isaac Perlmutter Cancer Center, New York, New York, 10016, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Hillman Cancer Center Research Pavilion, Pittsburgh, Pennsylvania, 15213, United States|UTSW Medical Center, Dallas, Texas, 75390, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Aurora Cancer Center, Wauwatosa, Wisconsin, 53226, United States |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | https://clinicaltrials.gov/study/NCT05795595 | RECRUITING | BIOLOGICAL: CTX131 | CRISPR Therapeutics AG | 250 | INTERVENTIONAL | Research Site 3, Duarte, California, 91010, United States|Research Site 2, Saint Louis, Missouri, 63110, United States|Research Site 4, Durham, North Carolina, 27710, United States|Research Site 1, Nashville, Tennessee, 37203, United States|Research Site 5, Houston, Texas, 77030, United States | ||
| NCT02012699 | Integrated Cancer Repository for Cancer Research | https://clinicaltrials.gov/study/NCT02012699 | iCaRe2 | RECRUITING | University of Nebraska | 999999 | OBSERVATIONAL | Penrose Cancer Center, Colorado Springs, Colorado, 80907, United States|Porter Adventist Hospital, Denver, Colorado, 80210, United States|Mercy Regional Medical Center, Durango, Colorado, 81301, United States|St. Anthony Hospital, Lakewood, Colorado, 80228, United States|Littleton Cancer Center, Littleton, Colorado, 80122, United States|Longmont Cancer Center, Longmont, Colorado, 80501, United States|Avista Cancer Center, Louisville, Colorado, 80027, United States|Parker Adventist Hospital, Parker, Colorado, 80138, United States|St. Mary Corwin Medical Center, Pueblo, Colorado, 81004, United States|St. Anthony North Cancer Center, Westminster, Colorado, 80228, United States|Florida Hospital Memorial Medical Center, Daytona Beach, Florida, 32117, United States|Florida Hospital DeLand, DeLand, Florida, 32720, United States|Florida Hospital FISH, Orange City, Florida, 32763, United States|Florida Hospital Flagler, Palm Coast, Florida, 32164, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, 32308, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, 60504, United States|Trinity Medical Center, Moline, Illinois, 61265, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, 60560, United States|Parkview Research Center, Fort Wayne, Indiana, 46845, United States|Community Health Network, Indianapolis, Indiana, 46219, United States|Community Cancer Center South, Indianapolis, Indiana, 46227, United States|Community Cancer Center North, Indianapolis, Indiana, 46256, United States|Community Howard Regional Hospital, Kokomo, Indiana, 46902, United States|Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa, 51503, United States|Genesis Medical Center, Davenport, Iowa, 52804, United States|Abben Cancer Center, Spencer, Iowa, 51301, United States|Covenant Medical Center, Inc, Waterloo, Iowa, 50702, United States|Saint Luke’s Cancer Instititue – South, Overland Park, Kansas, 66213, United States|Tulane University, New Orleans, Louisiana, 70112, United States|Breast Care Specialists of Maine, Portland, Maine, 04102, United States|Northwest Hospital, Randallstown, Maryland, 21133, United States|William E Kahlert Regional Cancer Center, Westminster, Maryland, 21157, United States|Holyoke Medical Center, Holyoke, Massachusetts, 01040, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Riverwood Healthcare Center, Aitkin, Minnesota, 56431, United States|Essentia Health-St. Joseph’s Medical Center, Brainerd, Minnesota, 56401, United States|Essentia Health – Duluth Clinic, Duluth, Minnesota, 55805, United States|St. Luke’s Hospital of Duluth, Duluth, Minnesota, 55805, United States|Lake Region Healthcare, Fergus Falls, Minnesota, 56537, United States|Avera Cancer Institute- Marshall, Marshall, Minnesota, 56258, United States|Mercy Hospital – Joplin, Joplin, Missouri, 64804, United States|Saint Luke’s Cancer Institute, East, Kansas City, Missouri, 64086, United States|Saint Luke’s Cancer Institute, Kansas City, Missouri, 64111, United States|Saint Luke’s Cancer Institute, Kansas City North, Kansas City, Missouri, 64118, United States|Saint Luke’s Cancer Institute, Liberty, Liberty, Missouri, 64068, United States|Heartland Regional Medical Center dba Mosaic Life Care, Saint Joseph, Missouri, 64507, United States|Bozeman Health Deaconess Hospital, Bozeman, Montana, 59715, United States|Logan Health, Kalispell, Montana, 59901, United States|Providence St. Patrick Hospital Montana Cancer Center, Missoula, Montana, 59802, United States|Mary Lanning Healthcare, Morrison Cancer Center, Hastings, Nebraska, 68901, United States|Faith Regional Health Services, Carson Cancer Center, Norfolk, Nebraska, 68701, United States|Great Plains Regional Medical Center, North Platte, Nebraska, 69101, United States|Avera St. Anthony’s Hospital, O’Neill, Nebraska, 68763, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, 68114, United States|Nebraska Methodist Health System, Omaha, Nebraska, 68114, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Regional West Health Services, Scottsbluff, Nebraska, 69361, United States|C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls, New York, 12801, United States|Faxton St. Luke’s Healthcare, Mohawk Valley, Utica, New York, 13501, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, 28304, United States|Essentia Health, Fargo, North Dakota, 58103, United States|Trinity Hospital Cancer Care Center, Minot, North Dakota, 58701, United States|Aultman Alliance Community Hospital, Alliance, Ohio, 44601, United States|Aultman Hospital, Canton, Ohio, 44710, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15323, United States|Avera Medical Group Oncology and Hematology Aberdeen, Aberdeen, South Dakota, 57401, United States|Avera Cancer Institute, Mitchell, South Dakota, 57301, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Sanford Health, Sioux Falls, South Dakota, 57105, United States|Avera Cancer Center Yankton, Yankton, South Dakota, 57078, United States|Avera Sacred Heart Hospital, Yankton, South Dakota, 57078, United States|Yankton Medical Clinic, Yankton, South Dakota, 57078, United States|Rutland Regional Medical Center, Rutland, Vermont, 05701, United States|Mary Washington Hospital, Fredericksburg, Virginia, 22401, United States|Ascension St. Elizabeth Hospital, Appleton, Wisconsin, 54915, United States|Wheaton Franciscan Healthcare – Elmbrook Memorial Hospital, Brookfield, Wisconsin, 53045, United States|Wheaton Franciscan Healthcare, Reiman Cancer Care, Franklin, Wisconsin, 53132, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, 54305, United States|Columbia St. Mary’s, Mequon, Wisconsin, 53097, United States|Columbia St. Mary’s, Milwaukee, Wisconsin, 53211, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, 54904, United States|Wheaton Franciscan Healthcare, All Saints, Racine, Wisconsin, 53405, United States|Wheaton Franciscan Healthcare, Wauwatosa Cancer Care, Wauwatosa, Wisconsin, 53226, United States | ||
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | https://clinicaltrials.gov/study/NCT04301011 | RAPTOR | ACTIVE_NOT_RECRUITING | BIOLOGICAL: TBio-6517|BIOLOGICAL: Pembrolizumab | Turnstone Biologics, Corp. | Takeda | 27 | INTERVENTIONAL | Mayo Clinic, Phoenix, Arizona, 85054, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Sylvester Comprehensive Cancer Center / UMHC, Miami, Florida, 33136, United States|University of Kansas Medical Center, Kansas City, Kansas, 66205, United States|Clinical Site 1007, Boston, Massachusetts, 02215, United States|Mayo Clinic, Rochester, Minnesota, 55902, United States|The Billings Clinic, Billings, Montana, 31031, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Ottawa Hospital and Research Institute (OHRI), Ottawa, Ontario, Canada|National Cancer Center, Ilsandong, 10408, Korea, Republic of|Seoul National University Hospital (SNUH), Junggu, 03080, Korea, Republic of |
| NCT00024076 | Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer | https://clinicaltrials.gov/study/NCT00024076 | COMPLETED | PROCEDURE: radiofrequency ablation | Jonsson Comprehensive Cancer Center | 30 | INTERVENTIONAL | Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States | ||
| NCT05932199 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | https://clinicaltrials.gov/study/NCT05932199 | NOT_YET_RECRUITING | DRUG: Durvalumab / tremelimumab|DRUG: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab | Baylor College of Medicine | Duke Cancer Institute | 52 | INTERVENTIONAL | Duke Cancer Institute, Durham, North Carolina, 27710, United States|Baylor St Lukes, Houston, Texas, 77030, United States | |
| NCT00715611 | Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00715611 | ACTIVE_NOT_RECRUITING | PROCEDURE: Pleurectomy/Decortication|DRUG: pemetrexed and cisplatin or carboplatin|RADIATION: Intensity Modulated Radiation Therapy | Memorial Sloan Kettering Cancer Center | M.D. Anderson Cancer Center|Princess Margaret Hospital, Canada|Mayo Clinic|Brigham and Women’s Hospital | 65 | INTERVENTIONAL | Moffitt Cancer Center, Tampa, Florida, 33612, United States|Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, 11725, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, 10591, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States|Md Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | https://clinicaltrials.gov/study/NCT06051695 | EVEREST-2 | NOT_YET_RECRUITING | BIOLOGICAL: A2B694|DIAGNOSTIC_TEST: xT CDx with HLA-LOH Assay | A2 Biotherapeutics Inc. | Tempus Labs | 230 | INTERVENTIONAL | City of Hope, Duarte, California, 91010, United States|UCSD Moores Cancer Center, La Jolla, California, 92093, United States|UCLA Medical Center, Los Angeles, California, 90404, United States|Stanford University, Stanford, California, 94305, United States|Moffitt Cancer Center, Tampa, Florida, 33606, United States|Massachusetts General Hopsital/Dana Farber Cancer Center, Boston, Massachusetts, 02114, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Washington University, Saint Louis, Missouri, 63110, United States|NYU Langone Medical Center, New York, New York, 10016, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | https://clinicaltrials.gov/study/NCT02062632 | TERMINATED | DRUG: Doxepin Hydrochloride|OTHER: Placebo|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration | Mayo Clinic | National Cancer Institute (NCI) | 5 | INTERVENTIONAL | Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Green Bay Oncology Limited at Saint Mary’s Hospital, Green Bay, Wisconsin, 54303, United States | |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | https://clinicaltrials.gov/study/NCT05275478 | RECRUITING | DRUG: TNG908 | Tango Therapeutics, Inc. | 192 | INTERVENTIONAL | Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Washington University, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10022, United States|Sarah Cannon Tennessee Oncology, Nashville, Tennessee, 37203, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology, Fairfax, Virginia, 22031, United States|Centre Léon Bérard, Lyon, 69373, France|Institute Gustav Roussy, Villejuif, 94805, France | ||
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT03608618 | TERMINATED | BIOLOGICAL: MCY-M11|DRUG: Cyclophosphamide | MaxCyte, Inc. | CTI Clinical Trial and Consulting Services | 14 | INTERVENTIONAL | National Cancer Institute, National Institutes of Health, Rockville, Maryland, 20892, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Washington University at St. Louis, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States | |
| NCT00054002 | Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT00054002 | COMPLETED | PROCEDURE: adjuvant therapy|PROCEDURE: conventional surgery|DRUG: porfimer sodium | Roswell Park Cancer Institute | 12 | INTERVENTIONAL | Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States | ||
| NCT03436732 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT03436732 | TERMINATED | DRUG: LMB-100|DRUG: SEL-110 | National Cancer Institute (NCI) | 5 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | https://clinicaltrials.gov/study/NCT03054298 | RECRUITING | BIOLOGICAL: huCART-meso cells | University of Pennsylvania | National Institutes of Health (NIH)|Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company) | 27 | INTERVENTIONAL | University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | |
| NCT02714374 | Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery | https://clinicaltrials.gov/study/NCT02714374 | TERMINATED | BIOLOGICAL: GL-ONC1 | Kaitlyn Kelly, MD | Genelux Corporation | 5 | INTERVENTIONAL | UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States | |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | https://clinicaltrials.gov/study/NCT00030498 | COMPLETED | DRUG: erlotinib hydrochloride|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 75 | INTERVENTIONAL | Cancer and Leukemia Group B, Chicago, Illinois, 60606, United States | ||
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT05215574 | RECRUITING | DRUG: NGM831|DRUG: NGM831 plus pembrolizumab|DRUG: NGM831 | NGM Biopharmaceuticals, Inc | Merck Sharp & Dohme LLC | 79 | INTERVENTIONAL | NGM Clinical Study Site, Gilbert, Arizona, 85234, United States|NGM Clinical Study Site, Los Angeles, California, 90025, United States|NGM Clinical Study Site, Sarasota, Florida, 34232, United States|NGM Clinical Study Site, Tampa, Florida, 33612, United States|NGM Clinical Study Site, Grand Rapids, Michigan, 49546, United States|NGM Clinical Study Site, New York, New York, 10016, United States|NGM Clinical Study Site, Oklahoma City, Oklahoma, 73104, United States|NGM Clinical Study Site, Austin, Texas, 78758, United States|NGM Clinical Study Site, Houston, Texas, 77030, United States | |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | https://clinicaltrials.gov/study/NCT03233724 | TERMINATED | DRUG: Decitabine (DAC)|DRUG: Tetrahydrouridine (THU)|DRUG: Pembrolizumab | National Cancer Institute (NCI) | 9 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | https://clinicaltrials.gov/study/NCT02460224 | COMPLETED | DRUG: LAG525|DRUG: PDR001 | Novartis Pharmaceuticals | 490 | INTERVENTIONAL | Columbia University Medical Center SC LAG X2101C, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center SC, New York, New York, 10065, United States|Duke Clinical Research Institute SC, Durham, North Carolina, 27704, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Cancer Therapy and Research Center UT Health Science Center CTRC 2, San Antonio, Texas, 78229, United States|Huntsman Cancer Institute Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Novartis Investigative Site, Westmead, New South Wales, 2145, Australia|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Lyon Cedex, 69373, France|Novartis Investigative Site, Saint-Herblain Cédex, 44805, France|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Modena, MO, 41124, Italy|Novartis Investigative Site, Fukuoka-city, Fukuoka, 811-1395, Japan|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Singapore, 169610, Singapore|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Taipei, 10002, Taiwan | ||
| NCT00020124 | Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs | https://clinicaltrials.gov/study/NCT00020124 | COMPLETED | DRUG: doxorubicin hydrochloride | National Institutes of Health Clinical Center (CC) | National Cancer Institute (NCI) | INTERVENTIONAL | Warren Grant Magnuson Clinical Center – NCI Clinical Studies Support, Bethesda, Maryland, 20892-1182, United States | ||
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | https://clinicaltrials.gov/study/NCT02611024 | RECRUITING | DRUG: Lurbinectedin|DRUG: Irinotecan | PharmaMar | 320 | INTERVENTIONAL | Massachusetts General Hospital -, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Virgen Del Rocio, Sevilla, 41013, Spain | ||
| NCT04431024 | Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome | https://clinicaltrials.gov/study/NCT04431024 | RECRUITING | National Cancer Institute (NCI) | 800 | OBSERVATIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | |||
| NCT02610140 | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | https://clinicaltrials.gov/study/NCT02610140 | COMPLETED | DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Vinorelbine | Bayer | ImmunoGen and MorphoSys | 248 | INTERVENTIONAL | La Jolla, California, 92093-1503, United States|Aurora, Colorado, 80045, United States|Norwich, Connecticut, 06360, United States|Tampa, Florida, 33612, United States|Chicago, Illinois, 60612, United States|Chicago, Illinois, 60637, United States|New Orleans, Louisiana, 70121, United States|Bethesda, Maryland, 20814, United States|Rochester, Minnesota, 55905, United States|Buffalo, New York, 14263-0001, United States|New York, New York, 10016, United States|Durham, North Carolina, 27710, United States|Cleveland, Ohio, 44195, United States|Dallas, Texas, 75251, United States|Houston, Texas, 77030, United States|St Leonards, New South Wales, 2065, Australia|Woolloogabba, Queensland, 4102, Australia|Adelaide, South Australia, 5043, Australia|Richmond, Victoria, 3122, Australia|Nedlands, Western Australia, 6009, Australia|Bruxelles – Brussel, 1200, Belgium|Edegem, 2650, Belgium|Gent, 9000, Belgium|Leuven, 3000, Belgium|Liege, 4000, Belgium|Sint-niklaas, 9100, Belgium|Calgary, Alberta, T2N 4N2, Canada|Hamilton, Ontario, L8V 5C2, Canada|London, Ontario, N6A 4L6, Canada|Toronto, Ontario, M5G 2M9, Canada|Helsinki, 00290, Finland|Turku, 20520, Finland|Vaasa, 65130, Finland|Bordeaux Cedex, 33076, France|Caen Cedex 5, 14076, France|Lille Cedex, 59037, France|Marseille, 13915, France|Paris, 75018, France|Paris, 75020, France|Pierre Benite, 69495, France|Pordenone, Friuli-Venezia Giulia, 33081, Italy|Bergamo, Lombardia, 24125, Italy|Milano, Lombardia, 20089, Italy|Milano, Lombardia, 20133, Italy|Monza Brianza, Lombardia, 20900, Italy|Torino, Piemonte, 10043, Italy|Siena, Toscana, 53100, Italy|Seoul, 05505, Korea, Republic of|Seoul, 06351, Korea, Republic of|Amsterdam, 1066 CX, Netherlands|Rotterdam, 3015 CE, Netherlands|Gdansk, 80-952, Poland|Krakow, 31-202, Poland|Krakow, 31-501, Poland|Szczecin, 70-891, Poland|Omsk, 644013, Russian Federation|Yekaterinburg, 620036, Russian Federation|A Coruña, 15006, Spain|Alicante, 03010, Spain|Barcelona, 08035, Spain|Madrid, 28041, Spain|Málaga, 29010, Spain|Adana, 01330, Turkey|Ankara, 06100, Turkey|Eskisehir, 26480, Turkey|Istanbul, 34899, Turkey|Malatya, 44280, Turkey|Yenimahalle, 06200, Turkey|Plymouth, Devon, PL6 8DH, United Kingdom|Maidstone, Kent, ME16 9QQ, United Kingdom|Leicester, Leicestershire, LE1 5WW, United Kingdom|Glasgow, G12 0YN, United Kingdom|London, SE1 9RT, United Kingdom|Manchester, M23 9LT, United Kingdom|Newcastle Upon Tyne, NE7 7DN, United Kingdom | |
| NCT00242723 | Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining | https://clinicaltrials.gov/study/NCT00242723 | RECRUITING | National Cancer Institute (NCI) | 1100 | OBSERVATIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | |||
| NCT05199584 | A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | https://clinicaltrials.gov/study/NCT05199584 | RECRUITING | DRUG: ENV-101 (taladegib) | Endeavor Biomedicines, Inc. | 44 | INTERVENTIONAL | Research Site, Los Angeles, California, 90095, United States|Research Site, San Diego, California, 92037, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Tampa, Florida, 33609, United States|Research Site, Zion, Illinois, 60099, United States|Research Site, Covington, Louisiana, 70433, United States|Research Site, Las Vegas, Nevada, 89102, United States|Research Site, New York, New York, 10065, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Cincinnati, Ohio, 45229, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Pittsburgh, Pennsylvania, 15232, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Fredericksburg, Virginia, 22408, United States|Research Site, Lynchburg, Virginia, 24501, United States|Research Site, Madison, Wisconsin, 53792, United States | ||
| NCT03830229 | Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes | https://clinicaltrials.gov/study/NCT03830229 | RECRUITING | National Cancer Institute (NCI) | 1000 | OBSERVATIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | |||
| NCT05001880 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT05001880 | RECRUITING | BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Cytoreductive Surgery|DRUG: Hyperthermic Intraperitoneal Chemotherapy|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography | National Cancer Institute (NCI) | 66 | INTERVENTIONAL | Mayo Clinic Hospital in Arizona, Phoenix, Arizona, 85054, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Carle at The Riverfront, Danville, Illinois, 61832, United States|Carle Physician Group-Effingham, Effingham, Illinois, 62401, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, 61938, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|The Carle Foundation Hospital, Urbana, Illinois, 61801, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States|Alliance for Clinical Trials in Oncology, Boston, Massachusetts, 02115, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, 56601, United States|Fairview Southdale Hospital, Edina, Minnesota, 55435, United States|Unity Hospital, Fridley, Minnesota, 55432, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, 55407, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Park Nicollet Clinic – Saint Louis Park, Saint Louis Park, Minnesota, 55416, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States|United Hospital, Saint Paul, Minnesota, 55102, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, 58501, United States|Sanford Broadway Medical Center, Fargo, North Dakota, 58122, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, 58122, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, 57104, United States|Sanford USD Medical Center – Sioux Falls, Sioux Falls, South Dakota, 57117-5134, United States|MD Anderson in The Woodlands, Conroe, Texas, 77384, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|MD Anderson West Houston, Houston, Texas, 77079, United States|MD Anderson League City, League City, Texas, 77573, United States|MD Anderson in Sugar Land, Sugar Land, Texas, 77478, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, 54911, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, 54701, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, 54449, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, 54548, United States|Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, 54482, United States|Marshfield Medical Center – Weston, Weston, Wisconsin, 54476, United States | ||
| NCT05568680 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | https://clinicaltrials.gov/study/NCT05568680 | RECRUITING | BIOLOGICAL: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR | Verismo Therapeutics | 42 | INTERVENTIONAL | University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT03683680 | Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers | https://clinicaltrials.gov/study/NCT03683680 | RECRUITING | OTHER: MPT Test|OTHER: CLDN15/VIM Test | Dana-Farber Cancer Institute | National Cancer Institute (NCI) | 240 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02215, United States | |
| NCT00243074 | S0509 – AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery | https://clinicaltrials.gov/study/NCT00243074 | COMPLETED | DRUG: cediranib maleate|OTHER: laboratory biomarker analysis | National Cancer Institute (NCI) | 54 | INTERVENTIONAL | Southwest Oncology Group, San Antonio, Texas, 78245, United States | ||
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | https://clinicaltrials.gov/study/NCT05415098 | RECRUITING | DRUG: APG-5918 | Ascentage Pharma Group Inc. | 90 | INTERVENTIONAL | Highlands Oncology, Springdale, Arkansas, 72762, United States | ||
| NCT00006981 | Immunotoxin Therapy in Treating Patients With Advanced Cancer | https://clinicaltrials.gov/study/NCT00006981 | COMPLETED | BIOLOGICAL: SS1(dsFv)-PE38 immunotoxin | National Cancer Institute (NCI) | INTERVENTIONAL | Warren Grant Magnuson Clinical Center – NCI Clinical Studies Support, Bethesda, Maryland, 20892-1182, United States | |||
| NCT00003974 | Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma | https://clinicaltrials.gov/study/NCT00003974 | COMPLETED | BIOLOGICAL: lung tumor associated antigen|DRUG: DetoxPC|DRUG: chemotherapy|DRUG: cyclophosphamide | Roswell Park Cancer Institute | 20 | INTERVENTIONAL | Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States | ||
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00652574 | COMPLETED | DRUG: Dasatinib | M.D. Anderson Cancer Center | Bristol-Myers Squibb|United States Department of Defense | 56 | INTERVENTIONAL | University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT03531840 | Olaparib in People With Malignant Mesothelioma | https://clinicaltrials.gov/study/NCT03531840 | COMPLETED | DRUG: Olaparib|DEVICE: ClinOmics | National Cancer Institute (NCI) | 23 | INTERVENTIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | ||
| NCT00372840 | Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer | https://clinicaltrials.gov/study/NCT00372840 | COMPLETED | OTHER: educational intervention|PROCEDURE: psychosocial assessment and care|PROCEDURE: quality-of-life assessment | Fox Chase Cancer Center | National Cancer Institute (NCI) | 340 | INTERVENTIONAL | Fox Chase Cancer Center – Philadelphia, Philadelphia, Pennsylvania, 19111-2497, United States | |
| NCT00859495 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00859495 | TERMINATED | DRUG: Doxorubicin|DRUG: Cisplatin|DRUG: Pemetrexed|RADIATION: Radiotherapy | Columbia University | 9 | INTERVENTIONAL | Columbia University Medical Center, New York, New York, 10032, United States | ||
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | https://clinicaltrials.gov/study/NCT05337735 | RECRUITING | DRUG: XmAb20717 | M.D. Anderson Cancer Center | 140 | INTERVENTIONAL | M D Anderson Cancer Center, Houston, Texas, 77030, United States | ||
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | https://clinicaltrials.gov/study/NCT02628535 | TERMINATED | BIOLOGICAL: MGD009 | MacroGenics | 67 | INTERVENTIONAL | UCLA, Los Angeles, California, 90095, United States|Stanford University School of Medicine, Palo Alto, California, 94304, United States|University of California – San Francisco, San Francisco, California, 94143, United States|Georgetown University, Washington, District of Columbia, 20007, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|New York University, New York, New York, 10016, United States|Columbia University Medical Center, New York, New York, 10032, United States|Carolina BioOncology Institute, Huntersville, North Carolina, 28078, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, 19104, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, 37232, United States|Mary Crowley Cancer Research Center, Dallas, Texas, 75230, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, 78229, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22034, United States|Chris O’Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Saint Vincent’s Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Linear Clinical Research, Nedlands, Western Australia, 6009, Australia|Princess Margaret Cancer Centre, Toronto, Ontario, M5G1Z5, Canada | ||
| NCT00859469 | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | https://clinicaltrials.gov/study/NCT00859469 | COMPLETED | DRUG: Oxaliplatin|DRUG: Gemcitabine | Columbia University | 29 | INTERVENTIONAL | Columbia University Medical Center, New York, New York, 10032, United States | ||
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | https://clinicaltrials.gov/study/NCT03074513 | ACTIVE_NOT_RECRUITING | DRUG: Atezolizumab|BIOLOGICAL: Bevacizumab|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | 133 | INTERVENTIONAL | M D Anderson Cancer Center, Houston, Texas, 77030, United States | |
| NCT02948413 | Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials | https://clinicaltrials.gov/study/NCT02948413 | COMPLETED | National Institutes of Health Clinical Center (CC) | 55 | OBSERVATIONAL | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | |||
| NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | https://clinicaltrials.gov/study/NCT02414269 | ACTIVE_NOT_RECRUITING | GENETIC: iCasp9M28z T cell infusions|DRUG: cyclophosphamide|DRUG: pembrolizumab | Memorial Sloan Kettering Cancer Center | Bellicum Pharmaceuticals|United States Department of Defense | 113 | INTERVENTIONAL | Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Consent and Follow-Up), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Consent and Follow-Up), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack (Consent and Follow-Up), Commack, New York, United States|Memorial Sloan Kettering Westchester (Consent and Follow-Up), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center (Consent and Follow-Up), New York, New York, 10065, United States | |
| NCT04234113 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT04234113 | ACTIVE_NOT_RECRUITING | DRUG: SO-C101|DRUG: pembrolizumab | SOTIO Biotech AG | SOTIO Biotech a.s. | 200 | INTERVENTIONAL | Yale Cancer Center, New Haven, Connecticut, 06520, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15216, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Masarykův Onkologický Ústav Brno Klinika komplexní onkologické péče, Brno, 65653, Czechia|Centre Léon Bérard, Lyon, 69379, France|Hôpitaux Universitaires de Marseille Timone, Marseille, 13005, France|Hopital Saint Louis, Paris, 75010, France|Institut Gustave Roussy, Paris, 94805, France|Institut de Cancerologie de L’Ouest, Saint Herblain, 44805, France|Institut Claudius Regaud, Toulouse, 31059, France|Vall d’Hebron Institute of Oncology, Barcelona, 08035, Spain|University Hospital Sanchinarro, Madrid, 28050, Spain | |
| NCT00087698 | Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00087698 | COMPLETED | DRUG: pemetrexed|DRUG: cisplatin | Eli Lilly and Company | 77 | INTERVENTIONAL | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician., Houston, Texas, United States | ||
| NCT00571298 | Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT00571298 | COMPLETED | PROCEDURE: Extrapleural pneumonectomy (EPP)|DRUG: Cisplatin|DRUG: gemcitabine|DRUG: amifostine|DRUG: sodium thiosulfate|PROCEDURE: Pleurectomy/Decortication | Brigham and Women’s Hospital | Dana-Farber Cancer Institute | 141 | INTERVENTIONAL | Brigham and Women’s Hospital, Boston, Massachusetts, 02115, United States | |
| NCT03071757 | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/study/NCT03071757 | COMPLETED | DRUG: ABBV-368|DRUG: ABBV-181 | AbbVie | 139 | INTERVENTIONAL | Moores Cancer Center at UC San Diego /ID# 201334, La Jolla, California, 92093, United States|University of California, Davis Comprehensive Cancer Center /ID# 201342, Sacramento, California, 95817, United States|Stanford University /ID# 206949, Stanford, California, 94305, United States|Yale University /ID# 207895, New Haven, Connecticut, 06510, United States|Carolina BioOncology Institute /ID# 160786, Huntersville, North Carolina, 28078, United States|Greenville Hospital System /ID# 160785, Greenville, South Carolina, 29605, United States|University of Texas Southwestern Medical Center /ID# 201934, Dallas, Texas, 75390-7208, United States|South Texas Accelerated Research Therapeutics /ID# 160788, San Antonio, Texas, 78229, United States|University of Virginia /ID# 212895, Charlottesville, Virginia, 22908, United States|Virginia Cancer Specialists – Fairfax /ID# 160787, Fairfax, Virginia, 22031, United States|AP-HM – Hopital de la Timone /ID# 165036, Marseille CEDEX 05, Bouches-du-Rhone, 13385, France|Institut Curie /ID# 165038, Paris CEDEX 05, Ile-de-France, 75248, France|Centre Leon Berard /ID# 165037, Lyon CEDEX 08, Rhone, 69373, France|Institut Gustave Roussy /ID# 165035, Villejuif Cedex, Val-de-Marne, 94805, France|National Cancer Center Hospital East /ID# 214530, Kashiwa-shi, Chiba, 277-8577, Japan|National Cancer Center Hospital /ID# 214531, Chuo-ku, Tokyo, 104-0045, Japan|Pan American Center for Oncology Trials, LLC /ID# 213809, Rio Piedras, 00935, Puerto Rico|Hospital Duran i Reynals /ID# 205997, Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Universitario Puerta de Hierro, Majadahonda /ID# 206973, Majadahonda, Madrid, 28222, Spain|CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 208879, Pamplona, Navarra, 31008, Spain|Hospital General Universitario Gregorio Maranon /ID# 205999, Madrid, 28007, Spain|CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 205996, Madrid, 28027, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 211500, Madrid, 28040, Spain|Hospital Clinico Universitario de Valencia /ID# 211499, Valencia, 46010, Spain|National Cheng Kung University Hospital /ID# 164002, Tainan, 704, Taiwan|National Taiwan University Hospital /ID# 164000, Taipei City, 100, Taiwan|Taipei Medical University Hospital /ID# 164001, Taipei City, 11031, Taiwan | ||
| NCT01160458 | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | https://clinicaltrials.gov/study/NCT01160458 | COMPLETED | DRUG: IMC-A12 | National Cancer Institute (NCI) | 20 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | https://clinicaltrials.gov/study/NCT02349958 | HIPEC/IPHC | UNKNOWN | DEVICE: HIPEC: MMC 30mg @ T0, 10mg @ T45min|DEVICE: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|DEVICE: HIPEC: CDDP 75 mg/m2 @T0|DEVICE: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 | Bay Area Gynecology Oncology | 200 | INTERVENTIONAL | James Lilja, Los Gatos, California, 95032, United States | |
| NCT01445392 | SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | https://clinicaltrials.gov/study/NCT01445392 | TERMINATED | BIOLOGICAL: Multicycle SS1P|DRUG: Pemetrexed|DRUG: Cisplatin|BIOLOGICAL: Single cycle SS1P | National Cancer Institute (NCI) | 24 | INTERVENTIONAL | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States | ||
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | https://clinicaltrials.gov/study/NCT05107674 | RECRUITING | DRUG: NX-1607|DRUG: Paclitaxel | Nurix Therapeutics, Inc. | 363 | INTERVENTIONAL | City of Hope, Duarte, California, 91010, United States|University of Southern California, Los Angeles, California, 90007, United States|University of California, San Francisco, San Francisco, California, 94158, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Virginia, Charlottesville, Virginia, 22908, United States|Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom|University College London Hospitals NHS Foundation Trust, Bloomsbury, W1T 7HA, United Kingdom|Addenbrookes Cambridge University Hospital, Cambridge, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Sarah Cannon Research Institute, London, W1G 6AD, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Northern Centre for Cancer Care, Newcastle, NE7 7DN, United Kingdom|Churchill Hospital, Oxford, OX3 7LE, United Kingdom | ||
| NCT00005636 | Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery | https://clinicaltrials.gov/study/NCT00005636 | COMPLETED | DRUG: cisplatin|DRUG: pemetrexed disodium | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL | Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Ireland Cancer Center, Cleveland, Ohio, 44106-5065, United States | ||
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT04272034 | ACTIVE_NOT_RECRUITING | DRUG: INCB099318 | Incyte Corporation | 105 | INTERVENTIONAL | Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Prisma Health Cancer Institute Faris, Greenville, South Carolina, 29605, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Universitair Ziekenhuis Brussel, Brussels, 01090, Belgium|Institut Jules Bordet, Brussels, B-1070, Belgium|Universitair Ziekenhuis Antwerpen (Uza), Edegem, 02650, Belgium|Ghent University Hospital, Ghent, 09000, Belgium|Universitaire Ziekenhuis Leuven – Gasthuisberg, Leuven, 03000, Belgium|Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen, 02100, Denmark|Helsinki University Central Hospital, Helsinki, 00029, Finland|Docrates Cancer Center, Helsinki, 00180, Finland|Tampere University Hospital, Tampere, 33520, Finland|Turku University Hospital, Turku, 20520, Finland|Haukeland University Hospital, Bergen, 05051, Norway|Oslo University Hospital, Oslo, 00450, Norway|Sahlgrenska University Hospital, Goteborg, 41345, Sweden|Karolinska University Hospital Solna, Solna, 17164, Sweden|Uppsala Universitet – Akademiska Sjukhuset, Uppsala, 75185, Sweden|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Guys and St Thomas Nhs Foundation Trust, London, SE1 9RT, United Kingdom|The Royal Marsden Hospital Nhs Trust London, London, SM2 5PT, United Kingdom|Imperial College Healthcare Nhs Trust – Hammersmith Hospital, London, W12 0HS, United Kingdom|Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust, Newcastle Upon Tyne, NE7 7DN, United Kingdom | ||
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | https://clinicaltrials.gov/study/NCT05425576 | NOT_YET_RECRUITING | DRUG: OT-101 | Oncotelic Inc. | 63 | INTERVENTIONAL | University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States | ||
| NCT06057935 | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | https://clinicaltrials.gov/study/NCT06057935 | RECRUITING | DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin | Memorial Sloan Kettering Cancer Center | 64 | INTERVENTIONAL | University of Chicago (Data Collection Only), Chicago, Illinois, 60637, United States|University of Nebraska (Data collection only), Omaha, Nebraska, 68198-7680, United States|Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States|Rutgers University (Data Collection Only), New Brunswick, New Jersey, 08903, United States|Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activites), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, 11553, United States|Allegheny Health Network (Data Collection Only), Pittsburgh, Pennsylvania, 15212, United States |